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Painful diabetic neuropathy (PDN) affects 25-30% of people with diabetes. PDN is a debilitating 
condition and has significant impacts on the physical and mental wellbeing. Specifically, it is 
associated with poor quality of life, impaired sleep, physical disability and increased anxiety and 
depression. Pharmacological treatments for PDN have limited effectiveness and often intolerable 
side effects. Previous research suggested that psychological interventions may be beneficial for 
chronic pain, but only a few trials have been conducted specifically for people with PDN. Acceptance 
and Commitment Therapy (ACT) has growing evidence of its effectiveness for chronic pain. However, 
there is no study applying an ACT-based intervention to people with PDN. This thesis focuses on 
examining PDN within the framework of the psychological flexibility model and, relatedly, 
considering the potential usefulness of ACT for people with PDN. This thesis comprises of 3 studies. 
Study 1: A systematic review examining and summarising evidence from observational studies of 
psychosocial factors and treatment trials of psychological interventions conducted with populations 
of people with PDN. Results suggest that sleep, quality of life, anxiety and depression are the most 
studied variables, within the PDN literature, and each is consistently associated with pain intensity. 
While only three Randomised Controlled Trials included psychological treatments applied to this 
population, there were promising results for their effectiveness. Evidence from commonly studied 
variables in chronic pain, such as coping or pain beliefs, was lacking in PDN research. Due to the lack 
of research, a study examining theoretically based psychosocial factors was suggested.  
Study 2: The second study in this set was a cross-sectional survey investigating the association 
between facets of psychological flexibility (acceptance of pain, committed action, cognitive fusion 
and self as a context), and distress and daily functioning in people with PDN. Overall, 225 
participants with PDN were recruited from hospital diabetes outpatient clinics and online. Through 
correlation analyses, acceptance of pain is shown to be negatively correlated with pain intensity, 
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pain distress, functional impairment, depression severity, and depression impact. Cognitive fusion 
correlated positively with pain intensity, functional impairment, depression severity, and depression 
impact. Committed action correlated negatively with functional impairment, depression severity and 
depression impact. In regression analyses, the combination of the four variables representing 
psychological flexibility accounted for significant variance in all equations except in the case of pain 
distress. The results of this study suggest that psychological flexibility may play a meaningful role in 
the context of PDN, and psychological treatment focused on psychological flexibility was indicated. 
Study 3: The third study tested the feasibility of ACT among individuals with PDN in the UK. This was 
a single-cohort study of an online ACT treatment package, which was originally developed for 
chronic pain populations. Primary feasibility outcomes were recruitment, retention and treatment 
completion rates. Secondary outcomes were within-groups effects on pain outcomes and 
psychological flexibility. Process and outcome variables were measured at pre-treatment and 3 
months post-treatment. The treatment completion rate was 40% for the ACT online treatment with 
all participants completing the follow-up questionnaires. Treatment completers demonstrated 
significantly lower levels of pain intensity and distress, depression and functional impairment and 
higher levels of committed action over time compared with non-completers. However, online ACT 
for people with PDN, seems to have limited feasibility and changes to the protocol, treatment 
content, and delivery may be needed before further testing in a larger feasibility study. 
Certainly, further developments in treatments for people with PDN are needed. In turn, this will 
require greater attention to PDN by clinical researchers conducting studies of psychosocial processes 
linked to clinical outcomes. The set of studies described here produced preliminary evidence for a 
particular set of psychosocial factors and application of a psychological intervention for people with 
PDN, based on the psychological flexibility model. It provided some support for the feasibility of ACT, 
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including suggestive evidence around clinical outcomes. Further study of a modified ACT-based 
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Chapter 1: The problem of Diabetes Mellitus and Painful Diabetic Neuropathy 
1.1 Chapter Overview 
To give a context for the body of work presented in the present PhD thesis, this chapter will provide 
an overview of Diabetes Mellitus (DM). This overview will include a brief historical perspective, and 
then summaries of the prevalence, individual and socioeconomic impacts, and associated 
complications of DM. Treatment options will then be discussed, with a focus on monitoring blood 
glucose, dietary and physical activity management, oral anti-diabetic medication, insulin and 
injectable therapy. Finally, this chapter will provide a brief overview of research concerning Painful 
Diabetic Neuropathy (PDN). This overview will include a definition of PDN, brief description of the 
pathological process and diagnosis. Finally, the prevalence, impact, and management of PDN 
including pharmacological and psychological treatment options is reviewed. 
1.2 Statement of the Problem  
It is estimated by Public Health England (2016) that 3.8 million people in England have DM, either 
diagnosed or undiagnosed. There are many complications associated with this condition, but one of 
the most frequent complication is PDN. Approximately 20-25% of this population suffer from PDN 
(DUK, 2017). This has a large economic, social and personal impact on individuals (Institute for 
Health Metrics and Evaluation, 2017). Healthcare providers prescribe medication options to improve 
health outcomes and produce limited effects (National Institute of Neurological Disorders and 
Stroke, 2019). Psychological interventions may improve pain outcomes and help with condition 
management (Nathan et al., 2017), however, there are currently limited studies available to inform 





The World Health Organization (WHO) defines DM as ‘’a metabolic disorder of multiple aetiology 
characterised by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, insulin action or both’’ (WHO, 1999). This 
disruption to insulin production or effectiveness causes blood glucose levels to rise 
(hyperglycaemia). High blood glucose levels are toxic to small blood vessels and, if sustained, this can 
lead to retinopathy (damage to the retina and therefore eyesight), nephropathy (kidney damage), 
and neuropathy (nerve damage) (Alberti, Zimmet, & Shaw, 2005; Holt & Hanley, 2012a).  
 
Figure 1: Sculpture: Pain without words by Deborah Ann (Reproduced with permission) 
The most common types of DM are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus 
(T2DM). T1DM is an autoimmune endocrine disorder and has traditionally been associated with 
diagnosis in childhood or adolescence, although more recent data suggests half of all cases are now 
diagnosed in adulthood (Thunander et al., 2008). T1DM is characterised by the destruction of β-cells 
within the pancreas which leads to a complete lack of insulin and then requires lifelong management 




T2DM is usually diagnosed after adolescence and results from depleted insulin production by β-cells 
and/or resistance to insulin (Alberti & Zimmet, 1998; Holt & Hanley, 2012b). The onset of T2DM 
seems to be associated with age, ethnicity, family history of diabetes and obesity (DUK, 
2018). T2DM is also a major risk factor for complications, such as cardiovascular disease, as not only 
is hyperglycaemia problematic to the microvascular circulation in T2DM, it is also associated with 
high blood pressure (hypertension) and high levels of blood cholesterol (hypercholesteremia). These 
affect macro-circulation and therefore put the individual at increased risk of stroke and myocardial 
infarction (heart attack). DM is not only a problem of physical health but it is also associated with 
increased levels of anxiety (Grigsby, Anderson, Freedland, Clouse, & Lustman, 2002), depression 
(Anderson, Freedland, Clouse, & Lustman, 2001; Badescu et al., 2016) and psychological suffering 
(Polonsky et al., 2005). This results in significant, adverse, economic and social impact (Alberti et al., 
2005). There seems to be a bi-directional relationship between mood disorders and diabetes and 
existing evidence shows that this may be due to shared pathophysiological mechanisms (Berge & 
Riise, 2015; Moulton, Pickup, & Ismail, 2015). Possible pathophysiological mechanisms are stress and 
cytokines. Both reviews (Berge & Riise, 2015; Moulton, Pickup, & Ismail, 2015), supporting these 
conclusions, explored the shared mechanisms between depression and diabetes. However, their 
definitions of depression differ and are not consistent with DSM-IV. 
Another potential complication of DM is painful diabetic neuropathy (PDN), a persistent condition 
resulting from nerve damage or dysfunction, which leads to sensory loss and pain, in the feet and 
hands (Belapurkar, More, Patil, & Mohan, 2018) (See Figure 1). PDN arises in the peripheral nerve of 
either the autonomic or somatic nervous systems (Boulton et al., 2005). The primary cause of PDN is 
hyperglycaemia. Even though there has been progress to normalise glycaemia in diabetes with 
hypoglycaemic agents, dietary changes, and insulin, neuropathy continues to be a serious problem 




1.4 Historical Background of Diabetes Mellitus 
DM was first described in Egyptian papyri in 1500 BC, as a disease which caused patients to lose 
weight and urine quickly. Increased sugar, in blood and urine, was first noticed by the Indians (5th 
century BC) and was also mentioned in Greek medical texts (2nd century AD). DM was officially 
established by Dobson in Britain (1776). The term “diabetes” came from the Greek word diabainein 
(meaning “to come through”) and was recognised by Araetus of Cappodocia (81-133 AD). The term 
“mellitus” came from the Greek word meli (meaning “honey”) and was introduced by Thomas Willis 
(1675), because of the sweet taste of the blood and urine of patients with DM (Ahmed, 2002). 
A milestone of great significance for experimental medicine was the discovery of insulin and the 
establishment of its therapeutic use for people with DM. Insulin discovery started with two 
concepts, introduced by Claude Bernard in France (1857): that DM is characterised by increased 
glucose production; and that the liver plays a significant role in glycogenesis. Mering and Minkowski 
(1889; Karamanou, Protogerou, Tsoucalas, Androutsos, & Poulakou-Rebelakou, 2016), proposed the 
role of the pancreas in the pathogenesis of DM, which in turn leads to the isolation of insulin islets 
and the therapeutic use of insulin for people with T1DM, by Banting and Best in Canada (1921) (cited 
in Holt & Hanley, 2012a). Insulin treatment meant that for the first-time people with DM could 
expect to live for longer. In 1955, the first orally administered anti-hyperglycaemic treatments, 
tolbutamide and carbutamide, were developed and tested in people with T2DM (Ahmed, 2002; 
Alhadramy, 2016).  
1.5 The Epidemiology and Diagnosis of Diabetes Mellitus  
DM is a major global public health problem which is steadily reaching epidemic levels (WHO, 2016). 
Between 1980 and 2014 the prevalence of people diagnosed with DM increased from 4.7% to 8.5% 




2010, 2012; WHO, 2016). This dramatic increase is evident due to the continuous growth of 
population, unhealthy lifestyle, increasing lifespan, and obesity levels (Alberti & Zimmet, 2013; Hu, 
2011; Narayan, 2006). However, the actual number of people who have the condition is likely much 
higher than this, as estimates suggest 630,000 people are undiagnosed (DUK, 2014). Worldwide, it is 
estimated by the WHO, that in 2014 approximately 422 million adults (>18 years) were diagnosed 
with DM and this number is expected to double by 2025. The largest numbers were found in the 
Western Pacific, with 67 million people diagnosed with DM, followed by Europe with 53 million. 
Evidence suggests that India has approximately 40.9 million people with DM and China 39.8 million 
(Tabish, 2007) (See Figure 2). 
 
Figure 2: The latest figures, information and projections on diabetes worldwide (International 





T1DM and T2DM are the most common types of DM, and it is estimated that 90% of people with a 
diabetes diagnosis suffer from T2DM and 10% from T1DM (NICE, 2015). However, there are no 
accurate global estimates for the exact percentage of people who are diagnosed with either T1DM 
or T2DM (WHO, 2016). 
The diagnosis of diabetes is conventionally based on two abnormal glucose tests. Diagnosis of 
diabetes in a person with symptoms is made following an oral glucose tolerance test or an eight-
hour fasting state test. An oral glucose tolerance test has questionable reliability because the 
produced results are influenced by the laboratories and adopted techniques, and is also expensive 
for the patients (Bennett, Guo, & Dharmage, 2007). The eight-hour fasting state test, has high 
specificity (mean 0.94, 95% CI: 0.92-0.96) and low sensitivity (mean 0.25, 95% CI: 0.19-0.32), which 
may lead to false or misleading results (Barry et al., 2017). In order to have an accurate and reliable 
diagnosis, both tests need to be used to evaluate the combination of the results (Holt & Hanley, 
2012a). If the person is asymptomatic at least two blood glucose tests must be performed on 
different days, the results of which must both fall in the diabetic range which is 126 mg/dL (7 
mmol/L) or higher. 
Moving forward from the traditional methods of diagnosis, there is an additional test which includes 
measurement of glycated haemoglobin levels (HbA1c). Glucose in the blood plasma binds to 
haemoglobin molecules, waiting for the body to take in the erythrocytes (Bennett et al., 2007; 
Kilpatrick, Bloomgarden, & Zimmet, 2009). It is worth noting that the WHO provides a definition of 
HbA1c of ≥6.5% (≥48mmol/mol) for diabetes diagnosis, and HbA1c 5.7%- 6.4% (40-47 mmol/mol) for 





Figure 3: WHO diagnostic criteria for diabetes, 1999 (Holt & Hanley, 2012a; Reproduced with 
permission) 
In the UK, the National Institute for Health and Care Excellence (NICE, 2015) describes the diagnosis 
of T1DM when adults present hyperglycaemia and have one or more of the following: family history 
of diabetes, sudden weight loss, age below 50 years old, ketosis, BMI below 25 kg/m2.  
1.6 Treatment 
T1DM is a result of an autoimmune metabolic disorder which destroys β-cells and may lead to the 
complete termination of insulin production. The suggested treatment for T1DM is insulin therapy, 
either through insulin injections or pumps. Additionally, the treatment plan for T1DM includes 
regular health checks and living a healthy lifestyle with a focus on increased physical activity and a 
healthy diet (Holt & Hanley, 2012a). These treatment options reduce mortality rates but increase the 
rates of individuals living long-term with T1DM and experiencing its complications (Alberti & 
Zimmet, 2013).  
Therapeutic options for T2DM are major lifestyle modifications and behavioural changes, involving 
increased physical activity, diet and anti-diabetic medication, including injectable therapies such as 




of β-cells over time and so supplementary insulin therapy becomes necessary (Smith-Spangler, 
Bhattacharya, & Goldhaber-Fiebert, 2012). In both T1DM and T2DM, blood glucose management is 
of crucial importance in order to avoid hyperglycaemia which is a strong predictor of cardiovascular 
diseases, stroke and other complications (Callaghan, Little, Feldman, & Hughes, 2012; Sherwani, 
Khan, Ekhzaimy, Masood, & Sakharkar, 2016). 
National Health Service (NHS), Diabetes UK (DUK) and NICE provide guidelines for DM management. 
NHS and DUK advise individuals who suffer from DM not to skip meals, eat regularly, increase 
dietary fibre intake, consume five portions of vegetables and fruit per day, limit the consumption of 
alcohol and salt and keep hydrated (DUK, 2018; NHS, 2018). NICE (2015), highlights the importance 
of education in relation to the condition, physical activity, healthy eating, blood glucose and blood 
pressure management, and medication. Data from a systematic review (Orozco et al., 2008) 
demonstrated that increased physical activity and healthy eating reduced the risk of developing DM 
by 37% (95% CI: 0.49, d=0.79). While Boulé, Haddad, Kenny, Wells, and Sigal, (2001) found that 
increased physical activity reduced blood pressure, body weight, and waist circumference. 
WHO (2005) defines adherence as "the degree to which the person's behaviour corresponds with 
the agreed recommendations from a health care provider". Another, more recent, proposed 
definition by Frost, Levati, McClurg, Brady, and Williams, (2017), describes adherence as “the extent 
to which individuals undertake a prescribed behaviour accurately and at the agreed frequency, 
intensity and duration (p.2)”. Many people diagnosed with DM face difficulties in managing their 
condition and adhering to recommended treatment (Gonzalez, Tanenbaum, & Commissariat, 2016). 
Evidence shows that in the US less than 1 in 5 adults, diagnosed with DM, are managing their 
condition as recommended by Health Care Professionals (HCPs) (Casagrande, Fradkin, Saydah, Rust, 
& Cowie, 2013). This refers to adherence behaviours in relation to medication, diet, physical activity, 




Non-adherence in T2DM is linked to complications, mortality, increased healthcare costs, emergency 
rooms visits, and inadequate glycaemic control. Poor adherence is also associated with demographic 
characteristics (i.e. low education level), nonpatient factors (i.e. lack of multidisciplinary care), and 
altered patient beliefs regarding their medications (i.e. treatment complexity) (Polonsky & Henry, 
2016).  
Adherence behaviours are influenced by various cognitive-behavioural factors according to the 
literature. A meta-analysis by Gonzalez et al. (2008), including 47 studies, demonstrated a strong link 
between depression and nonadherence to treatment. The reported weighted effect size was 
statistically significant of medium impact (r= 0.21, 95% CI: 0.17-0.25). However, the quality of the 
included studies was not assessed, making the evidence questionable. Other factors which have 
been linked to diabetes management and adherence are problem-solving skills, self-regulatory skills, 
emotional states, health beliefs (Gonzalez et al., 2016), and diabetes distress (Tareen & Tareen, 
2017). 
It is important to support individuals with DM though effective behavioural/psychosocial 
interventions to facilitate their self-management of diabetes and related distress (Peyrot & Rubin, 
2007). According to the NHS, self-management is "a term used to include all the actions taken by 
people to recognise, treat and manage their own health. They may do this independently or in 
partnership with the healthcare system." The most commonly used interventions, aiming at 
behaviour change, are problem-solving and self-monitoring techniques, goal setting, coping skills, 
social support, incentives, environmental change, motivation enhancement, and behavioural 
contracting (Grey, Boland, Davidson, Li, & Tamborlane, 2000; Hardeman et al., 2005; Hill-Briggs, 
Cooper, Loman, Brancati, & Cooper, 2003; Rollnick et al., 2005). A meta-analysis by Harvey (2015) 
showed that, in people with T1DM, psychosocial interventions reduce HbA1c, noting a reduction of 




HbA1c by 0.76% (Harvey, 2015). These are significant findings, noting again that higher HbA1c 
increases the risk of developing diabetes-related complications (DUK, 2018). In this review, Cognitive 
Behavioural Therapy (CBT) was among the most effective interventions for reducing HbA1c (Harvey, 
2015). A more recent Randomised Controlled Trial (RCT) conducted by Ismail et al. (2008), applied 
nurse-delivered motivational enhancement therapy with and without CBT in 344 adults with T1DM. 
Participants had DM for more than two years, HbA1c levels 8.2.%-15% and did not report any 
complications. This study found a significant reduction in HbA1c in the motivational enhancement 
therapy with CBT of 46% (95% CI: -0.81% to -0.11%) compared to the motivational enhancement 
group alone, of 19% (95% CI: -0.53% to 0.16%). Regardless of the importance of this evidence, this 
study did not achieve data completeness, as data was missing on the primary outcomes in 11.3% of 
participants. This intervention also, could not separate the effect of CBT as an addition to the 
motivational enhancement therapy, making the results more focused on the effectiveness of 
motivational enchantment therapy. 
1.7 Impact of Diabetes Mellitus 
DM has a significant socioeconomic impact on the global health system and the wider economy. 
Meanwhile the diagnosis and its related complications significantly affect the physical and 
psychological health of the individual. 
1.7.1 Physical and Psychosocial Impact of Diabetes Mellitus 
Evidence shows that DM has many significant negative impacts on the psychological and physical 
health of individuals; it impairs quality of life and increases anxiety and depressive symptoms. These 
are not only consequences of DM but, in turn, they also exert their own adverse health impacts and 
affect how individuals self-manage this long-term condition. A systematic review (Schram, Baan, & 




participants, examined the association between depression and quality of life in people with 
diabetes. All studies found a negative association between depression and at least one aspect of 
quality of life. Even though the overall quality of the included studies was not assessed by the 
authors, the measures used within the studies were reliable and validated (i.e. SF-36). 
A literature review from Clarke (2003), highlighted that there are numerous factors underlying the 
impact of DM on the individual. The most vital ones include age, since younger mean age is 
positively associated with increased emotional distress; and the individuals’ perceptions of the 
severity of the condition, which may affect DM management. A large-scale follow-up survey (Sudore 
et al., 2012), including 13,171 participants (47% females, white, Hispanic, African-American and 
Asian, with mean age 60.0 + SD 9.9), investigated the impacts on people with DM. Results suggested 
that 23.5% had depressive symptoms, and 24.2% had sleep impairment. Similarly, a cross-sectional 
survey (Collins, Corcoran, & Perry, 2009), including 1,456 participants investigated the presence of 
depression and anxiety in people with T1DM and T2DM which was assessed with the Hospital 
Anxiety and Depression Scale (HADS). Results suggested that 22.4% of respondents (95% CI: 20.2% - 
24.7%) were suffering from mild/severe depression while 32% (95% CI: 29.5% - 34.6%) were 
suffering from mild/severe anxiety. This study had a high response rate (71%) from participants. The 
clinical significance of the results suggests the reliable conclusion that there is high prevalence of 
depression and anxiety in people with diabetes. A more recent cross-sectional study (Ugur et al., 
2019), included 193 participants, 52 with T1DM, 86 with T2DM and 55 controls. This study assessed 
the prevalence of depression and anxiety using HADS, finding that participants with T2DM had 
reported significantly higher levels of depression and anxiety than participants with T1DM and 
controls. Interestingly, this study reported that, even though not significant, there was a positive 
correlation between HbA1C levels and depression (r=0.088, p=0.298) and anxiety (r=0.089, p=0.292) 




Pain seems to be another direct result of DM. Evidence shows that pain is associated with chronic 
fatigue in both T1DM and T2DM. One cross-sectional study, (Menting et al., 2016) including 214 
participants, found that pain acts as a predictor for severe chronic fatigue and that is prevalent more 
in people with T1DM than T2DM. Results were statistically significant suggesting that 76% of 
participants had severe fatigue which persisted over time. 
The literature indicates various potential mechanisms explaining links between diabetes and 
depression and anxiety. A literature review by Korczak, Pereira, Koulajian, Matejcek, and Giacca, 
(2011), suggested a biological link between T1DM and depression. Particularly, elevated circulating 
cytokines are linked to DM. This is a result from reduced insulin for metabolism, effects of iatrogenic 
hypoglycaemia, long-term hypoglycaemia, and/or hyperactivity of the hypothalamic-pituitary-
adrenal (HPA) axis. Another literature review by Badescu et al. (2016), highlights that depression in 
T2DM is potentially linked with stress and inflammation. This result emphasises the importance of 
screening for depression in people with diabetes. This evidence, although useful, is of unclear 
quality. The review is presented more like a recommendation, to HCPs, to become aware that 
depression is a major co-morbidity, mostly undiagnosed, in people with diabetes. 
The negative effects of DM are complex and bi-directional. Poor glycaemic management and poor 
uptake of therapies lead to high prevalence of depression in people with DM (Bogner, Morales, de 
Vries, & Cappola, 2012; Egede & Ellis, 2010; McSharry, Bishop, Moss-Morris, Holt, & Kendrick, 2015). 
Prevalence of anxiety and affective disorders are 85-123% higher in adults with DM than adults with 
no DM, and for diabetes distress and depression is 60% higher, which is explained by either the 
different use of psychotropic medication or by the fact that clinicians minimize patients’ distress 
because they consider it to be normal (Fisher et al., 2008). 
Besides the impact of DM on psychological wellbeing, society and the global economy, DM also has 




(Didjurgeit, Kruse, Schmitz, Stückenschneider, & Sawicki, 2002; Donahue & Orchard, 1992; Otterman 
et al., 2011). Research shows that retinopathy, kidney failure, blindness, and macrovascular 
complications, which lead to cardiovascular disease (Eckel, Grundy, & Zimmet, 2005), pain (Sudore 
et al., 2012), and diabetic neuropathy, which leads to limb damage, sensory and mobility loss (Tölle, 
Xu, & Sadosky, 2006) are the most common complications of DM. Given the focus on PDN in this 
thesis, further details on this specific complication, including prevalence and pathogenesis, will be 
provided in the final sections of this chapter. 
While most diabetes education covers the potential for micro- and macro-vascular complications, 
few people are advised regarding the association with neurological deficits. There is growing 
research, however, that people with DM are at greater risk of vascular dementia (RR 2.0-2.5) and 
Alzheimer’s disease (RR 1.5-2.0) (Biessels, Deary, & Ryan, 2008). A systematic review by Biessels, 
Staekenborg, Brunner, Brayne, and Scheltens, (2006), including 14 high quality studies, revealed that 
potential mechanisms linking diabetes with dementia and Alzheimer’s include changes in glucose 
and insulin levels, and metabolism of amyloid-beta peptide. While there is not enough evidence to 
show which of these factors are the most clinically relevant, there is strong evidence suggesting that 
people with T2DM are at higher risk for developing dementia and cognitive impairment than people 
without diabetes. The main cognitive domains affected are mental speed, mental flexibility, learning 
and memory (Cukierman, Gerstein, & Williamson, 2005; Gregg & Caspersen, 2005; Xu et al., 2010).  
In a recent meta-analysis by Cheng, Huang, Deng, and Wang, (2012) it was similarly found that the 
risk of developing dementia for people with DM is 1.46 higher than people without DM, and 2.48 
times higher for vascular dementia. A Cochrane systematic review of 7 studies, including 4 RCTs, of 
people with T2DM, assessed the effect on cognitive function by type of intervention and level of 
metabolic control. This review found that no intervention was effective on the prevention or 




interventions were not different in their effectiveness on cognitive functioning in a period of 40-60 
months (Sastre, Vernooij, González-Colaço Harmand, & Martínez, 2017).  
1.7.2 Economic Impact of Diabetes Mellitus 
DM has a substantial economic impact worldwide. Financial costs have increased by 26% from 2012 
to 2017 due to the growing prevalence of DM (DUK, 2019). This includes direct and indirect medical 
costs and health resource expenditure. Direct medical costs result from medical management, such 
as hospital fees charged to patients and/or the health system. Indirect costs are a result of reduced 
productivity, increased absenteeism or lost wages. The health resource expenditures come from 
costs for prevention, medical care and rehabilitation (DUK, 2014; WHO, 2008, 2016). 
In the UK, DM represents a huge economic burden as it is estimated that £23.7 billion per year is 
spent by the NHS for diabetes management and this number is expected to rise to £39.8 billion by 
2035/36, meaning an increase of 13% of the worldwide public health burden (Barry et al., 2017). This 
amount includes £9.8 billion of direct medical costs, and £13.9 billion of indirect costs (Hex, Bartlett, 
Wright, Taylor, & Varley, 2012). Meanwhile diabetic neuropathy as a complication alone reaches 
approximately £100 million per year (DUK, 2014). DM is currently responsible for 10% of the total 
health resource expenditures in the UK (Hex et al., 2012).  
In the USA the annual direct health care costs for diabetes alone due to outpatient visits and 
hospitalisation reach US$6,632 per person, while for diabetic neuropathy the current estimation is 
US$71,178 (Sadosky et al., 2015). The American Diabetes Association (ADA) estimated that in 2017 
the total costs for people with diagnosed DM were US$ 327 billion. This amount includes direct 
medical costs of US$ 237 billion and indirect costs of US$ 90 billion, while health resource 
expenditures are estimated to US$ 9600 per person annually. One study predicted that in the period 
2011-2030 losses in GDP worldwide would be in total US$ 1.7 trillion (Bloom et al., 2018). In 




US$ 900 billion for high-income countries, comprising both direct and indirect costs and health 
resource expenditure (Bloom et al., 2011). Another study including 699,042 people with diabetes 
showed that the largest costs for the healthcare system were a year after the diagnosis, more 
specifically the costs for women were US$3,785 per person (95% CI: 3708 - 3862) and for men 
US$3,826 (95% CI: 3751 - 3901) (Rosella et al., 2016). This data collectively highlights the enormous 
economic burden of DM. 
1.8 Pathological Process and Diagnosis of Painful Diabetic Neuropathy 
The pathogenesis of PDN is complex and involves a combination of processes which take place in the 
peripheral sensory nerves, at the dorsal horn of the spinal cord, and higher cortical centres 
(Schreiber, 2015). Prolonged hyperglycaemia in the peripheral nerves leads to the generation of 
reactive oxygen species and accumulation of advanced glycated end-products. This reduces the 
capacity of capillary membranes to vasodilate and influences the production and release of pro-
inflammatory cytokines (Interleukines-1 and 6, Tumour Necrosis Factor-α) and nerve growth factors 
(insulin-like growth factor and platelet-derived growth factor). The results of these multiple 
mechanisms are disruption to the mitochondrial energy supply for epithelial cells, microvascular 
ischaemia, and damage to epithelial capillary linings (Shakher & Stevens, 2011; Tesfaye et al., 2010). 






Figure 4: Pathogenesis of painful diabetic neuropathy (Kaur, Pandhi, & Dutta, 2011; Reproduced with 
permission) 
These pathological processes start in the presence of severe hyperglycaemia and are specific to DM, 
appearing, on average, approximately after 25 years of the initial diagnosis (Kaur et al., 2011). Risk 
factors which seem to be associated with increased likelihood of developing neuropathy in people 
with DM are age (Kisozi et al., 2017), duration of diabetes (Barbosa et al., 2019; Mørkrid, Ali, & 
Hussain, 2010), hypertension (Barbosa et al., 2019), and hypoglycaemia (Papanas & Ziegler, 2015). 
Similar alterations in peripheral nerves seem to cause neuropathic symptoms following radiotherapy 




Loprinzi, 2008), pharmacological treatments for human immunodeficiency virus (HIV) (Scott et al., 
2018a) and high alcohol consumption (Chopra & Tiwari, 2012). 
The multiple pathological and physiological processes can lead to the development of clinical 
symptoms, of PDN, which are burning, stabbing, aching and/or pricking senses, but the most 
common sensation is sharp pain, and clinical symptoms like bilateral numbness and/or pain in a sock 
and glove distribution (Gore, Brandenburg, Hoffman, Tai, & Stacey, 2006; Hoffman, Sadosky, Dukes, 
& Alvir, 2010; Kulkantrakorn & Lorsuwansiri, 2013). 
A definitive clinical diagnosis of PDN includes the use of skin biopsy and intra-epidermal nerve fibre 
density (IENFD) to assess nerve fibres and functioning, assessment of sudomotor function, 
neurophysiology examination through nerve conduction studies (NCS) of sensory and motor nerves, 
or corneal confocal microscopy through Heidelberg Retina Tomograph III Rostock Corneal Module 
(HRT III RCM) (Petropoulos et al., 2018). The downside of these options is that they are highly 
invasive and not every patient is suitable for them. Table 1 includes a summary of common tests 





Table 1: Common tests for neuropathy assessment (Akter, 2019) 
Note: CCM: corneal confocal microscopy, NDS: Neuropathy disability score, QST: quantitative sensory testing 
Clinical signs and symptoms do not provide definitive PDN diagnosis but are used as screening tools. 
They are advantageous as they are easy to assess, non-invasive and have good sensitivity for 
identifying neuropathy, as indicated by the gold standard skin biopsy (Themistocleous et al., 2016). 
Some of the most frequently used interview-based self-report screening tools of autonomic, motor 
and sensory impairment are: Douleur Neuropathique en 4 (DN4) (Spallone et al., 2012), the Leeds 
Assessment of Neuropathic Symptoms and Signs (LANSS) (Bennett, 2001), the Neuropathic Pain 
Questionnaire (NPQ) (Bouhassira et al., 2004), the Neuropathic Pain Symptoms Inventory 
(NPSI) (Dyck et al., 1980), the Neurological Symptom Score (NSS) (Meijer et al., 2002), the Diabetic 
Neuropathy Symptom (DNS) score (Krause & Backonja, 2003), and the McGill Pain Questionnaire 
(Melzack, 1987). 
The Toronto Diabetic Neuropathy Expert group (Tesfaye et al., 2010) highlighted that diabetic 
neuropathies’ diagnostic definitions include confirmed neuropathy where there is abnormal nerve 
conduction and a sign or symptom of neuropathy, probable neuropathy in which there should be 
Test Advantage Disadvantage Type of Nerve 
NCS Sensitive, specific, reproducible, easily 
tenderized gold standard technique 
Must be done by trained 
professionals 
Large fibre 
NDS Good predictor for risk for ulceration Does not detect sub-clinical 
large fibre damage 
Large and small fibre 
QST Reproducible, reliable Subjective Large and small fibre 
Skin biopsy Gold standard, reliable, reproducible Invasive procedure, needs 
specialized laboratory service 
Small fibre 
CCM Rapid reproducible, non-invasive, can 
detect small fibre damage and track 
progression 






two or more signs of either decreased/absent ankle reflexes, decreased/absent distal sensation or 
neuropathic symptoms, and possible neuropathy where any of the signs below need to be evident: 
neuropathic sensory symptoms, decreased sensation, decrease ankle reflexes or symptoms of 
symmetric decrease of distal sensation.  
The above-mentioned grading system has been upgraded by Finnerup et al. (2016). The new 
classification is the following: possible neuropathic pain, probable neuropathic pain and definite 
neuropathic pain. Possible neuropathic pain is characterised by the patient’s history of a relevant 
neurological disease and the pain distribution which should be anatomically plausible with the 
possible location of the disease in the nervous system. Probable neuropathic pain requires a clinical 
examination which should confirm partial or complete sensory loss. Definite neuropathic pain 
involves the use of objective tests (e.g. skin biopsy). See Figure 5. 
 




For the evaluation of PDN, it seems like simple clinical tests are most effective, while the most 
beneficiary strategy for early diagnosis is screening programs at frequent intervals. These programs 
may contain the nerve damage and also be cost-efficient (Gylfadottir et al., 2019).  
Clinicians need to consider alternate diagnosis for diabetes-related neuropathy, such as neuropathy 
due to excessive alcohol consumption, musculoskeletal and vascular causes or vitamin B12 
deficiency (Doupis et al., 2009; Hartemann et al., 2011). Nondiabetic neuropathies may be present in 
the DM population and may be manageable through specific treatment options, for example, 
physical therapy, anti-seizure and analgesic medications (Pop-Busui et al., 2016).  
1.9 Prevalence of Painful Diabetic Neuropathy 
Within the DM population, 16-23% are likely to develop neuropathy after 25 years of being 
diagnosed with DM (Daousi et al., 2004; Juster-Switlyk & Smith, 2016), which means approximately 
600,000 people in the UK. Evidence shows that the prevalence is higher for individuals with T2DM 
(18%) than T1DM (6%) (Abbott, Malik, van Ross, Kulkarni, & Boulton, 2011; Hartemann et al., 2011). 
Table 2 includes further information on prevalence. 
PDN differs in pain severity across patients. Cross-sectional studies (Gordois, Scuffham, Shearer, 
Oglesby, & Tobian, 2003; Tölle, Xu, & Sadosky, 2006; Zelman, Brandenburg, & Gore, 2005) 
demonstrate that 25-33% of people with PDN rate their pain as ‘severe’, 47-57% as ‘moderate’ and 
only 15-20% as ‘mild’, based on a common rating scale. The classification of pain categories is 
necessary for research, public policy and clinical evaluation (Zelman, Dukes, Brandenburg, Bostrom, 
& Gore, 2005). The last audit by the British Pain Society (BPS) in 2012, highlighted that neuropathic 
pain is common but under-studied. It is worth mentioning that not everyone with diabetes-related 
neuropathy experiences pain. Painful neuropathies are experienced by approximately 18% of people 




2011; Fedele et al., 1997; Miralles-García, de Pablos-Velasco, Cabrerizo, Pérez, & López-Gómez, 
2010; Shaw, Zimmet, Gries, & Ziegler, 2003; Van Acker et al., 2009). Both types share the same risk 
marker, which is the relationship with obesity, but it is unclear which demographic and social factors 
are associated with each type (Spallone & Greco, 2013).   
Table 2: DM & PDN Prevalence rates (DUK, 2017) 
 
1.10 Impact of Painful Diabetic Neuropathy 
PDN mainly affects the hands, toes, legs, and feet and results in significant interference with 
mobility, balance, mood, social interactions, and overall quality of life. PDN has a great individual 
and socio-economic burden worldwide which seems to grow with higher pain severity (Alleman et 
al., 2015). A recent systematic review (Girach et al., 2019) investigating the quality of life in people 
with painful peripheral neuropathies from various aetiologies, included 66 articles of which 47 were 
concerned with participants with PDN. Results suggested that PDN leads to impaired quality of life 
and reduced physical activity. No further statistical analysis was conducted to reveal the effects of 
this association. This systematic review searched articles from only one database, Pubmed. The 
inclusion of more databases would possibly reveal more eligible articles.  
It appears that PDN may impact on individuals’ mental health through increasing levels of anxiety, 
catastrophic thinking, depression and fears (Geelen et al., 2017; Vileikyte et al., 2009) resulting, in 
Country DM diagnosis Diabetic Neuropathy diagnosis 
UK 3.7 million 16-23% 
China 114.4 million 60% 
India >10 million 8-59% 
USA 30.3 million 60% 
Brazil >10 million 50% 




turn, in poorer outcomes overall, such as pain-related disability (Gore et al., 2005). Most patients 
report that their pain worsens at night, hence causing disturbed sleep (Zelman et al., 2006). 
Severe pain of any kind is strongly associated with depression and anxiety (Campbell, Clauw, & 
Keefe, 2003; McCracken, Spertus, Janeck, Sinclair, & Wetzel, 1999). Existing evidence shows that 
PDN has a significant impact on anxiety, depression and catastrophic thinking (Jain, Jain, Raison, & 
Maletic, 2011; Selvarajah et al., 2014; Sullivan, Lynch, & Clark, 2005). This is consistent with results 
from a meta-analysis of 27 studies investigating depression in people with diabetes, demonstrating a 
significant correlation between depression and diabetes complications (r = 0.25; 95% CI: 0.22-0.28) 
(De Groot, Anderson, Freedland, Clouse, & Lustman, 2001). 
Studies which examined the impact of PDN on sleep found that PDN is associated with disturbed 
sleep, low adequacy and quantity. Gore et al. (2005) conducted a community-based cross-sectional 
survey with 265 participants. Results found a strong association between PDN and sleep disturbance 
d = 1.46 (95% CI: 1.11 - 1.8). While two recent studies also found statistically significant effects 
between PDN and sleep disturbance, d = 1.12 (95% CI: 0.98 - 1.27) (Jacovides et al., 2014) and r = 
0.30 (p<0.001) (Hughes et al., 2016). Taken together, these studies show that sleep is affected by 
PDN. 
PDN also has an impact on occupational functioning. A cross-sectional study (N=1506) reported that 
51.2% of individuals diagnosed with PDN had severe pain and were more likely to be unable to work 
than individuals with diabetes alone (4.74% PDN sample versus 3.49% diabetes alone sample) and to 
self-report as having an overall work impairment (19.77% PDN sample versus 13.75% diabetes alone 
sample) (DiBonaventura, Cappelleri, & Joshi, 2011). The main limitation of this study is that the 
sample was recruited online, so the results cannot be generalised, and the diagnosis is not 





1.11 Management for Painful Diabetic Neuropathy 
Treating PDN is challenging. People with rapid changes in glycaemic control are usually the ones who 
receive a neuropathy diagnosis (Gibbons & Freeman, 2009). As already described, existing evidence 
shows us that glycaemic control, targeted to reduce neuropathy development, and pain 
management, targeted to decrease symptoms severity, are the currently available treatment 
options. However, there is also promising research for effective prevention of the condition. 
A review by Callaghan et al. (2012) found seven studies looking into treatments for T1DM. Two out 
of the seven studies were of high quality and a meta-analysis was possible, involving 1,228 
participants. The review highlights that the only effective ways to treat nerve damage are glucose 
control and pain management. The results showed that patients who adhere properly to glucose 
control had an annualised risk difference of 1.84% for the development of clinically meaningful 
neuropathy. Eight studies for T2DM were used in a meta-analysis, including 6,669 participants. The 
results demonstrated no difference between participants adhering to glycaemic control approaches 
and those who have impaired glucose control. Overall, the review concluded that aggressive 
glycaemic control might be preventive for neuropathy in T1DM more than T2DM and that there is an 
urgent need for disease-modifying therapies, such as good glucose control, and not symptom-
modifying therapies in order to improve patients’ overall quality of life. According to a statement by 
the ADA, glycaemic control can slow down the progression of diabetic neuropathy in people with 
T1DM (78% approximate risk reduction) and with T2DM (5%-9% approximate risk reduction) (Pop-
Busui et al., 2016). There was high-quality evidence in the included studies, which supported the 
benefit of enhanced glucose control in T1DM. Similarly, studies with moderate-quality evidence 
favoured enhanced glucose control in T2DM. However, it is worth noting that there was also high-
quality evidence in adverse events, coming for enhanced glucose control, like weight gain and death 




A systematic review of 174 RCTs (Finnerup, Sindrup, & Jensen, 2010), and a meta-analysis of 229 
RCTs (Finnerup et al., 2015) examined pharmacological treatments for neuropathic pain (not specific 
to PDN). The meta-analysis found that the number needed to treat (NNT; >50% relief) was 6.4 (95% 
CI: 5.2-8.4) for duloxetine, 7.7 (95% CI: 6.5-9.4) for pregabalin, 7.7 (95% CI: 6.5-9.4) for gabapentin, 
and 10.6 (95% CI: 7.4-19.0) for capsaicin patches. The evidence from these studies were of high 
quality for capsaicin patches and low for lidocaine patches. Overall the quality of the included 
studies was moderate. The evidence from these studies concludes that even when patients adhere 
to medication, they still experience pain and severe side effects. Given the existing evidence and 
impact of neuropathy on peoples’ overall quality of life, there is an urgent need for early diagnosis 
and effective treatment (Yorek, Malik, Calcutt, Vinik, & Yagihashi, 2018). 
In the UK when there is a neuropathic pain diagnosis there are several guidelines to be followed 
(NICE, 2013). NICE guidelines (2013) recommend Duloxetine as a first-line drug for PDN or 
Amitriptyline if the patient cannot take Duloxetine for any reasons (i.e. allergy). The guidelines 
recommend as a second-line drug, if the patient is on Duloxetine, to switch to Amitriptyline or 
combine with Pregabalin. If the patient was on Amitriptyline, it is suggested to combine this with 
Pregabalin. If these pain management treatments do not decrease pain, the third-line drug 
recommended is an opioid pain medication called Tramadol. NICE does not advise on the use of 
controlled opioid analgesics. The current guidelines (NICE, 2013) recommend HCPs and clinicians to 
select whichever course of action from Gabapentin, Pregabalin, Duloxetine and Amitriptyline 
according to patients’ needs, reported side effects and personal history. If none of these options 
seems to be effective for pain, NICE suggests that the patient should be referred to speciality pain 
management clinics (see Table 3). 
The most dominant form of treatment for PDN is the pharmacological one, which can lead to side 




effects often leads people to not adhere to medication (Quilici et al., 2009). Meanwhile, the burden 
of neuropathy due to diabetes is significant, including disability and suffering, while medical options 
are limited (McCracken, 2013). The management of PDN requires early diagnosis and a multifactorial 
approach (Javed, Hayat, Menon, Alam, & Malik, 2019). 
Different types of pain usually do not require different types of psychological treatment, since any 
pain has a significant impact on peoples’ lives with or without the specific neuropathy diagnosis 
(McCracken & Thompson, 2011). Evidence shows that most or all aspects of peoples’ lives are 
affected both by neuropathic pain and by chronic pain in general (Closs, Staples, Reid, Bennett, & 
Briggs, 2009; Cohen, Quintner, Nielsen, & Guy, 2011; Duenas, Ojeda, Salazar, Mico, & Failde, 2016). 
Here chronic pain means “persistent or recurrent pain lasting longer than 3 months. p.2” (Treede et 
al., 2015).  
For example, studies which compare people who suffer from neuropathic and non-neuropathic pain 
have found the two groups to be much more similar than expected. Daniel et al. (2008) conducted a 
controlled trial including 57 participants with low-back pain and 49 with postherpetic neuralgia, 
aiming to identify any physical or psychological differences between the two groups. The two groups 
did not appear to be different. Results were statistically significant and suggested that measures of 
pain acceptance, fear, mood and pain were similar for people with low back pain and postherpetic 
neuralgia. These results cannot be generalised to other populations. The findings are specific to 
people with postherpetic neuralgia attending pain clinics. Similarly, another study including people 
with trigeminal neuralgia and orofacial pain, found that the measures were no different on social 
and physical functioning, anxiety, depression and catastrophic thinking (Gustin et al., 2011). 
However, statistical significance was not found and the evidence may be altered if differences in 




Psychological treatments for PDN are limited and at a premature stage. This statement is supported 
by a recent systematic review we conducted (Kioskli, Scott, Winkley, Kylakos, & McCracken, 2019), 
identifying only three psychological treatments applied in the PDN population. After the undertaking 
of this systematic review, two more psychological treatments were identified. All five of them will be 
described and evaluated in detail below. In the case of other long-term conditions, like chronic pain 
in general, many psychological treatments have been applied to these patients, which may also 
prove effective and acceptable to the PDN population. Evidence and examples will be provided in 
Chapter 2. 
Table 3: Medication options for Painful Diabetic Neuropathy according to NICE (2013) 
Note: NNT: Number Needed to Treat 
  
Type of medication/Drug name NNT NICE recommendation 
Tricyclic agents (TCAs)/ Amitriptyline 1.3 First line 
Serotonin-norepinephrine reuptake inhibitors (SNRIs)/ Duloxetine 6.0 First line 
γ-aminobutyric acid (GABA)/ Gabapentin 5.8 First line 
γ-aminobutyric acid (GABA)/ Pregabalin 5.0 First line 





DM is a significant global public health challenge. It creates substantial individual suffering and 
economic burden. Existing research indicates a high prevalence of DM worldwide, which seems to be 
associated with psychosocial, health-care system, and economic factors. All these factors need to be 
taken into consideration to enhance the existing policies, promote the sustainability of healthcare 
and improve the therapeutic options for individuals who suffer from DM. It is clear that DM is a 
crucial health problem which needs to be treated as a priority. 
PDN is a debilitating condition associated with DM, which, is also causing great suffering and 
disability for many people and producing its own significant associated costs worldwide. Existing 
evidence indicates high prevalence of PDN since approximately 30% of people with diabetes will 
develop this condition. Given the multifaceted nature of this problem, and paucity of research 
exploring psychological factors and treatment approaches, further research is necessary. People 
with PDN also deserve to be treated as a priority by both clinicians and healthcare systems. The next 
chapter will focus on existing behavioural models and psychological approaches to chronic pain.  
1.12 Thesis Aims and Objectives   
The overarching purpose of this thesis is to provide a better understanding of the psychosocial 
factors associated with people with PDN and assess the potential feasibility and acceptability of an 
Acceptance and Commitment Therapy-based psychological intervention in the same population. 
Research question: Is the Psychological Flexibility model and Acceptance and Commitment Therapy 
treatment approach appropriate for people with PDN? 




1. To identify and evaluate the evidence of psychosocial factors and available psychological treatments 
associated with people with PDN. 
2. To examine the relevance of the Psychological Flexibility model in a sample of people with PDN in 
the UK. 
3. To explore the feasibility of an Acceptance and Commitment based treatment for people with PDN. 
1.13 Thesis Layout and Chapter Format 
This thesis incorporates publications arising during the PhD study period. The included studies are a 
systematic review, a cross-sectional survey and a feasibility study. With regard to timeline each 
study was conducted separately and not simultaneously. The results from the systematic review fed 
into the survey, by identifying the lack of studied psychosocial factors, and the results from both the 
systematic review and the survey guided, the feasibility study by highlighting the lack of 
psychological interventions and PF factors for the PDN population. This set of studies is considered 
an acceptable way to inform an intervention in the chronic pain literature. 
The studies in chapters 3, 4 and 5 have been published and each of these chapters has an expanded 
unpublished format and discussion to allow integration of the chapters into a larger narrative and to 
highlight the links between studies. The appendices for these chapters can be found at the end of 
the thesis (see Appendix Q). Chapter 6 summarises how each of the chapters has addressed the 
thesis aims, outlines the strengths and limitations of the programme of work, integrates the findings 




Chapter 2: Psychological Models and Treatments for Chronic Pain 
2.1 Chapter Overview 
This chapter will present conceptual and theoretical models of pain. These will include the 
biomedical model of pain and its historical background, and then psychological models, including the 
operant, the cognitive-behavioural, and the fear-avoidance models. Within the cognitive behavioural 
model, a detailed description of contextual cognitive behavioural approaches with a focus on 
Acceptance Commitment Therapy (ACT) will be provided. A literature review of psychological 
interventions for people with chronic pain, in general, is presented. Finally, this chapter includes 
evidence for the psychological treatment of Painful Diabetic Neuropathy (PDN) and highlights gaps in 
the literature.  
2.2 Biomedical Model of Pain, and its Historical Perspective  
Pain is a common human experience and has been defined by the International Association for the 
Study of Pain (IASP) as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage or described in terms of such damage (p.2)” (Rolf-Detlef Treede, 2018).  
Another, proposed definition, given by Williams and Craig, (2016) is: “pain is a distressing experience 
associated with actual or potential tissue damage with sensory, emotional, cognitive, and social 
components (p.2420)”. 
One key distinction is that pain can be acute or chronic. Acute pain is caused by an injury or as a 
result of a health condition and typically involves the musculoskeletal or sympathetic nervous 
system. Chronic pain lasts for three months or longer, which is generally regarded as past the normal 
duration of healing if an injury has occurred (Harvey, 1995). It may be musculoskeletal, sympathetic, 




In order to present a historical perspective on pain, selected key events will be discussed in this 
section. Starting in the 3rd century, Aelius or Claudius Galenus (better known simply as Galen, 129-
210 AD), a Greek philosopher, surgeon and physician, located in the Roman Empire, focused his 
work on the human soul and spirit. His research in medicine, anatomy, and philosophy was 
innovative for the time and had a substantial impact on the study of pain perception and pathology. 
Galen was researching the pain experience and human body and identified, via dissection, that the 
circulatory system consists of two different systems. He reported that in the first system the liver 
produced venous blood which was then distributed throughout the whole body. Within the second 
system, he suggested that arterial blood was produced by the heart and once again was spread 
throughout the body. He also described multiple blood vessels which he referred to as ‘mirabile’ in 
the carotid sinus (Aird, 2011). His achievements within the field of medicine and anatomy led Galen 
to become interested in combining medicine and anatomy with philosophy and treat it as a 
multidisciplinary subject, which was innovative for the time. Based on his understanding of the 
circulatory system he developed a personality theory and proposed that mental health was 
influenced by physiology. After his death, his theories on circulation and personality, described 
above, were proven to be flawed and were vastly criticised (Gill, 2007). This fact revealed the urgent 
need for the development of a theoretical evidence-based model for science to progress. 
Perhaps the next significant shift in history was when physicians started to view the body as a 
machine which moves continuously and consists of different parts. The earliest version of modern 
physiology was introduced by the French philosopher, mathematician and scientist, René Descartes 
(1596-1650 AD). His perspectives on physiology predominated within the medical professions across 
North America and Western Europe. 
Descartes viewed pain in mechanistic terms and had a dualistic view of the mind-body interaction.  




producing sensations corresponding to the magnitude of the physical motion of the spirits. 
Accordingly, Descartes viewed pain intensity as directly influenced by the degree of external 
stimulation or injury. This was an early example and a model of pain whereby pain was considered 
to directly correspond to the magnitude of injury or tissue damage. He depicted pain with an image 
of a boy who puts his foot directly in the fire and illustrating a string and a bell within his body 
(image from L’Homme see Figure 6). This represented a movement or touch starting from where the 
peripheral nerves end and then proceed to the brain, where it resulted in stimulation of the soul of 
the individual (Bonica, 1991; Procacci & Maresca, 1994).  
 
Figure 6: René Descartes, L`Homme, (1632) 
Descartes made another innovative contribution to the field of pain research by introducing the 
term ‘central pain’ to explain phantom limb pain. He used a female who had her arm and forearm 
amputated as an example. Descartes pictured active nerves going through her arm and forearm, 
which are capable to result into identical sensations, as if the woman would still have these parts 
(Rey, 1993). 
In the 19th century, the concept of pain sensation was further specified, due to the evolution of 




Specific Sensory Energies” which highlighted that the quality of sensations depends on the 
stimulated pathways and sensory organs (Kull, 1999; Müller, 1837). In 1858 there was a change in 
thinking with the development of “Specificity Theory” by Moritz Schiff (1823-1896). This theory 
stated that pain and touch are separate concepts with different peripheral and nervous system 
pathways (Schiff, 1859). In opposition to this theory in 1874 Wilhelm H. Erb (1840-1921), developed 
“Pattern Theory”, which proposed that nerve stimulation, causing pain, is initiated by non-specific 
receptors. This means that any sensory stimuli may cause pain with the appropriate intensity. 
The formal application of psychology to pain was introduced in the 20th century with the term 
‘psychogenic pain’, which has a negative connotation and is defined as “pain which is independent of 
peripheral stimulation or of damage to the nervous system and due to emotional factors, or else 
pain in which any peripheral change (e.g. muscle tension) is a consequence of emotional factors 
p.170” (Merskey & Spear, 1967). Essentially, emotional experiences were linked to pain experiences 
(Binswanger, 1904; Titchener, 1908). Later, the definition and contrast of nociception and pain 
became evident where nociception was defined as “a physical reaction to a painful stimulus” and 
pain as “a subjective sensorial or emotional event” (Brooks & Tracey, 2005). 
It is also worth noting that theories which focus on peripheral pathophysiology, are ‘bottom-up’ 
models to make sense of pain and are stimulus-driven influenced by physical factors. Subsequent 
theories included ‘top-down processes’, which are subject-driven and influenced by cognitive factors 
(Ossipov, Dussor, & Porreca, 2010). 
In 1965 Melzack and Wall, made a breakthrough with the “Gate-Control-Theory” to describe 
mechanisms of pain. In this theory, mechanisms included emotional experiences and did not 
dichotomise pain as emotional or physical (Figure 7). This theory was proposed to update and 
extend all the existing theories of pain and was mainly influenced by Pattern Theory and Specificity 




incorporated biopsychosocial aspects of pain and paved the way for psychosocial treatments in pain 
management (Melzack, 1969, 1991).  
 
Figure 7: Gate Control Theory (Melzack & Wall, 1965) 
Melzack and Wall proposed that noxious stimulation from the peripheral nervous system, allows 
nerve fibres to transfer information to the following destinations in the spinal cord: the dorsal 
column that projects towards the brain, the cells of the substantia gelatinosa and the central 
transmission cells in the dorsal horn. The interaction of these systems determines pain (Figure 8). 
The source stimulation comes from the following three places: central, other peripheral sites, and 
the “pain” location. Small nerve fibres represent 70-90% of all peripheral nerve fibres and are the 
first fibres to be damaged in diabetes (Smith & Singleton, 2008). While large nerve fibres are thicker 





Figure 8: Physiology of Gate Control Theory (Cho & Min, 2015; Melzack & Wall, 1965) 
Melzack (1990) extended the Gate Control Theory to the Neuromatrix theory of pain, which 
identifies brain regions involved in modulating pain. More specifically, the Neuromatrix theory 
(Figure 9) proposes that the perception of a painful stimulus results in the brain’s active generation 
of subjective experiences, via a chain of neurons called the Neuromatrix (Melzack, 1990). The 
‘neurosignature’ underpins the ‘neuromatrix’, which explains that psychological experiences, such as 
affective states and pain, and the genetic make-up, such as sensory and cognitive experiences, are 
unique to each person (Merskey, 1991). Even though both of the ‘neurosignature’ and ‘neuromatrix’ 
seem to be based on genetical factors, new experiences and learning can come to the equation and 






Figure 9: The body-self Neuromatrix theory (Melzack, 1999) 
Following on from these theories, in the late 1960s, Fordyce presented a complete behavioural 
model of pain, the operant model, perhaps the first well developed modern-day psychological 
model. In 1983, Woolf introduced the central sensitization theory, an important theory highlighting 
that some pain conditions, even though persistent, have not been caused by tissue damage or 
ongoing injury (Moseley & Butler, 2015). Central sensitization is when the nervous system stays in a 
constant active state, and pain experience is present regardless of the original condition (Woolf, 
2011).  
Furthermore, it has an additive effect to continuously widespread pain and sensitivity to stimulation. 
It also results in poor sleep, emotional distress, anxiety and irritability (Mao & Kitz, 2017). According 
to the Institute for Chronic Pain (2015), central sensitization increases the reactivity of the nervous 
system, and leads to exacerbated pain. 
Today, the main frameworks used by HCPs include the operant approach (Fordyce, 1976, 1982; 
Fordyce et al., 1973; Fordyce, Fowler, Lehmann, & Delateur, 1968), the cognitive behavioural 
approach, which is typically regarded as incorporating the operant (Turk, Meichenbaum, & Genest, 




incorporate, or are based on elements, of the operant or cognitive behavioural approaches and this 
includes what are called “contextual cognitive behavioural” approaches. 
2.3 The Operant Approach 
The key defining feature of the operant approach was its focus on pain behaviour and pain-related 
disability (Fordyce et al., 1968; Fordyce, 1976). It emphasized the observable phenomena of pain, 
including avoidance, such actions as bracing and guarding, seeking help, moaning, complaining, 
coming from pain sufferers and reflecting for observers the presence of pain. 
This framework incorporates operant conditioning principles of reinforcement described by BF 
Skinner, including social and non-social environmental factors in two ways. Firstly, through positive 
reinforcement; when the patient indicates the presence of pain, observers around them may react 
to the given signals and provide consolation or medication. These reactions may, in turn, reinforce 
the pain behaviour and increase its frequency. Secondly, Fordyce (1982) supported that through 
negative reinforcement or “avoidance learning”, which produces “behaviours, which serve either to 
escape a noxious stimulus, or to avoid or postpone a noxious stimulus (p. 319)”. This model 
incorporates the use of behavioural or learning principles and applies social factors to pain 
management. Therefore, Fordyce and colleagues (1968) used the operant principles to build 
innovative pain management programmes. 
The operant approach appears to promote well-being, positive coping behaviour and to reduce pain 
behaviour. As applied to chronic pain, its primary proposed mechanism of action is the modification 
of environmental contingencies related to pain behaviour and “well” behaviour. Operant 
behavioural treatment involves the identification of the manipulatable events which are associated 




behaviours and the increase in events that encourage effective, healthy, well behaviour (Roberts, 
1981). 
Furthermore, this approach is supported by evidence. Outcome studies from treatments that include 
operant principles have shown significant positive outcomes, although sample sizes have typically 
been small. An early treatment study of occupational and physical therapy, including 3 participants, 
reported a decrease of medication consumption and increase of physical activity after participants 
finished the pain management program (Fordyce et al., 1968). Another treatment study, 
implementing an operant conditioning program, with 36 participants, also reported a decrease in 
medication consumption and an increase in physical activity, for all participants both at post-
treatment and follow-up (Fordyce et al., 1973).  
Cairns and Pasino (1977), conducted an RCT implementing operant therapy to 9 participants 
suffering from chronic lower back pain. They reported that the experimental group increased their 
physical activity, compared to the control group. Roberts and Reinhardt (1980), conducted a trial 
including 26 participants in the experimental group, compared to a similar number rejected from 
participating in treatment, and reported that 77% of participants who completed an eight-week pain 
management programme eliminated their medication intake for one to eight years. Regardless of 
the importance of this study, most participants were lost in follow up making the results of limited 
clinical significance.  
Turner, Clancy, McQuade, and Cardenas (1990), also conducted a trial with 96 participants, with 
chronic low back pain, who were randomised into the following groups: behavioural therapy in 
addition to aerobic exercise, solely aerobic exercise, solely behavioural therapy, and control group. 
This study concluded that the group receiving behavioural therapy in addition to aerobic exercise 




were not conducted making it ambiguous if the clinically significant effects were because of the 
received treatment. 
There are potential limitations typically associated with the operant approach. First, the operant 
approach addresses the social context in treatment. However, the extent to which results from this 
context generalise and transfer to the patient’s everyday social environment, including within their 
family relations, is unclear. For example, even if the treatment group alters contingencies during 
treatment, such as by praising helpful behaviours and ignoring disabling behaviours, the patient’s 
spouse/family may continue to reinforce disability behaviours when they return home, such as 
offering too much assistance. Another major criticism of the operant approach is that it does not 
address the person’s experience of pain, but only pain behaviours, and thus does not address 
thoughts and feelings about pain that contribute to distress and disability (Keefe & Gil, 1986). 
Furthermore, there is a remarkable lack of recent, high-quality RCTs to support the effectiveness of 
the approach (Williams, Eccleston, & Morley, 2012).  
However, the operant approach did not aim to achieve pain reduction, or to necessarily focus on 
change in thoughts and feelings, but targeted disability reduction, nonetheless this criticism remains 
valid to a degree. Certainly, on the positive side, it is recognised that the operant approach 
highlighted the importance of applying psychological interventions for chronic pain treatment. 
2.4 The Cognitive Behavioural Approach  
2.4.1 Description of the Fear-Avoidance model 
The fear-avoidance (FA) model currently plays a central role in the cognitive behavioural approaches 
(Figure 10). It appears to be one of the most important developments within this wider set of 
approaches (Philips, 1987; Vlaeyen & Linton, 2000). The FA model is a set of cognitive, emotional, 




Lethem, Slade, Troup, & Bentley, 1983; Turk et al., 1983; Philips, 1987; Waddell, Newton, 
Henderson, Sommerville, & Main, 1993). It is worth noting that ‘pain catastrophizing’, “an 
exaggerated negative mental set brought to bear during actual or anticipated painful experience 
(p.524),” (Sullivan et al., 2001) is a crucial cognitive appraisal that contributes to pain-related fear 
and avoidance in this model. At the core of the model is the way people perceive pain, 
catastrophically or not, and how this may lead to two routes: one in which the interpretation of pain 
is non-threatening and so individuals continue to pursue physical activities and usual daily activities, 
which in extension can contribute to their recovery; or the other in which pain is interpreted as 
threatening, a catastrophe. The latter, can potentially lead to pain-related fear and avoidance of 
daily activities, resulting in a worsening of their condition (Vlaeyen & Linton, 2000).  
 
Figure 10: Fear-Avoidance Model (Vlaeyen & Linton, 2000) 
Numerous studies have explored potential associations between the individual components in the 
FA model. Components examined include: catastrophic thinking; pain severity; attention to pain; 
vulnerability; disability; disuse; and avoidance. A literature review by Leeuw et al. (2007a), examined 
the existing scientific evidence for these components and their relationships. Results from the 
included studies suggested that catastrophising and excessive attention are associated with more 




2007b; Peters, Vlaeyen, & Weber, 2005; Sullivan et al., 2005). Also, pain-related fear is correlated 
with pain, disability and avoidance (Boersma & Linton, 2005b; Goubert, Crombez, & Lysens, 2005; 
Turner, Mancl, & Aaron, 2004). 
A more recent systematic review by Wertli et al. (2014), examined fear-avoidance beliefs (FAB) in 
patients with low-back pain and how these beliefs impact treatment efficacy. This review included 
18 RCTs, and the examined treatments were: nonsteroidal anti-inflammatory drug versus placebo, 
graded activity versus usual care, physical therapy versus muscle conditioning on training devices 
versus low-impact aerobics, exercise versus usual care and multidisciplinary rehabilitation. Studies 
were of moderate quality according to the Grading of Recommendations, Assessment, Development 
and Evaluations (GRADE) tool. Results indicated that for patients experiencing low-back pain for up 
to six months FABs were associated with worse outcomes for pain and disability, while decreased 
FABs were correlated with decreased pain and disability at follow-up. This systematic review 
concluded that FABs are associated with reduced treatment efficacy, but patients with high FABs are 
more likely to improve if these are addressed. 
Even though the FA model has been a successful model for psychological treatment development 
and disability prevention, it also has several limitations (De Jong et al., 2005; Turk & Wilson, 2010). 
To begin with, this model is not broad enough, since evidence does not consistently support the 
proposed sequential process relationships within the FA model. In fact, many people experience 
chronic pain and disability in the absence of significant fear, and the model does not account for 
these cases (Wideman et al., 2013). The model does not recognise that patients are likely to have 
different levels of pain intensity and pain-related disability of different durations. Also, the FA model 
does not take into consideration other psychosocial factors which may contribute to pain and 
disability, such as anxiety not associated with pain, shame, guilt, or embarrassment (Pincus, Smeets, 




context and/or positive processes of therapeutic change and can result in focusing on a narrow set 
of treatment methods (Crombez, Eccleston, Van Damme, Vlaeyen, & Karoly, 2012; Turk & Wilson, 
2010).  
2.4.2 Description of the Cognitive Behavioural Approach 
Turk and colleagues (1983), expanded Fordyce’s behavioural theory of pain with the development of 
the cognitive behavioural approach to chronic pain. Cognitive behavioural approaches can be 
applied in many different ways, but the main idea behind them is essentially the same, that 
behaviour is regulated by a person’s interpretation of the world. This approach was inspired by the 
development of cognitive behavioural therapy (CBT) in the 1960s, which is focused on examining the 
interplay between thoughts, emotions and behaviours (Beck, 1964). 
In general, the goals of conventional forms of CBT are to increase adaptive beliefs and positive 
automatic thoughts. Further develop skills which will help with the management of negative feelings 
and emotions associated with pain, infuse a sense of hope and achieve behaviour change via 
conducting behavioural experiments, such as graded activity increase (Turk et al., 1983). Essentially, 
it aims to change the individual’s focus and to establish reconceptualisation of the pain as non-
threatening and manageable by one’s own efforts. CBT uses specific learning techniques. Individuals 
are trained to become aware that their pain condition may worsen with stress, negative emotions, 
and decreased social support (Turk & Winter, 2006). They are encouraged to control their fear and 
avoidance, which are mostly associated with pain through various techniques such as graded 
exposure, and to control depression through behavioural activation and cognitive restructuring. CBT 
employs other techniques such as mindfulness, development of communication and problem-solving 
skills, and coping strategies (Keefe, Jacobs, & Edwards, 1997). These techniques aim to help 
individuals to take charge of their condition, manage the physical challenges and gradually return to 




completion of homework assignments which encourage active learning and integration of changes 
into daily life (Turk, 2003). During treatment, future challenges are anticipated and planned for, and 
particular responses are adopted to prevent drop-out or relapse and encourage better long-term 
outcomes (Turk et al., 2008). As a result, individuals are encouraged to develop coping mechanisms 
and react appropriately to future setbacks. 
There have been a number of systematic and literature reviews of studies of psychological 
interventions for people with chronic pain (i.e. Eccleston, Williams, & Morley, 2009; Morley, 
Eccleston, & Williams, 1999), and they all support the applicability and potential effectiveness of 
cognitive behavioural approaches to improve wellbeing and reduce pain. The most recent update of 
a systematic review (Williams et al., 2012), focused on the effectiveness of psychological 
interventions for people who suffer from chronic pain in general (excluding headaches). This review 
identified and included 35 RCTs overall in a meta-analysis. Results comparing psychological therapies 
with treatment as usual, revealed small to medium effects post-treatment, from -0.05 (95% CI: -0.19 
to 0.09) to -0.19 (95% CI: -0.33 to -0.05), and almost none at follow up when the treatment group 
was compared to an active control group, from -0.15 (95% CI: -0.28 to -0.02) to 0.07 (95% CI: -0.18 to 
0.05). While this study showed the potential effectiveness of cognitive behavioural approaches the 
effect sizes demonstrated were modest. 
2.5 The Contextual Cognitive Behavioural Approaches  
2.5.1 Functional Contextualism: Philosophical Underpinnings of Acceptance and Commitment 
Therapy 
The first person to develop the term “contextual cognitive behavioural” as a description of a kind of 
CBT was Steven C. Hayes (Hayes, 1987). Hayes appears to have both established the term ‘clinical 




analysis of language and cognition (Zettle, Hayes, Barnes-Holmes, & Biglan, 2016). Hayes used 
relational frame theory (RFT) to develop ACT as a form of psychotherapy (described in subsequent 
sections). RFT addresses how behaviour is influenced by verbal-symbolic processes. This theory 
proposes that the same processes that are involved in typical language development may also 
facilitate the emergence of human suffering. This is because verbal processes can relate any 
situation to any other situation, including pain and avoidance. Once this has happened the functions 
connected to those situations are then transferred across to related situations, so that pain, 
avoidance and suffering can appear anywhere (Hayes, Barnes-Holmes, & Roche, 2001).  
The philosophical assumption guiding ACT is ‘Functional Contextualism’ (Biglan & Hayes, 1996). It 
importantly focuses not only on predicting and explaining behaviour, helpful and not, but also on 
changing behaviour (Hayes, 1993a). Functional Contextualism acts as a philosophical basis for some 
wings of present-day behaviour analysis, as "the development of an organized system of empirically-
based verbal concepts and rules that allow behavioural phenomena to be predicted and influenced 
with precision, scope and depth (pp. 50-51)" (Biglan & Hayes, 1996). Functional Contextualism is 
underpinned by two assumptions, with important implications for research and practice. These 
include subject matter, “the act in context” and an epistemological assumption, “pragmatic truth 
criterion” (Hayes, Strosahl, & Wilson, 1999). Briefly, “the act in context” refers to the holistic 
contextual view of behaviour as the activity of the whole organism, interacting in and with a context 
that includes feelings, thoughts, and body sensations and that is considered functionally (Hayes, 
1987). The “pragmatic truth criterion” as defined by Hayes et al. (1999) is “what is true is what works 
(p.133)” and refers to how knowledge generation is based on demonstration of the successful 




2.5.2 Psychological Flexibility Model 
Psychological Flexibility (PF) is the contextual behavioural model of wellbeing and behavioural 
performance characterised by the ability to “contact the moment as a conscious human being more 
fully as it is, not as what the mind says it is, and based on what the situation affords, persisting or 
changing in behaviour in the service of chosen values (p.187)” (Hayes, Levin, Plumb-Vilardaga, 
Villatte, & Pistorello, 2013). PF is a psychological model including six main processes: acceptance, 
cognitive defusion, present-moment awareness, self-as-context, values-based and committed action 
(Figure 11). The processes have been characterised more recently as behaviour that is “open, aware, 
and engaged (p.160)” (Hayes, Villatte, Levin, & Hildebrandt, 2011).  
Acceptance is the first process of ACT, which aims to enhance the willingness of individuals to 
become exposed to unpleasant experiences. Cognitive defusion targets the separation between an 
individual’s thoughts and events without altering cognitive content, which means changing the 
interaction with our thoughts to create helpful functions. Another process promoted by ACT is being 
present, meaning to have on-going awareness of current events in a non-judgemental way. Self-as-
context is the process of observing your own experiences without letting them affect you. Values-
based actions reflect an individual’s capacity to connect with qualities they hold as important, and to 
engage in actions that are personally meaningful. Lastly, committed action is the skill which 
empowers the individual to pursue the values-based actions, persist with them in the face of 
challenges, and to change goals when they are not workable. These processes are considered to 
interact and overlap in their influence on behaviour (Hayes et al., 1999; Hayes et al., 2011). Table 4 







Table 4: Application of PF components in the PDN experience 
 
Each process of psychological flexibility has a corresponding process of psychological inflexibility. PF 
processes also show how inflexibility towards pain experiences may contribute to pain-related 
distress and disability (McCracken & Vowles, 2014). Not all components of PF have been studied to 
the same extent in the literature. For example, committed action and self-as-context are the least 
studied, even though existing data reveals its association with physical and psychological functioning 
and well-being (McCracken, 2013; McCracken et al., 2015).  
Psychological Flexibility Components PF Components Examples in PDN 
Acceptance 
 
‘I will try to exercise even if my feet will hurt while doing it.’ 
Cognitive defusion 
 
‘My stinging pain is a bodily sensation which should not stop me from doing my 
chores.’ 
Contact with the present moment 
 
‘Amputation is not a possibility at the moment, thinking that it might be in the 




‘I notice that my hands are in pain when a piece of cloth is touching them, 
however, I realise that I am more than this experience, or I am able to separate 
myself from this.’ 
Values-based actions 
 
‘I will do what matters to me despite my burning pain.’ 
Committed action 
 
‘When the numbing in my hands worsens, while I am in the middle of an action 
that matters to me, I will either change my approach or take small steps in the 





Figure 11: Acceptance and Commitment Therapy Model (Hayes, Luoma, Bond, Masuda, & Lillis, 
2006) 
2.5.3 Rule-Governed Behaviour and Relational Frame Theory 
Rule-governed behaviour is an example of verbal behaviour. It refers to a specific behaviour arising 
from instruction-based learning or other verbal-learning patterns and procedures (Skinner, 1974). 
This specific behaviour is likely to become insensitive and persistent even when this is not helpful. 
History of verbal instructions given either by another individual, or by yourself, or by other learning 
methods (i.e. book, internet) is the base of a behaviour for following a specific set of rules 
(McCracken, 2005). An example of a rule which is followed is: If I have pain, that must mean I am 
damaging my body. Pain is therefore harmful. I must not move when I am in pain. This rule may 
work in the context of an acute injury. However, following this rule is impervious to the context of 




Rule-governed behaviour (Hayes, 1987) and Relational Frame Theory (RFT; Hayes et al., 2001), are 
basic science theories associated with PF. PF processes are not technical definitions but are rather so 
called “mid-level” terms, which are easily applied by researchers and practicing psychologists 
(Williams & Craig, 2016). These two approaches are based on behavioural analysis and have acted as 
a philosophical base for ACT.  
At the core of RFT is the term ‘verbal behaviour’ (Skinner, 1957). Verbal behaviour is contextually 
determined relational responding, where the “speaker” and “listener” behaviours are verbal. The 
most frequently used definition of verbal behaviour is “(a) a response is emitted by an individual; (b) 
the critical consequence is provided by the behaviour of another individual (the listener); (c) the 
listener's behaviour is explicitly conditioned to respond to the stimuli produced by the first 
individual; and (d) the explicit conditioning of the listener involves conditioning to arbitrary stimulus 
relations, probably conditioning to relational classes, for example, equivalence classes. (p.206)” 
(Chase & Danforth, 1991). Overall, relational framing is a core process by which rule-following and 
derived relational responding come to facilitate behavioural inflexibility and rigidity. In the case of 
PDN, pain responses and feelings could derive that pain response in novel contexts, by framing the 
new context as similar to or the same as a previous one associated with pain. Thus, for people with 
PDN, pain responses can transfer widely and lead to PF or rigid behaviours that do not help a person 
function or adapt well to the condition in many different life contexts. 
2.5.4 ACT Treatment Techniques and Process 
ACT is a form of psychotherapy based on the PF model (Hayes et al., 1999; Hayes et al., 2011). The 
ultimate goal of ACT is to enhance PF. According to the American Psychological Association, Society 
of Clinical Psychology (Division 12), ACT can be applied to people suffering from psychosis, 
depression, obsessive compulsory disorder (OCD), mixed anxiety and chronic pain, and has modest 




chronic pain when allocated to a psychological intervention (i.e. ACT, CBT) are guided through the 
following broad technique categories: acceptance, mindfulness and commitment. They are generally 
advised to set goals based on their values, and then act upon these goals even if that means dealing 
with unpleasant experiences. See Table 5 for more information on distinctions between traditional 
CBT and ACT treatment techniques. 
Table 5: Treatment techniques of CBT and ACT 
 
ACT does not have a single endorsed or approved protocol which may be used as a manual for 
psychological therapy (Yang & McCracken, 2014). However, there are several treatment manuals 
available that can guide clinicians (i.e. Hayes et al., 2011; Westrup & Wright, 2017). These treatment 
manuals give a detailed description of the role of the therapist, who is focused on the individualised 
use of metaphors and experiential exercises (Hayes et al., 1999) to achieve behaviour change and 
Comparison of traditional CBT techniques with ACT techniques 
Cognitive Behavioural Therapy (CBT) Acceptance and Commitment Therapy (ACT) 
Pain education Mindfulness strategies 
Cognitive restructuring Positive reinforcement 
Graded exposure Use of metaphors 
Cognitive skills training Use of paradox 
Relaxation Experiential exercises 
Pacing/activity management Identifying values 
Problem solving/goal setting Enhance PF 
Communication skills training Therapeutic alliance and stance 
Physical exercise Values-based goals setting 
Key Shifts of Emphasis in CBT 
Cognitive Behavioural Therapy (CBT) Acceptance and Commitment Therapy (ACT) 






enhance the PF of the individual (Luoma, Hayes, & Walser, 2007). The therapist plays a crucial role 
which is to encourage the individual to be goal-oriented, open, aware and engaged according to 
ACT’s components. More specifically, the therapist should conceptualise momentary experiences 
(i.e. when someone is experiencing pain), remain sensitive to them and use these experiences to 
promote behaviour change to the individual. After the implementation of appropriate actions (i.e. 
set goals, use of metaphors) to promote PF, the therapist needs to assess the impact of these 
actions, and either persist with them or alter them according to the individual’s needs. Some 
worksheet examples which are used during ACT therapy can be found in Appendix P. 
ACT is differentiated from traditional didactic approaches, such as verbal persuasion or solely 
providing information. In a literature review by Yu and McCracken (2016), ACT-based interventions 
were described as focused on the increase of values-based and goal-oriented actions. This may be 
achieved through ‘experiential methods’ targeted at changing peoples’ behaviour with exposure-
based methods. These methods are usually metaphors, mindfulness exercises and role-play, among 
others.  
2.5.5 Efficacy of the Contextual Cognitive Behavioural Approaches  
Contextual approaches, which are more recent than behavioural therapy and CBT, are called ‘third 
generation approaches’ or ‘third wave CBT’ (Hayes, 2004). Some of these are based on Functional 
Contextualism, and others predate the development of Functional Contextualism. A feature that 
most of these contextual approaches have in common is that they do not intend to directly change 
feelings, thoughts or emotions but alter “the individual’s relation to” these psychological events 
(Teasdale, 2003). There has been a rapid shift towards the development of contextual psychological 
treatments in the last 10 years (Harvey & Gumport, 2015). 
Some examples of contextual cognitive behavioural approaches include mindfulness, which is based 




way (Kabat-Zinn, 1990); mindfulness-based cognitive therapy (MBCT), which is a psychotherapy 
approach combining mindfulness and CBT (Segal, Williams, & Teasdale, 2001); dialectical behaviour 
therapy (DBT) which supports the idea that some individuals react in a more intense way when they 
find themselves in an emotional situation (Linehan, 1993); and ACT (Hayes et al., 2006), which was 
discussed in the previous section. 
There is a growing body of evidence supporting the efficacy of contextual-based interventions for 
people with chronic pain. A recent systematic review investigating the impact of internet delivered 
ACT (iACT) on people with anxiety conditions, suggested that 18 out of the 20 included studies found 
significant improvements after iACT delivery, with within-group effect sizes ranging from 0.32-2.14 
(pre to post) (Kelson, Rollin, Ridout, & Campbell, 2019). Another systematic review examining 
whether ACT is helpful for people with cancer found that individuals who received ACT had great 
improvements in quality of life, increased PF and improved mental state (Gonzalez-Fernandez & 
Fernandez-Rodriguez, 2018). In a systematic review of 9 controlled and 13 uncontrolled studies by 
Veehof, Oskam, Schreurs, and Bohlmeijer, (2011), 19 contextual, “acceptance-based,” interventions 
for people with chronic pain were identified and included, yielding statistically significant moderate 
effect sizes (SMD= 0.47-0.69) for depression, anxiety, wellbeing, quality of life and pain. Results from 
this study suggested that contextual interventions are as good as traditional CBT. This systematic 
review was updated recently (Veehof, Trompetter, Bohlmeijer, & Schreurs, 2016), this time including 
25 RCTs of ACT and mindfulness approaches. Significant and small effect sizes were reported for 
disability (SMD=0.40, 95% CI: 0.01-0.79), pain intensity (SMD=0.24, 95% CI: 0.06- 0.42), and 
depression (SMD=0.43, 95% CI: 0.18-0.68). Moderate effect sizes were reported at post-treatment, 
for anxiety (SMD= 0.51, 95% CI: 0.10-0.92) and pain interference (SMD= 0.62, 95% CI: 0.21-1.03). 
Overall results indicated improvements in all outcomes at follow-up with small to large effect sizes 




2.5.6 Challenges of Acceptance and Commitment Therapy and Future Considerations 
ACT faces several challenges. These mainly include the question about whether it is truly an 
innovative or distinct treatment, if it is better than CBT in any way (Hoffman & Asmundson, 2008; 
Öst, 2008), and whether it is evidence-based and empirically supported (Öst, 2008, 2014). 
Firstly, researchers and therapists who focus on ACT do not support the suggestion that it is superior 
to CBT. On the contrary, it is recognised that ACT has been influenced by other evidence-based 
therapies, like CBT, and this is the reason why it includes components such as behavioural activation, 
goal-setting, exposure, and skills training (Hayes et al., 1999). Even so, there are important 
differences from other forms of CBT, in terms of the underlying philosophical assumptions and 
treatment processes.  
It is acknowledged that CBT is a recognised, established and evidence-based form of psychotherapy, 
while ACT is still relatively new with emerging, and therefore less, evidence to support its 
effectiveness (Yang & McCracken, 2014). However, the evidence is growing, for example in 2018, 50 
RCTs were published which applied ACT to a range of conditions showing modest to strong evidence 
of its effectiveness. In addition, the American Psychological Association (APA, 2006) considers ACT as 
an evidence-based approach for chronic pain. 
Future studies comparing ACT and CBT should consider examining the differences in key treatment 
processes, or perhaps seek some other method for progressing the field rather than head to head 
trials focused on clinical outcomes.  
2.6 Online Treatment Delivery for Chronic Pain 
In this modern era, the use of the internet has increased rapidly. Using the internet for delivering 
psychological interventions is growing in order to address issues of affordability and accessibility 




online CBT treatment programs (Eccleston et al., 2014; Ruehlman, Karoly, & Enders, 2012; Scott, 
Chilcot, Guildford, Daly-Eichenhardt, & McCracken, 2018), interactive voice response (IVR) (Liberman 
& Naylor, 2012), and videoconferencing (Yuen et al., 2019). 
Online CBT-based treatment trials for chronic pain (Carpenter, Stoner, Mundt, & Stoelb, 2012; Dear 
et al., 2013; Schultz et al., 2018; Scott et al., 2018b) have been shown to be as effective as face to 
face therapy (Eccleston et al., 2014; Hedman, Ljótsson, & Lindefors, 2012), where main outcomes 
are designed to improve quality of life and functioning. Systematic reviews investigating the 
effectiveness and acceptability of online treatments yield small to moderate statistically significant 
effect sizes, while improvement in some factors, like anxiety, is inconsistent across the literature 
(Bender, Radhakrishnan, Diorio, Englesakis, & Jadad, 2011; Buhrman et al., 2013; Eccleston et al., 
2014; Garg, Garg, Turin, & Chowdhury, 2016; Macea, Gajos, Daglia-Calil, & Fregni, 2010; Spijkerman, 
Pots, & Bohlmeijer, 2016). Online treatments differ vastly in content, duration, outcomes and 
retention rates (Eccleston et al., 2014; Jensen & Turk, 2014). The main issue with online treatments 
is potentially low retention rates. It is suggested that retention rates may improve based on the 
therapist, real-time responses and length of the treatment (Eccleston et al., 2014). 
However, there are several limitations emerging from online treatment delivery which need to be 
considered. Firstly, some information given by the participant may be lost (i.e. due to disrupted 
internet connection), which may lead to problems such as diagnostic inaccuracy (Andersson & Titov, 
2014). Also, it is unclear which group of patients may benefit the most from online treatment, for 
example, in terms of condition, age, gender, ethnicity (Andersson, Carlbring, & Grimlund, 2008). To 
continue, there are no specific measures to observe the negative outcomes for the patients who 
have not benefited (Nordgreen et al., 2012). High dropout rates and patients’ non-completion of 




Griffiths, & Farrer, 2009). Future studies are encouraged to further investigate the characteristics of 
people who are likely to mostly benefit from online treatment, since it is still unclear. 
2.7 The Lack of Development in Psychological Approaches to Painful Diabetic Neuropathy 
Certain pain conditions are well represented in the evidence of psychological treatments for chronic 
pain, such as chronic musculoskeletal pain, low back pain and fibromyalgia. Other conditions are not 
well represented. Research into psychological treatments for PDN is sparse and inconsistent. Many 
questions remain unanswered and this situation indicates the need for the development and 
application of effective, innovative and acceptable interventions. A recent systematic review (Van 
Laake-Geelen, Smeets, Quadflieg, Kleijnen, & Verbunt, 2019), examined the effects of physical 
therapy in combination to psychological interventions to improve quality of life for people with PDN, 
and found no existing studies reporting on multidisciplinary rehabilitation of that kind. 
There are only five RCTs of psychological treatments for PDN (Hussain & Said, 2019; Nathan et al., 
2017; Otis et al., 2013; Pfammatter, 2010; Teixeira, 2010) including treatments of mindfulness-based 
meditation (MM), progressive relaxation meditation (PM), mindfulness-based stress reduction 
(MBSR), CBT and thermal biofeedback (TB). This is inconsistent with the general chronic pain 
literature, where a highly selective systematic review identified 40 RCTs of psychological treatments 
for chronic pain in general (Eccleston, Hearn, & Williams, 2015); and the neuropathy literature, 
where a systematic review identified 14 studies (3 RCTs) with participants having any form of 
neuropathic pain and interventions of cognitive or behavioural context (Wetering, Lemmens, 
Nieboer, & Huijsman, 2010). 
The MM study (Teixeira, 2010) included 20 participants in total (10 in the experimental group and 10 
in the control group). Results showed a small between-group effect in the mindfulness group 




sleep in the overall sample r= 0.53 (95% CI: 0.048 - 0.813). This study had evidence of moderate 
quality due to the use of self-reported measures, small sample size and complete lack of follow-up 
measures. These limitations restrict the generalisability of the results to the diabetes population. 
The TB study (Pfammatter, 2010), included 21 participants overall, 10 were allocated in the 
experimental group and 11 in the control group. The experimental group received 6 sessions with 
thermal biofeedback assisted relaxation (TBAR), while the control group received 6 sessions talking 
with a therapist about non-stressful events of life. Evidence from the biofeedback study was of very 
low quality and did not show any statistically significant effects between the experimental and the 
control group. 
The CBT study (Otis et al., 2013), included 20 participants overall, 12 participants were allocated to 
the experimental group and received 11 weekly CBT sessions, and 8 participants received treatment 
as usual (TAU). Participants were assessed at baseline and at 4th month follow-up. Results suggested 
large between group effects in pain-interference, at post treatment d=0.91 (95% CI: 0.02 - 1.8) and 
follow up d=0.85 (95% CI: -0.03 - 1.74), large effects in pain severity, at post treatment d=0.88 (95% 
CI: -0.01 - 1.77) and follow up d=0.83 (95% CI: -0.05 - 1.71), and medium between group effects in 
depression, at post treatment d=0.68 (95% CI: -0.19 - 1.55). Besides the small sample size, the study 
was of high-quality which makes the evidence reliable. No harmful or adverse events were reported 
from the participants’ involvement in the CBT programme as well. 
The MBSR study (Nathan et al., 2017), included 62 participants (32 in the control group and 30 in the 
experimental group). Results suggested that within the experimental group, which received 9 online 
MBSR sessions, more than half of the participants (19/30) reported improvement in pain 
interference using the Brief Pain Inventory (BPI) (mean BPI score of ≥1.0), function, quality of life, 
depression and pain catastrophizing. Overall, the evidence was of high-quality. However, it is unclear 




The PM and MM study (Hussain & Said, 2019) included 105 participants in total. Results showed that 
both groups reported reduction in their pain intensity, using the BPI, compared to baseline (28.7% 
and 39.7%, accordingly and p< .05). The MM group compared to the control meditation group, 
appear to experience more significant pain intensity reduction (of 5.2 + 1.2 dropped to 3.0 + 1.1 by 
week 12 of treatment and p< .01). The evidence was of high quality. However, the major limitations 
of this study were the use of self-reported measures and the lack of generalisability to other 
populations. 
Nevertheless, the existing studies support the potential efficacy of psychological interventions for 
this condition. However, to date there have been no studies investigating the effectiveness of ACT 
on enhancing PF and improving the wellbeing of people with PDN. 
2.8 Summary 
This chapter has provided an overview of the biomedical model of pain and the shift in the 
understanding of pain over time. The operant approach was discussed as an important development 
of the biomedical model of pain towards an understanding of pain on behavioural grounds. This shift 
encouraged clinicians to treat pain more holistically, rather than just physically and initiated the 
development of psychological treatments for chronic pain. Even though cognitive processes such as 
coping, attention and beliefs did not appear in these stages, they now play a significant role in 
treatment development. Furthermore, this chapter has given an overview of the theoretical 
underpinning of ACT and psychological interventions that have been applied to the treatment of 
chronic pain in general, and PDN in particular. There has been a shift towards cognitive behavioural 
approaches for the treatment of chronic pain, which are focused on improving pain coping 
behaviours, beliefs around pain, attention to pain and emotional responses. The next chapter will 
present a systematic review of controlled and uncontrolled trials and survey studies, of psychosocial 




Chapter 3: Psychosocial factors in Painful Diabetic Neuropathy: A Systematic 
Review of Treatment Outcomes and Survey Studies 
3.1 Chapter Overview  
As discussed in previous chapters, psychological models and treatment approaches appear to be 
beneficial to the wellbeing and functioning of people with chronic pain (e.g. Eccleston et al., 2015). 
Even though there is a large body of literature investigating the influence of psychosocial factors and 
effectiveness of psychological therapies in people with general chronic pain, the literature in PDN is 
relatively sparse. This chapter examines this literature. This includes a systematic review of evidence 
from treatment trials and survey studies in relation to psychological and social factors in people with 
PDN. The review also includes an assessment of quality for each study. 
This chapter is published in the following article at Pain Medicine Journal (Appendix Q): 
Kioskli, K., Scott, W., Winkley, K., Kylakos, S., & McCracken, L. (2019). Psychosocial Factors in Painful 
Diabetic Neuropathy: A Systematic Review of Treatment Trials and Survey Studies. Pain Medicine, 
20(9), 1756-1773. doi: 10.1093/pm/pnz071. 
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Objective: Diabetes mellitus is associated with a number of complications that can adversely impact 
patients’ quality of life. A common and often painful complication is painful diabetic neuropathy. The 
aims of this study were to systematically review and summarise evidence from studies of 
psychological treatments and psychosocial factors related to painful diabetic neuropathy and assess 
the methodological quality of these studies. 
Methods: Electronic databases, related reviews, and associated reference lists were searched. 
Summaries of participants’ data relating to the efficacy of psychological treatments, and/or to 
associations between psychosocial factors and outcomes, in painful diabetic neuropathy were 
extracted from the included studies. The methodological quality of included studies was assessed 
using two standardised quality assessment tools. 
Results: From 2,921 potentially relevant titles identified, twenty-seven studies were included in this 
systematic review. The evidence suggests that depression, anxiety, sleep and quality of life are the 
most studied variables in relation to pain outcomes in PDN and are consistently associated with pain 
intensity. The magnitude of the associations ranged from small to large. 
Conclusions: Research into psychosocial factors in painful diabetic neuropathy is unexpectedly 
limited. Available evidence is inconsistent and leaves a number of questions unanswered, 
particularly with respect to causal associations between variables. The evidence reviewed indicates 
that depression, anxiety, low quality of life, and poor sleep are associated with pain in painful 
diabetic neuropathy. The disproportionate lack of research into psychological treatments for painful 
diabetic neuropathy represents a significant opportunity for future research. 






Diabetes mellitus (DM) is highly prevalent and a significant public health problem (WHO, 2018). The 
International Diabetes Federation estimates that 425 million people are diagnosed with diabetes 
worldwide and these levels will rise to 628 million by 2045 (IDF, 2017) - it is a virtual epidemic. 
Common complications of DM include cerebrovascular and cardiac diseases, kidney failure, stroke, 
foot ulcer, blindness, and amputation (Brock et al., 2012; Dobrota et al., 2014). Another frequent 
complication of DM is painful diabetic neuropathy (PDN) affecting 25-30% of people with DM 
(Dobrota et al., 2014; Galer, Gianas, & Jensen, 2000; Spallone et al., 2011). 
Existing literature on the epidemiology of PDN is heterogeneous, this is because of the differences in 
participants, settings, definitions of PDN, and assessment measures (Akter, 2019). For example, the 
Rochester Neuropathy study conducted by Dyck et al. (1993), included 380 participants with 
diabetes and assessed neuropathy via nerve conduction studies, neuropathy disability score and 
neuropathy symptom score. Results suggested that the majority of participants (66%), were 
diagnosed with some type of neuropathy from an unknown aetiology. The San Luis Valley Diabetes 
Study was a cohort study, including 279 people with diabetes which found that 25.8% of them were 
diagnosed with PDN (Franklin, Kahn, Baxter, Marshall, & Hamman, 1990). A more recent community-
based study, which included 15.000 participants with a diagnosis of diabetes found that 34% of the 
individuals were showing symptoms of PDN, the main demographic characteristics of these 
participants were T2DM, South Asian origin, and women (Abbott et al., 2011). The European 
Diabetes (EURODIAB) Prospective Complications Study, which included 3000 participants from 
across 16 regions found 28% of PDN prevalence at baseline, with an increase of 23.5% after a period 
of 7 years. This study identified as risk factors: duration of diabetes, hypertension, cholesterol, 
triglycerides, smoking, obesity and age (Tesfaye et al., 2005). The Epidemiology of Diabetes 




PDN in participants following intensive treatment, compared to conventional (Martin, Albers, & Pop-
Busui, 2013). 
PDN diagnosis is a clinical one and is based on the patient’s description of pain, which is often 
described as a prickling, burning, deep aching, sharp sensation, similar to an electric shock 
(Kulkantrakorn & Lorsuwansiri, 2013). Subjective reporting of these painful symptoms can be used to 
screen for possible PDN; however, definitive diagnosis requires the presence of objective PDN signs 
(e.g., decreased ankle reflex) and findings confirming nerve dysfunction, such as using nerve 
conduction or through skin biopsy. While these objective indicators are required to confirm PDN 
diagnosis, for practical reasons, some studies rely on self-reported neuropathic pain symptoms for 
people with diabetes as an indicator of possible PDN (Galer et al., 2000). 
More specifically, the ‘’gold standard’’ for diagnosis is a skin biopsy, but this is invasive and not all 
patients are medically suitable for this. Another strategy is to screen for objective signs and 
symptoms. A third strategy is just to screen for symptoms through validated screening 
questionnaires which is the most efficient and least invasive. On the one hand, this reflects only 
‘possible neuropathic pain’ (Finnerup et al., 2016). On the other hand, in health psychology research, 
screening only for symptoms is acceptable since we are interested in symptoms and their impact on 
quality of life rather than pathophysiology. 
PDN primarily involves the toes, feet, and legs, and is associated with significant interference with 
mobility, sleep, mood, social interactions, and overall quality of life (QOL) (Barrett et al., 2007; 
Davies, Cramp, Gauntlett-Gilbert, Wynick, & McCabe, 2015; Geelen et al., 2017). PDN appears to 
significantly impact mental health, including anxiety and depression (Geelen et al., 2016; Vileikyte et 
al., 2005), which in turn contribute to poorer outcomes overall (Gore et al., 2005). Essentially, PDN is 
a chronic disease associated with long-term suffering and disability for many people (Mai et al., 




At present, most treatments for neuropathic pain are pharmacological (Edelsberg & Oster, 2009; 
Jensen, 2002; Marchettini et al., 2015). The ADA recommends optimization of glucose control to 
achieve the prevention or delay of PDN. The suggested first-line drugs, which targets pain 
management, are tricyclic antidepressants which aim to increase non-adrenaline and serotonin, and 
anticonvulsants like gabapentin, pregabalin and duloxetine (ADA, 2017). However, no single 
treatment has proven effective enough for pain relief or prevention (Javed, Petropoulos, Alam, & 
Malik, 2015). Findings are similar in the broader neuropathic pain literature. A systematic review of 
published and unpublished studies from 174 RCTs (Finnerup et al., 2010), and a meta-analysis of 229 
RCTs (Finnerup et al., 2015) examined the medical management of neuropathic pain. The meta-
analysis found that outcomes from trials were modest, including a number needed to treat (NNT; 
>50% relief) of 6.4 (95% CI: 5.2-8.4) for duloxetine, 7.7 (95%: 6.5-9.4) for pregabalin, 7.7 (95% CI: 6.5-
9.4) for gabapentin, and 10.6 (95% CI: 7.4-19.0) for capsaicin patches. According to these results, 
even when PDN is treated with medication, many people continue to experience significant pain. 
These results suggest a need for new or additional treatments, potentially including non-
pharmacological interventions. 
Within the broader chronic pain literature, there is good evidence supporting psychological 
treatments, such as cognitive-behavioural therapy (CBT), for chronic pain (Bernardy, Klose, Welsch, 
& Häuser, 2018; Williams et al., 2012; Yu & McCracken, 2016). However, it appears that there are 
limited published studies of psychological treatments for people with diabetic neuropathies (Otis et 
al., 2013; Teixeira, 2010) and only one literature review examining physical and psychological 
interventions for people with PDN (Davies et al., 2015). This earlier review searched the literature up 
to July 2014 and identified only two psychological intervention studies. An updated review on this 
important topic appears due. It is also unknown which psychosocial factors might impact on 




factors could prove fruitful as it could lead to treatment developments that have not yet been 
conceived. 
The purpose of this study was to synthesise and evaluate the evidence from trials of psychological 
treatments for PDN and other research into psychosocial factors in relation to PDN outcomes.  From 
this we intended to (a) identify current psychological interventions for individuals who suffer from 
PDN and examine their effectiveness, (b) identify potentially modifiable psychosocial factors that 




This systematic review protocol is registered with PROSPERO (registration number 
CRD42017060339) and may be accessed online at: 
https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017060339. 
The current review was conducted according to the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines (Moher, 2009) and established guidelines for 
narrative synthesis (Rodgers et al., 2009). 
2.2 Search Strategy 
We searched the following electronic databases, from 1946 to 10 August 2018: Medline, Embase, 
PsycINFO, Cinahl, Web of Science, ISRCTN registry, ClinicalTrials.gov registry, and EU Clinical Trials 
registry. Also, the reference lists of all included papers and related published reviews (Eccleston et 
al., 2015) were screened to identify any additional eligible studies. The PICO framework was used to 




suffering from neuropathic pain due to diabetes. Included interventions were any study involving 
psychological treatments. In addition to treatment trials, observational studies examining relations 
between psychosocial factors and relevant outcome variables were also sought. All comparators 
were eligible. The selected outcomes were physical and emotional functioning, pain experience, 
pain-related interference with functioning, or QOL (see Table 6). 
Furthermore, the Medical Subject Headings (MeSH) and free-text terms were divided into three 
groups: PDN, and psychological interventions or psychosocial factors, including all study designs, in 
order to identify both observational studies and RCTs (see TableS1 in Appendix E). Particularly, the 
Boolean Operator “OR” was used to enable identification of either relevant RCTs or observational 




Table 6: PICOS Inclusion/Exclusion Criteria 
Note: “-”: not applicable 
 Inclusion Criteria Exclusion Criteria 
Population Adults (minimum age 18 years) & Clear diagnosis of PDN Children, adolescents (under 18 years) & Neuropathic pain 
due to other causes 
Intervention Any psychological treatment addressing psychosocial factors or 
studies measuring psychosocial factors for PDN and allowing the 
examination of these in relation to pain outcomes 
 
Interventions that are only educational 
Control All comparators are eligible for this systematic review - 
Outcomes  Physical functioning 
 Emotional functioning 
 Pain experience 
 Pain related interference 
 Symptoms and adverse effects 




Study design                Any Reviews  
Publication type                 Published full text articles Unpublished dissertations and articles, editorials, letters/ 
Uncompleted trials 




2.3 Inclusion and Exclusion Criteria 
We included any study involving psychological treatments incorporating any of the outcomes 
specified: physical or emotional functioning, pain experience, pain-related interference, or QOL, in 
individuals with PDN. Also, we included studies designed to investigate the association between 
psychosocial factors, for instance emotional responses, thoughts, beliefs, cognitive factors, or other 
behavioural patterns, and the designated pain outcomes. Studies examining potentially modifiable 
social processes, such as perceived quality of social support, in relation to pain outcomes were also 
included. Studies were excluded if they were not written in English or were not published as a full-
text article. Additionally, studies that only investigated pain prevalence, and not the association 
between pain outcomes and psychosocial factors were not eligible. Studies that assessed only 
unmodifiable sociodemographic (e.g., ethnicity) in relation to pain outcomes were excluded. Studies 
were also excluded if they were solely educational interventions (meaning primarily focused on 
enhancing knowledge or providing information, rather than more active processes of psychological 
or behavioural change). This requirement is similar to the criteria set in the Cochrane review of 
psychological therapies for pain (Williams et al., 2012). 
Participants within the included studies were adults, aged 18 years and older (at the time of their 
entry into the study), with a stated diagnosis of PDN. Studies of participants who suffered from 
neuropathic pain due to causes other than diabetes were not included. 
2.4 Screening of Studies 
After running searches in each electronic database, the predefined inclusion criteria were applied 
independently by two reviewers (KK; SK) in order to screen all potentially relevant titles and 
abstracts. After screening titles and abstracts for eligibility, the remaining potentially eligible full-text 




required, so that a consensus was reached. Disagreements that could not be resolved through 
discussion were settled from input by a third reviewer (LM, KW, or WS). 
2.5 Data Extraction 
The data extraction tool included the following: publication date; authors; country; journal; study 
design; types of interventions or psychosocial factors investigated; pain and related outcomes; 
participants’ characteristics; study setting; study inclusion and exclusion criteria; recruitment 
method; reported medications; duration of PDN; outcome measures used; and statistical analyses 
(see Appendix D). The data were extracted from the eligible studies by three reviewers (KK, SK, or 
WS). KK extracted data from all studies while SK and WS each independently extracted data from 
approximately half of the studies. If the reviewers failed to reach a consensus on the extracted data, 
a third opinion was provided by another member of the research team (LM or KW). 
2.6 Quality Assessment 
The methodological quality of the included studies was evaluated using the Downs and Black (1998) 
quality assessment tool (Downs & Black, 1998) for observational studies or the Cochrane risk of bias 
tool for RCTs (Higgins et al., 2011), depending on the design of the study (see Appendices B and C). 
The Downs and Black (1998) quality assessment tool has been identified as appropriate for the 
quality assessment in systematic reviews. It was applied to non-randomised trials and other 
observational studies. The checklist was modified minimally to meet the needs of the current 
systematic review. The methodological quality tool contained 27 items. The component ratings are 
divided as follow: A: Reporting, Score 0-10 (eight questions); B: External Validity, Score 0-3 (three 
questions); C: Internal Validity-Bias, Score 0-7 (seven questions); D: Internal Validity-Confounding, 




The Cochrane risk of bias tool (Higgins et al., 2011), is a widely used tool for assessing bias and flaws 
in the conduct, design, analysis and reporting of RCTs and is better suited to this than the Downs and 
Black tool. This risk of bias assessment tool includes: selection bias, performance bias, detection 
bias, attrition bias, reporting bias, and other bias. 
The checklists were administered by three independent reviewers (KK, SK, or WS) and cross-checked 
for consistency. Again, KK assessed all the studies and SK and WS each assessed half of the studies. 
Any disagreements were resolved by a third reviewer (LM or KW). 
2.7 Data Analysis and Data Synthesis 
Most studies investigated associations between more than one psychosocial variable and pain 
outcomes. The reported results are organised according to the specific psychosocial factors and pain 
outcomes included in the studies. The magnitude of relations from correlational methods was 
reported in terms of the correlation coefficient, r, when available. 
Cohen’s d was calculated by the first author (KK) to reflect effect sizes for between groups 
comparisons, based on means and standard deviations (SD) reported in each study. For variables 
that were assessed by more than one measure, a Cohen’s d was calculated for each measure, and 
the final effect size reported for the variable was the mean of the Cohen’s d of all measures (Muller 
& Cohen, 1989; Rosnow & Rosenthal, 1996). The calculated d values were interpreted, according to 
Cohen (1989), as small (d= 0.2), medium (d= 0.5) or large (d= 0.8). 
95% Confidence Intervals (CIs) were calculated for Cohen’s d and correlation coefficient r (for studies 
that reported a within-groups correlation coefficient). For Cohen’s d, the 95% CI was calculated by 
first identifying the t-value and then using the ‘ci.smd’ function of the MBESS package in R (Lakens, 




𝑡 = 𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 ×  √
𝑆𝑎𝑚𝑝𝑙𝑒 𝑆𝑖𝑧𝑒 1 ×  𝑆𝑎𝑚𝑝𝑙𝑒 𝑆𝑖𝑧𝑒 2
𝑆𝑎𝑚𝑝𝑙𝑒 𝑆𝑖𝑧𝑒 1 + 𝑆𝑎𝑚𝑝𝑙𝑒 𝑆𝑖𝑧𝑒 2
 
For the correlation coefficient r, the 95% CI was calculated by first transforming the r to z’, 
calculating the standard error for z’, the 95% CI for z’ and then transforming it back to values for r.  
The correlation coefficient r was transformed to z’ with the following formula (Lane, 2018): 
      𝑧′ = 0.5 × [𝑙𝑛(1 + 𝑟) − 𝑙𝑛(1 − 𝑟)]  
The standard error (SE) for z’ was calculated by: 
𝑆𝐸 =  
1
√𝑆𝑎𝑚𝑝𝑙𝑒 𝑆𝑖𝑧𝑒 − 3
 
The lower and upper bounds of the 95% CI for z’ were found as follows: 
𝐿𝑜𝑤𝑒𝑟 𝐵𝑜𝑢𝑛𝑑 = 𝑧′ − 1.96 × 𝑆𝐸 
𝑈𝑝𝑝𝑒𝑟 𝐵𝑜𝑢𝑛𝑑 =  𝑧′ + 1.96 × 𝑆𝐸 
Finally, the lower and upper bound values were transformed back to r values, by using the equation 
originally used to transform r to z’. 
3. Results 
3.1 Study Selection 
The detailed selection process for included studies can be found in Figure 12. Each database was 
searched individually, and the total number of hits was 2,922. 2,226 articles remained after 
deduplication. After applying the predefined inclusion and exclusion criteria to the titles and 
abstracts, 41 articles remained for full-text review by the two reviewers. The manual search of the 




the end of the screening and selection process, twenty-seven studies (twenty-nine published papers) 
met the criteria and were included in this systematic review. 
 
Figure 12: Flowchart-Selection process 
 
3.2 General Study Characteristics 
The twenty-seven studies found eligible for this systematic review were published between 1998 
(Benbow, 1998) and 2018 (Levterova, Naydenov, Todorov, & Levterov, 2018). The majority of the 
studies (17/27) were cross-sectional (AL-Mahmood et al., 2018; Bouhassira, Letanoux, & Hartemann, 
2013; Currie et al., 2006; Dobrota et al., 2014; Geelen et al., 2016; Geelen et al., 2017; Gore et al., 




Lorsuwansiri, 2013; Levterova et al., 2018; Sadosky et al., 2013; Selvarajah et al., 2014; 
Themistocleous et al., 2016; Tölle et al., 2006; Van Acker et al., 2009; Vileikyte et al., 2005; 
Wickramasinghe, Subasinghe, Withana, & Wellala, 2016; Zelman et al., 2005; Zelman et al., 2006). 
Two studies were described as case-control (Benbow, 1998; Lewko et al., 2007), three as prospective 
cohort designs (Galer et al., 2000; Mai et al., 2015; Vileikyte et al., 2009) and three were RCTs (Otis 
et al., 2013; Pfammatter, 2010; Teixeira, 2010). 
Most of the studies recruited participants from the USA (10 studies; 37%), the UK (6 studies; 22%) 
and the Netherlands (n=2; 8%). The remaining studies (9 studies; 33%), recruited participants from a 
range of countries across Europe, Asia, North and South America. The mean ages of participants and 
their standard deviations reported in the studies ranged from 45.9 ± 15 to 74.6 + 10.8. 26 out of the 
27 studies included both male and female participants, while one included only male participants 
(Otis et al., 2013). Detailed information regarding study characteristics can be found in Tables 5 and 
S2 (in Appendix E). 
3.3 Clinical Characteristics of the Studies 
Regarding the participants’ clinical characteristics, 40.9% to 88.3% of the participants were taking 
medication for PDN. The most common medication types reported within the studies were: tricyclic 
antidepressants (33.5%), nonsteroidal anti-inflammatory drugs (26.8%), anticonvulsants (26.1%),  
and opioids (13.6%) (Benbow, 1998; Bouhassira et al., 2013; Currie et al., 2006; Geelen et al., 2016; 
Geelen et al., 2017; Gore et al., 2005; Hoffman et al., 2009; Jacovides et al., 2014; Selvarajah et al., 
2014; Themistocleous et al., 2016; Tölle et al., 2006; Van Acker et al., 2009; Vileikyte et al., 2005; 
Wickramasinghe et al., 2016). Approximately 60% of the included studies did not report participants’ 
use of pain medication. 
Comorbid conditions were typically reported from 80% of participants in the included studies. The 




dyslipidaemia, retinopathy and fibromyalgia (Benbow, 1998; Bouhassira et al., 2013; Currie et al., 
2006; Dobrota et al., 2014; Geelen et al., 2016; Geelen et al., 2017; Gore et al., 2005; Hoffman et al., 
2009; Jacovides et al., 2014; Levterova et al., 2018; Selvarajah et al., 2014; Tölle et al., 2006; Van 
Acker et al., 2009; Vileikyte et al., 2005). 50% of the studies did not report participants’ 
comorbidities. 
PDN duration was not consistently reported. However, eleven studies included reports of 
participants time since PDN diagnosis (Bouhassira et al., 2013; Galer et al., 2000; Gore et al., 2005; 
Hoffman et al., 2009; Kulkantrakorn & Lorsuwansiri, 2013; Mai et al., 2015; Sadosky et al., 2013; 
Selvarajah et al., 2014; Teixeira, 2010; Tölle et al., 2006; Zelman et al., 2005). From the studies 
providing data, the PDN duration ranged from 2.4 to 7.8 years. 44% (12/27) of the studies did not 





Table 7: Studies’ general characteristics 







PDN Duration  
AL-Mahmood et al. 
(2018)  
Cross-Sectional Malaysia Medical Outpatient Department 
Clinic of Hospital (MOPD) clinic 
of hospital Tegku Ampaun 
Afzan (HTAA) 
T: 90 65 60/40 - 
Benbow (1998)  Case-control UK Adult hospital, diabetic clinic T: 116, PDN: 41,  
DM: 38, C: 37 
55.6 70/30 - 
Bouhassira et al. 
(2013)  
Cross-sectional France Hospital departments, private 
practice 
T: 766, PDN: 156, T1DM: 
297, T2DM: 469 
48.3 55/45 At least 1 year at 
57.4% of the 
participants 
 
Currie et al. (2006)  Cross-sectional UK 
 
Hospital Trust T:1125, T1DM: 236, 
T2DM: 889 
64 56/44 - 
Dobrota et al. (2014)  Cross-sectional Croatia Clinical hospital, university clinic 
for diabetes 
T: 160,  
PDN: 80, DM: 80 
62.4 52/48 - 
Galer et al. (2000)  Prospective 
cohort 
USA Advertisements, newsletters, 
letters to physicians 
T: 105 62.9 50/50 (diagnosed at 56.7 
years of age) SC 
Geelen et al. (2016; 
2017)  
Cross-sectional Netherlands Informative letter to regional 
hospital 
T: 154  65.7 62/38 - 
Gore et al. (2005; 
2006)  




Hoffman et al. (2009)  Cross-sectional Asia, Latin 
America, 
Middle East  
Investigational centres T: 401 57.3 38/62 2.73 y 
Jacovides et al. (2014)  Cross-sectional South Africa Public and private outpatient 
clinics 
T: 961, 
PDN: 291, DM: 670 
55.9  51/49 - 
Kulkantrakorn & 
Lorsuwansiri (2013)  
Cross-sectional Thailand Internal medicine and 
neurology clinic at a University 
Hospital 
T: 33 60.5 46/54 4 y 
Levterova et al. (2018)  Cross-sectional Bulgaria University Hospital “Kaspela”, 
Plovdiv 
T: 37 58.3 57/43 - 
Lewko et al. (2007)  Case-control Poland Endocrinology, Diabetes and 
Internal Medicine clinics at the 
Medical University of Bialystok 
T: 59, 
PDN: 22, DM: 37 
61.3 18/32 - 
Mai et al. (2015)  Prospective- 
observational  
 
Canada The Canadian Neuropathic Pain 
Database 
T: 60 57.1 57/43 4.9 y 
Otis et al. (2013)  Single-blind, RCT  
 
USA Advertisements in the Dept. of 
Veterans Affairs medical centre 
T: 19, 
CBT: 11, C: 8 
63  100/0 - 




T: 21, BF: 10, C: 11 59.3 53/47 - 
Sadosky et al. (2013)  Cross-sectional USA Community-based physician 
practices 





Selvarajah et al. (2014)  Cross-sectional UK Multidisciplinary outpatient 
service 
T: 142 61.2 57/43 8.4 y 
Teixeira, (2010)  Open label, RCT 
 
USA Medical practices and 
retirement communities 
T: 20 74.6 25/75 7.76 y 
Themistocleous et al. 
(2016)  
Cross-sectional UK Primary care practices, diabetes 
clinics, teaching hospitals, 
neurology clinics, 
advertisements 
T: 191, No PDN: 80 
Mild PDN: 41 
Moderate/Severe PDN: 
70 
67.23 45/55 - 





Community-based practices T: 140 65.6 58/42 3-6 m: 14% 
7-12 m:  22% 
13-35 m: 43% 
≥ 36 m: 61% SC 
Van Acker et al. (2009)  Cross-sectional Belgium Outpatients diabetes clinics T: 1111, PDN: 478, 










Vileikyte et al. (2005)  Cross-sectional UK; USA - T: 484 61.86 70/30 - 
Vileikyte et al. (2009)  Prospective 
cohort 
UK; USA - T: 495 61.24 71/29 - 
Wickramasinghe et al. 
(2016)  
 
Cross-sectional Sri Lanka Diabetic Clinic T: 235 56 35/65 - 
Zelman et al. (2005) Cross-sectional USA Primary Care T: 255 61.3 45/51 6.4 y 




Note: T: Total, DM: Diabetes Mellitus, T1DM: Type 1 Diabetes Mellitus, T2DM: Type 2 Diabetes Mellitus, C: 
Control Group, PDN: Painful Diabetic Neuropathy, CBT: Cognitive Behavioural Therapy, BF: Biofeedback, “-”: 
not reported. Location: At the time, the location is provided to the lowest level reported (i.e. city). Recruitment 
sites: Where the recruitment site is not reported, recruitment methods are. Sample size: Sample sizes are 
provided in groups where given by the authors. Mean Age: Where the mean age is not reported, the 
alternative is. Only totals are reported. Male/Female: Only totals are reported. Where the % doesn’t add up to 
100, it means that there is missing data. PDN Duration: Most values are given as mean + SD. y: years, SC: Galer 
provides the mean age when PDN was diagnosed for the sample; Tölle presents the duration of PDN in ranges 




3.4 Treatment Outcomes  
Three out of the twenty-seven studies were RCTs of psychological treatments for patients suffering 
from diabetic neuropathies (Otis et al., 2013; Pfammatter, 2010; Teixeira, 2010). Please see Table 8 
and Table 10 for more details. 
Teixeira (2010), conducted a pilot trial of mindfulness meditation for PDN. The intervention group 
(n= 10) received training in mindfulness, and the control group (n= 10) received an “attention-
placebo” treatment, for four weeks. The results indicated a small effect in the mindfulness group 
compared to the control on QOL. It was also found that pain and poor sleep were positively 
correlated in the full sample.  
Pfammatter (2010), conducted a study of thermal biofeedback for PDN. The experimental group (n= 
10) received six sessions of thermal biofeedback, and the control group (n= 11) six sessions with a 
therapist talking about non-stressful topics. Overall this study did not produce any statistically 
significant effects between the experimental and control groups, or any other consistent 
associations. Notably, 11 out of the 21 participants withdrew from the study. 
Lastly, Otis et al. (2013) investigated CBT for PDN (n= 11), compared to treatment as usual (TAU) (n= 
8). Results indicated that participants in the CBT group improved on pain severity and interference 
compared to the TAU group at four-month follow-up, but there was no improvement on depressive 
symptoms for either group. Results suggested large between group effects in pain severity and 
interference, both at post treatment and follow up. For depression, medium and small between-




Table 8: Details of the psychological treatments’ content 
 
Study Groups Content Duration Frequency 
Teixeira (2010) Intervention/Attention-Placebo Mindfulness Meditation/Nutritional 
Information and Food diary 
20 sessions, 4 weeks, 60 
minutes per session 
5 days per week 
Pfammatter (2010) Experimental/Control Thermal Biofeedback Assisted 
Relaxation/Discussed about benign topics 
with experimenter 
6 sessions, 6 weeks, 15 
minutes per session 
Twice a day 
Otis et al. (2013) CBT/Treatment As Usual Cognitive-behavioural pain management 
therapy/Continued receiving their usual 
treatment by their healthcare providers  
11 sessions, weeks, 4 
months, 60 minutes per 
session 




3.5 Depression and Pain Outcomes 
Eight cross-sectional studies (Bouhassira et al., 2013; Dobrota et al., 2014; Gore et al., 2005; 
Hoffman et al., 2009; Selvarajah et al., 2014; Themistocleous et al., 2016; Vileikyte et al., 2005; 
Wickramasinghe et al., 2016) investigated the role of depression in relation to pain in PDN (Table 
10). Two studies investigated the association between depression and pain outcomes and reported 
large, positive effect sizes (Dobrota et al., 2014; Gore et al., 2006), one reported medium (Selvarajah 
et al., 2014) and another small (Vileikyte et al., 2005) (Table 10).  
One study found that depression and pain severity are positively, but weakly associated. This was a 
cross-sectional study which did a group comparison in three regions (Asia, Latin America, Middle 
East) (Hoffman et al., 2009). 
Three studies investigated depression in relation to pain, but data (mean and SDs) were not available 
to compute the effect sizes. One study (Bouhassira et al., 2013) reported that participants with 
chronic pain with neuropathic characteristics had higher depression scores than participants without 
neuropathic pain. One study (Themistocleous et al., 2016) reported a significant difference in 
depression between participants suffering from moderate/severe neuropathic pain to participants 
with no/mild neuropathic pain; and one study (Wickramasinghe et al., 2016), found that that 




Table 9: Outcomes associated with RCTs of psychological interventions 
 
Note: QOL: Quality Of Life, Correlation r: Correlation coefficient, “-”: not applicable, TB: Thermal Biofeedback, CI: Confidence Interval 
 
Study Intervention outcome/Psychosocial 
variable 







Otis et al. (2013)  CBT (posttreatment) -Depression Between-group 0.68 (-0.19 to 1.55) - Medium >0.05 
 
 CBT (follow-up) - Depression Between-group 0.47 (-0.39 to 1.33) - Small >0.05 
  CBT (posttreatment) - Pain 
interference 
Between-group 0.91 (0.02 to 1.8) - Large >0.05 
 
 
 CBT (follow-up)-Pain interference  Between-group 0.85 (-0.03 to 1.74) - Large >0.05 
  CBT (posttreatment)- Pain Severity Between-group 0.88 (-0.01 to 1.77) - Large >0.05 
  CBT (follow-up)- Pain Severity Between-group 0.83 (-0.05 to 1.71) - Large >0.05 
he Teixeira, (2010)  Mindfulness-QOL Between-group -0.16 (-1.1 to 0.78) - Small >0.05 
 
 QoL and Sleep Whole sample - 0.53 (0.048 to 0.813) Large <0.05 
 
Pfammatter, (2010)  TB-Pain Severity/Control (Session 1) Whole sample - -0.42 (-0.721 to 0.014) Large >0.05 
 
 TB-Pain Severity/Control (Session 4) Whole sample - -0.62 (-0.830 to -0.257) Large <0.05 
 





3.6 Anxiety and Pain Outcomes  
Five cross-sectional studies investigated anxiety in relation to pain severity and pain interference 
(Bouhassira et al., 2013; Gore et al., 2005; Hoffman et al., 2009; Selvarajah et al., 2014; 
Themistocleous et al., 2016) (Table 10). One study (Selvarajah et al., 2014) investigated the 
association between anxiety and pain in patients with confirmed PDN differing in pain intensity and 
found a medium effect size; and one study (Gore et al., 2005) found a large effect size, between 
patients with mild and severe PDN. However, contrary to this, another study (Hoffman et al., 2009) 
demonstrated an overall weak and negative effect size between anxiety and pain severity. This 
appeared to be due to unexpected high anxiety reported in some of their low pain participants, 
otherwise the trend was for those reporting severe pain to also report higher anxiety. 
Two further studies also investigated anxiety in relation to pain outcomes, but data were not 
available to compute the effect sizes. One study (Bouhassira et al., 2013) reported that participants 
with chronic pain and neuropathic characteristics had higher anxiety scores compared to those 
without neuropathic pain, and one study (Themistocleous et al., 2016) investigated pain-related 
anxiety and found that participants with moderate/severe neuropathy reported significantly higher 
scores compared to participants with mild/no neuropathy. 
3.7 Sleep and Pain Outcomes  
Seven cross-sectional studies examined the association between sleep and pain in PDN (Bouhassira 
et al., 2013; Gore et al., 2005; Hoffman et al., 2009; Jacovides et al., 2014; Selvarajah et al., 2014; 
Wickramasinghe et al., 2016; Zelman et al., 2006) (Table 10). Two studies reported large effect sizes. 
In the first study participants were grouped according to pain severity and a strong association 
between pain severity and sleep impairment was found (Gore et al., 2005). These findings were 




(Jacovides et al., 2014). One study found a medium effect when comparing individuals with PDN and 
the general US population. Whereas, another study (Hoffman et al., 2009), found a small effect 
between sleep and pain. 
Three studies also investigated the relation between sleep disturbances and pain but data were not 
available to compute the effect sizes. One study (Bouhassira et al., 2013) reported that participants 
with neuropathic pain had more sleep disturbance than participants without neuropathic pain. One 
study (Themistocleous et al., 2016) showed significantly greater sleep impairment in participants 
with moderate/severe neuropathy relative to those with mild/no neuropathy. One study 
(Wickramasinghe et al., 2016), concluded that 43.7% of the total sample had sleep disturbances due 
to their neuropathic symptoms. 
3.8 Catastrophic Thinking and Pain Outcomes 
Two cross-sectional studies (Selvarajah et al., 2014; Themistocleous et al., 2016) and one prospective 
cohort (Mai et al., 2015) examined pain catastrophizing (Table 10). It is worth noting that there are 
three dimensions within catastrophizing: rumination, magnification, and helplessness (Sullivan, 
Bishop, & Pivik, 1995). One study showed that helplessness and rumination are strongly associated 
with the experience of pain in diabetic neuropathy (Selvarajah et al., 2014). In another study, 
participants with moderate/severe PDN scored significantly higher on catastrophizing than those 
with no/mild PDN (Themistocleous et al., 2016). Finally, in one study catastrophizing did not predict 
outcome, possibly because the sample size was relatively small (N=60) (Mai et al., 2015). None of the 
studies described provided adequate data to compute effect sizes. 
3.9 Other Psychosocial Variables and Pain Outcomes 
One study investigated the association between acceptance of illness and QOL finding a large effect 




depression as an outcome variable at 18 months and found that this was predicted by increased pain 
from baseline to nine months (Vileikyte et al., 2009). Another study investigated the association 
between acceptance of pain, and anxiety and depression. The results demonstrated that lower 
acceptance scores were strongly associated with higher levels of depressive symptoms and anxiety. 
However, the data was insufficient to calculate an effect size (Selvarajah et al., 2014). 
One study investigated the role of a number of different fears, including fear of movement 
(kinesiophobia), fear of fatigue, fear of hypoglycaemia, fear of pain, fear of falling, and fear of 
negative evaluation, in relation to QOL. This study found medium to large correlations between QoL 
and these fear-related variables (range: r=0.39 to r=0.71). This study also found medium to large 
correlations between fear-related variables and disability (range: r=0.28 to 0.66) (Geelen et al., 
2017). 
3.10 Pain and Quality of Life  
Most of the studies included in this review (20/27) aimed to capture the perceived impact of PDN on 
QOL (Table 10). These studies were mainly cross-sectional and mostly concluded that pain is 
associated with reduced QOL. The factors framed as predictors of QOL, or independent variables, 
include presence of pain, pain intensity and pain severity. However, it is also possible to conceive 
QOL as a potential contributory psychosocial factor in relation to other pain-related outcomes. 
Indeed, common QOL measures often incorporate items assessing psychological functioning, such as 
depression and anxiety, as well as usual daily activities (EQ-5D-5L) (Van Reneen & Oppe, 2015). 
Eight studies provided sufficient data to calculate effect sizes, reflecting mostly large associations 
between QOL and pain. Six studies found large effects in comparisons between groups with severe 
versus mild PDN (Bouhassira et al., 2013; Geelen et al., 2016; Sadosky et al., 2013; Zelman et al., 
2005). One study found a medium and negative effect between pain severity and QOL (Levterova et 




2009). Twelve additional studies reported negative associations between QOL and pain but did not 
provide enough information to calculate effect sizes (AL-Mahmood et al., 2018; Benbow, 1998; 
Bouhassira et al., 2013; Galer et al., 2000; Kulkantrakorn & Lorsuwansiri, 2013; Mai et al., 2015; 
Selvarajah et al., 2014; Themistocleous et al., 2016; Tölle et al., 2006; Van Acker et al., 2009; 




Table 10: Associations between depression, anxiety, QOL, sleep and pain outcomes for studies reporting sufficient data to compute effect sizes 
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Note: “-”: not applicable. Only groups of absolute interest are reported in this table, a: The effect size reported 
is not originally calculated by the author of the study but by the first author of this systematic review. AIS: 
Acceptance of Illness Scale, BDI: Beck Depression Inventory, BFNE: Brief Fear of Negative Evaluation Scale, CI: 
Confidence Interval, DN4: Douleur Neuropathique 4, DSIS: Daily Sleep Interference Scale, EQ-5D: EuroQol, FES-
I: Falls Efficacy Scale-International, HADS: Hospital Anxiety and Depression scale, HFS: Hypoglycaemia Fear 
Survey, LANSS: Leeds Assessment of Neuropathic Symptoms and Signs, mBPI: modified Brief Pain Inventory, 
MOS: Medical Outcomes Study-sleep scale, MPQ: McGill Pain Questionnaire, NDS: Neuropathy Disability 
Score, NPS: Neuropathic Pain Scale, NeuroQol: Neuropathy and Foot Ulcer-specific Quality of Life Instrument, 
N/R: not reported, PASS-20: Pain Anxiety Symptom Scale, PDI: Pain Disability Index, P value: In instances where 
an effect size is calculated for a number of different subscales with different P values, a proportion of 
significance is reported as the number of comparisons of the total comparisons that reported a significant 
difference. QOL-DN: Norfolk Quality of Life Questionnaire, r: correlation coefficient effect size or otherwise 
explained in the comments, SF-12v2: Short Form Health Survey Version 2, SF-36: Short Form Health Survey, 
TSF: Tampa Scale of Fear of Fatigue, TSK: Tampa Scale of Kinesiophobia, VAS: Visual Analogue Scale, VRS: 
Verbal Rating Scale. For papers which had three or more groups based on pain severity, the comparison was 
undertaken between the group with the least severe symptoms and the most severe symptoms. *When both 
univariate and multivariate analyses were reported in the same paper, we extracted univariate data given 
differences in multivariate models across study which limit their interpretability. Where only a multivariate 




3.11 Quality Assessment 
The inter-rater reliability (IRR) in assessing the quality of the twenty-seven included studies was 
good, at 87.5% agreement between the two reviewers. There were some minor disagreements, 
mainly regarding the internal validity of the studies, but these were solved without consulting 
another member of the research team. 
Overall, the methodological quality score, using the Downs and Black (1998) quality assessment tool, 
was high in 14 studies (AL-Mahmood et al., 2018; Bouhassira et al., 2013; Currie et al., 2006; Dobrota 
et al., 2014; Galer et al., 2000; Geelen et al., 2017; Gore et al., 2005; Hoffman et al., 2009; Levterova 
et al., 2018; Selvarajah et al., 2014; Van Acker et al., 2009; Vileikyte et al., 2005; Vileikyte et al., 
2009; Wickramasinghe et al., 2016), medium in four studies (Mai et al., 2015; Sadosky et al., 2013; 
Themistocleous et al., 2016; Zelman et al., 2005) and low in five studies (Benbow, 1998; Jacovides et 
al., 2014; Lewko et al., 2007; Kulkantrakorn, & Lorsuwansiri, 2013; Tölle et al., 2006). Most common 
reasons for these studies losing points in the scoring was the External Validity component and 




Table 11: Methodological quality of observational studies (Downs & Black, 1998) 
 
Note: Component Score A: Reporting, score range 0-7, Component Score B: External Validity, score range 0-2, Component Score C: Internal Validity-Bias, score range 0-3, 
Component Score D: Internal Validity-Confounding (selection bias), score range 0-2 
Study Component Score: A Component Score: B Component Score: C Component Score: D Overall Score  
AL-Mahmood et al. (2018)  5 2 3 2 92.3% (12/13) 
Benbow (1998)  4 1 0 1 46.2% (6/13) 
Bouhassira et al. (2013)  5 2 3 2 92.3% (12/13) 
Currie et al. (2006)  6 0 3 2 84.7% (11/13) 
Dobrota et al. (2014)  5 2 3 2 92.3% (12/13) 
Galer et al. (2000)  5 2 2 1 71.4% (10/14) 
Geelen et al. (2016; 2017)  4 1 3 0 66.7% (8/12) 
Gore et al. (2005; 2006)  6 0 2 0 57.1% (8/14) 
Hoffman et al. (2009)  6 0 3 2 84.7% (11/13) 
Jacovides et al. (2014)  5 0 2 0 50% (7/14) 
Kulkantrakorn & Lorsuwansiri, (2013) 4 0 0 1 38.5% (5/13) 
Levterova et al. (2018)  5 2 3 2 92.3% (12/13) 
Lewko et al. (2007)  3 0 1 1 38.5% (5/13) 
Mai et al. (2015)  4 0 2 2 57.1% (8/14) 
Sadosky et al. (2013)  5 0 3 0 61.5% (8/13) 
Selvarajah et al. (2014)  5 1 3 1 77% (10/13) 
Themistocleous et al. (2016)  5 0 3 0 61.5% (8/13) 
Tölle et al. (2006)  5 0 1 0 46.2% (6/13) 
Van Acker et al. (2009)  5 2 3 2 92.3% (12/13) 
Vileikyte et al. (2009)  5 1 3 2 78.6% (11/14) 
Vileikyte et al. (2005)  5 1 3 2 84.7% (11/13) 
Wickramasinghe et al. (2016)  
 
5 1 3 1 77% (10/13) 
Zelman et al. (2005)  6 0 2 0 57.1% (8/14) 




The three RCTs were assessed with the Cochrane risk of bias tool, which showed that one study had 
low risk of bias (Otis et al., 2013), one study had unclear risk of bias (Teixeira, 2010) and the last had 
high risk of bias (Pfammatter, 2010). The studies were more likely to have low risk of bias for random 
sequence generation and high risk of bias in potential for selective reporting and “other” bias. More 
details on the quality assessment of the studies can be found in Tables 11, 12 and Figure 13. 
 
Figure 13: Quality of RCTs - Cochrane's Risk of Bias assessment tool 
4. Discussion and conclusions 
This systematic review was specifically focused on evidence for the role of psychosocial factors and 
related treatments in relation to outcomes in PDN. The relevant literature was heterogeneous and 
included few randomised-controlled trial designs. The search revealed twenty-seven studies 
(twenty-nine papers). These provide limited evidence of mixed quality for benefits from 
psychological interventions, and some high-quality evidence for associations between depression, 
anxiety, sleep, and QOL, typically in relation to pain in PDN. There was less evidence for other 
outcomes, such as physical, social, or emotional functioning. The results of this review identify a 
need for the further investigation of psychosocial processes in PDN, in relation to a wider set of 
clinical outcomes, guided by a clear theoretical model, and for theory-driven treatment 




The identification of only three small RCTs in the review limits the conclusions that can be drawn 
about the potential efficacy of psychosocial treatment for PDN. These were very small in size, 
included three distinctly different types of treatment and produced inconsistent results. The limited 
number of RCTs of psychological treatments for PDN contrasts the larger number of reasonably 
higher quality RCTs for chronic pain in general, estimated at 40 (Eccleston et al., 2015) and in 
conditions such as fibromyalgia where there are currently around 29 RCTs of CBT (Bernardy et al., 
2018). Notably, the lack of trials identified in the current review is consistent with a review of RCTs 
of psychological treatments for neuropathic pain (not restricted to PDN) (Eccleston et al., 2015). 
Unfortunately, the current evidence from these studies is not sufficient to support specific 
recommendations regarding effective psychological treatment for PDN. 
Current results provide limited clues regarding the types of psychosocial factors that might influence 
outcomes in PDN, and almost exclusively included psychological factors and not social ones.  With 
the exception of fear of negative evaluation, a clear social factor (Geelen et al., 2017), and a study of 
changing social perception (Vileikyte et al., 2009), none of the commonly studied social factors (e.g. 
social support, spouse responses), often found to relate to chronic pain, were featured in the 
available evidence here. 
This review found evidence of a mostly consistent positive association between depression and the 
presence, intensity or severity of pain in people with PDN, with effects ranging from small to large. 
This is consistent with a large body of findings in the wider chronic pain literature that persistently 
links depression and chronic pain outcomes and depressive symptoms with diabetes (Anderson et 
al., 2001; Banks & Kerns, 1996; Moreira, Amancio, Brum, Vasconcelos, & Nascimento, 2009; Rayner 
et al., 2016; Velly et al., 2011). Within the current review, the majority of the studies were cross-
sectional, which precludes statements about the direction of association between these variables. 




depression. Current results are also consistent with results from a meta-analysis of 27 studies 
investigating depression in diabetic patients that also showed a significant correlation between 
depression and complications of diabetes (De Groot et al., 2001). 
Another key finding arising from this review was the positive association, ranging from medium to 
large effects, between anxiety and pain severity or intensity. Only one of five studies found an 
inconsistent effect. This overall result is consistent with the broader chronic pain literature where 
anxiety is found to either contribute to, or reflect effects of, poor functioning and health (Kroenke et 
al., 2013). Anxiety and depression are often highly correlated when measured simultaneously in the 
same sample. The degree to which the present findings for these variables reflect significantly 
distinct processes and targets for change is unclear (McCracken & Morley, 2014; Turk, Audette, Levy, 
Mackey, & Stanos, 2010). 
Some of the most frequently studied variables in the context of chronic general or musculoskeletal 
pain include catastrophizing and acceptance (Quattrini & Tesfaye, 2003; Sugiura & Sugiura, 2016). 
Here, in contrast, only three studies included catastrophizing and two studies examined some form 
of acceptance. Overall, these studies did not provide a clear basis for inferring the size of the 
association or potential utility of either of these variables for guiding treatment development for 
PDN. Only one study (two papers) investigated the relationship between pain-related fears and pain. 
This study showed a large, positive association between various fears, including fears of pain, 
hyperglycaemia, falling, fatigue, with increased neuropathic disability, reduced QOL and pain 
intensity. This was, as far as we are aware, the first study aiming to specify pain-related fears in PDN 
population. The fact that there is only one study of fear in relation to PDN may appear surprising as 
the Fear-Avoidance Model is otherwise a widely applied and productive model of disability in chronic 
pain in general (Boselie & Vlaeyen, 2017; Leeuw et al., 2007a; Vlaeyen, de Jong, Geilen, Heuts, & van 




their measurement. This again can point to the need for conceptual clarity in the choice of variables 
we investigate. 
Evidence of medium to large associations was also found between pain and sleep disruption in the 
present systematic review, based on three studies. This may be a potentially useful relation as poor 
sleep appears common in individuals with neuropathic pain in general and with PDN in particular 
(Quattrini & Tesfaye, 2003; Zelman et al., 2006). Poor sleep in the context of chronic pain appears 
potentially modifiable (Daly-Eichenhardt, Scott, Howard-Jones, Nicolaou, & McCracken, 2016; Tang 
et al., 2015) and is a target that could guide treatment development. 
The majority of the studies reviewed included QOL. Predominantly these studies focused on the 
impact of the disease, designed to document the impact of PDN on QOL. Most studies found large 
associations between pain and poor QOL. This is not surprising and in fact both direct adverse 
impacts of PDN on QOL, and indirect impacts from depression and anxiety in the context of PDN, are 
well documented (Gormsen, Rosenberg, Bach, & Jensen, 2010; Grandy, Chapman, & Fox, 2008; 
Schram et al., 2009; Svendsen, Jensen, Hansen, & Bach, 2005). The reason that, in a sense, we have 
turned QOL around and conceived it as a potential influence on other outcomes in PDN, is that we 
feel that components of QOL, particularly the more behavioural components, such as social and 
physical activities, are essentially directly modifiable. We know from general chronic pain studies 
that it is possible to take a direct approach to improving daily activities, for example, and achieve 
both improvements in these activities and in such outcomes as pain, depression, and other 
symptoms at the same time (Hann & McCracken, 2014).  
It is notable that there were three additional studies of biofeedback identified during the literature 
search (Fiero, Galper, Cox, Phillips, & Fryburg, 2003; Pataky et al., 2009; Rodriguez et al., 2013). 
However, the reported treatment outcomes were physiological, for example temperature reduction, 




studies were excluded from this systematic review. Thus, future studies exploring biofeedback in this 
context might benefit from including measures of pain and functioning as outcomes. 
Overall, setting aside QOL as a direct treatment target, available evidence reveals that few 
modifiable psychosocial factors have been studied in the literature of PDN. Also, when they are 
studied, they are generally examined in relation to pain as an outcome, and not in relation to a wider 
range of outcomes, such as physical, social, or emotional functioning. In this systematic review, 
variables like anxiety, depression and QOL are treated as both outcomes and correlates of outcome. 
A few studies examined correlations with these variables, except for pain, pain severity, pain 
interference, and acceptance of pain. Most of the studies include anxiety and depression as 
potential independent variables. Only six studies, all cross-sectional, examined such otherwise 
frequently studied variables as catastrophizing, fear, or acceptance. What seems to be entirely 
missing are studies of conventional variables such as beliefs or coping (Eccleston et al., 2015) or 
other facets of psychological flexibility (McCracken & Morley, 2014). Hence, results, as they stand, 
do not identify specific psychosocial factors or treatment methods that ought to be targeted or 
applied in PDN, nor do they appear to provide clear guidance for treatment development, other than 
to highlight the potential role of emotional functioning, sleep, and perhaps a direct approach to daily 
functioning. The very limited studies of psychological treatments or psychosocial factors in PDN 
compared to other chronic pain conditions, particularly in the context of the clear treatment needs 
in PDN, raises question as to why this is the case, and what might be the barriers to psychological 
studies in this population. 
Several limitations of this systematic review need to be considered. Our defined population was 
explicitly adults, therefore, the results of this review cannot be generalised to children and 
adolescents. We used broad search terms for PDN, psychosocial factors and psychological 




possible that we may have missed studies. We calculated effect sizes based on the given mean and 
SDs, but not all studies provided sufficient data for effect sizes. We collapsed multiple between-
groups analyses into dichotomous comparisons to enable comparison across studies to minimise 
paired comparisons; however, this may have eliminated a more subtle understanding of the 
association between psychosocial factors and pain outcomes. 
Future research is encouraged to examine a wider array of theoretically-based psychosocial factors 
than currently done and to more deeply pursue the utility of such current theoretical models as Fear 
Avoidance Model and Psychological Flexibility model. Naturally, studies from either of these models 
can incorporate the role of emotional functioning, and ought to do so, as this domain is the one that 
is most clearly highlighted here as relevant, and it appears that the Psychological Flexibility Model 
can address sleep (Daly-Eichenhardt et al., 2016; McCracken, Williams, & Tang, 2011). 
There appears to be a clear potential for non-pharmacological, particularly psychological treatments, 
for PDN. The current review does not, however, clarify specific psychological processes to target, 
certainly not comprehensively. The absence of fully powered, high-quality studies of psychological 
treatment for PDN found here is notable.  Future trials may explore questions around non-
participation and drop-out and ways to enhance access and acceptability in addition to the core 
questions of effectiveness. It is recommended that future treatments aim not only to treat pain but 
also improve other aspects of the condition, such as emotional and physical functioning, and 
participation in life in general. The challenge here then seems to be the identification of a model of 
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3.3 Summary 
This chapter describes a systematic review aiming to identify psychosocial factors associated with 
PDN through survey studies and treatment trials. We identified 24 observational studies and 3 
treatment trials. Key results suggested that depression, anxiety, sleep and quality of life are the most 
studied variables in relation to pain outcomes in PDN, each demonstrating consistently predictable 
associations mostly in relation to pain in PDN. 
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Chapter 4: The Application of Psychological Flexibility and Acceptance and 
Commitment Therapy (ACT) in Adults with Painful Diabetic Neuropathy: A 
Cross-Sectional Survey 
4.1 Chapter Overview  
As discussed in chapter 2, there is a growing body of evidence supporting the acceptability and 
efficacy of ACT in people with chronic pain. Likewise, a growing number of studies have examined 
particular treatment processes within the PF model including acceptance, committed action, 
cognitive fusion, self as a context, and values in chronic pain. However, only two studies (Lewko et 
al., 2007; Selvarajah et al., 2014) have measured pain acceptance in PDN and no studies have 
investigated other PF processes or evaluated the applicability of the PF model and the potential 
suitability of ACT in people with PDN. This chapter aims to examine the role of PF in people with PDN 
and whether ACT is potentially relevant for this population via a cross-sectional survey.  
This chapter is published in the following article at The Journal of Contextual Cognitive Behavioral 
Science (Appendix Q): 
Kioskli, K., Winkley, K., & McCracken, L. M. (2019). Might psychological flexibility processes and 
Acceptance and Commitment Therapy (ACT) apply in adults with painful diabetic neuropathy? A 
cross-sectional survey. The Journal of Contextual Cognitive Behavioral Science. 13(2019), 66-73. 
Chapter naming and numbering are presented as they are in the published article. 
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4.2 Published Article  
Manuscript Number: JCBS_2019_37 
Title: Might psychological flexibility processes and Acceptance and Commitment Therapy (ACT) apply 
in adults with painful diabetic neuropathy? A cross-sectional survey 
Article Type: Research Article 
Corresponding Author: Lance M McCracken, PhD 
Corresponding Author's Institution: King's College London 
Authors: Kitty Kioskli, MSc; Kirsty Winkley, PhD 
Funding sources This study is funded through a PhD fellowship grant awarded from Diabetes UK. 
Professor Lance McCracken was partly funded through the Biomedical Research Centre at South 
London and Maudsley NHS Foundation Trust and King’s College London.  
Conflicts of interest: None declared. 
Note: This is the authors' accepted copy. 
Highlights: 
• Psychological Flexibility is thought to contribute to processes of pain, emotional experiences, and 
daily activities. 
• Pain severity is associated with psychological functioning for people with Painful Diabetic 
Neuropathy. 
• Psychological Flexibility components may improve psychological treatments for people with PDN. 
  




Painful diabetic neuropathy (PDN) is a distressing and disabling condition. There is, surprisingly, 
relatively little research into the role of psychological variables related to PDN. The aim of this study 
was to investigate the association between psychological flexibility, daily functioning, and distress in 
people with PDN. This cross-sectional study included 225 participants who were recruited from 
hospital services and online. In correlation analyses, acceptance of pain was shown to be negatively 
correlated with pain intensity (r=-0.21, p<0.01), pain distress (r=-0.25, p<0.01), functional 
impairment (r=-0.38, p<0.01), depression severity (r=-0.41, p<0.01), and depression impact (r=-0.41, 
p<0.01). Cognitive fusion correlated positively with pain intensity (r=0.14, p<0.05), functional 
impairment (r=0.24, p<0.01), depression severity (r=0.44, p<0.01), and depression impact (r=0.20, 
p<0.01). Committed action correlated negatively with functional impairment (r=-0.22, p<0.01), 
depression severity (r=-0.43, p<0.01), and depression impact (r=-0.21, p<0.01). In regression 
analyses, the four variables representing psychological flexibility accounted for significant variance in 
all the equations except in the case of pain distress. However, in some cases the variance accounted 
for was less than that accounted for by pain intensity. For example, in the equation for functional 
impairment, pain intensity accounted for 32.2% of the variance, while psychological flexibility 
accounted for 6.8% of the variance. These results suggest that psychological flexibility may play a 
smaller role, relative to pain intensity, in the context of PDN as compared to the larger populations 
of chronic, mostly musculoskeletal, pain. The reliability and generalisability of these results need to 
be established.  
Key Words: painful diabetic neuropathy; cross-sectional survey; psychological flexibility; Acceptance 
and Commitment Therapy 
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1. Introduction  
The World Health Organization (WHO, 2016) estimates that approximately 422 million adults live 
with diabetes mellitus (DM) worldwide. If DM is poorly managed, it can lead to complications, such 
as kidney failure, heart disease, stroke, blindness and neuropathy. The most common type of 
neuropathy caused by DM is painful diabetic neuropathy (PDN), affecting 25-30% of people with DM 
(Daousi et al., 2004; Davies, Brophy, Williams, & Taylor, 2006; Geelen et al., 2017). PDN is a complex 
condition affecting the peripheral nervous system (Treede et al., 2007), resulting in loss of sensation, 
numbness, and a burning, sharp, electrical, stinging pain in the affected area, which often worsens at 
night (Bouhassira et al., 2005; Daousi et al., 2004; Davies et al., 2006; Geelen et al., 2017). It is 
known to negatively affect physical and mental health, to reduce overall quality of life (Benbow, 
1998; Fernando et al., 2013; Galer et al., 2000; Gore et al., 2005; Van Acker et al., 2009; Vileikyte et 
al., 2009), and to impact work, social life, general activities, and sleep (Geelen et al., 2017). There are 
few studies of the role of psychological processes in people with PDN (Kioskli et al., 2019) and these 
have focused on a narrow set of variables, such as depression and anxiety (Gore et al., 2005), and 
fears (Geelen et al., 2017). 
Forms of cognitive behavioural therapy (CBT) are the most often used psychological treatments for 
chronic pain. These include contextual forms of CBT, such as Acceptance and Commitment Therapy 
(ACT) (Hayes et al., 1999; McCracken & Morley, 2014; McCracken & Vowles, 2014). ACT is a form of 
CBT that includes methods of acceptance, mindfulness and behaviour change (Hayes et al., 2003) 
and explicitly focuses on increasing psychological flexibility (PF; Hayes et al., 2011). PF is a model of 
wellbeing and performance that includes six related processes: acceptance, cognitive defusion, 
present moment awareness, self-as-context, values, and committed action (Hayes et al., 2006). This 
is sometimes referred to as a focus on openness to experiences, awareness of the present moment, 
and engagement in actions that are guided by values and goals (Hayes et al., 2011). The current 
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literature indicates that ACT and closely allied approaches are at least as effective as other 
psychological approaches for managing chronic pain (Hann & McCracken, 2014).  
Current treatment options for PDN are mainly pharmacological. There are only four RCTs of 
psychological treatments for PDN, including CBT, mindfulness, mindfulness-based stress reduction 
(MBSR) and thermal biofeedback assisted relaxation (Otis et al., 2013; Nathan et al., 2017; 
Pfammatter, 2010; Teixeira, 2010). The results from the mindfulness study (Teixeira, 2010) 
suggested a small between-group effect in the mindfulness group on quality of life (d=-0.16, 95% CI: 
-1.1 - 0.78) and large effect on sleep (r= 0.53, 95% CI: 0.048 - 0.813). No significance was speculated. 
Evidence from the biofeedback study (Pfammatter, 2010) did not produce any statistically significant 
results. The CBT study (Otis et al., 2013), an RCT (N=20), showed significant decreases in pain 
severity and pain interference in the CBT group, at post-treatment and follow-up (d= 0.83-0.91), 
compared to the control group. Results from the MBSR study (Nathan et al., 2017) showed that 
more than half of participants in the experimental group (19/30) improved in depression, pain 
interference, quality of life, catastrophizing and function. Overall, their results are promising and, at 
the same time, due to small sample sizes or small effects, show no clear evidence-based 
psychological approach for PDN. 
Previous studies of chronic pain provide support for the role of PF in relation to well-being and daily-
functioning, in people with mixed chronic musculoskeletal pain conditions, (McCracken, Gauntlett-
Gilbert, & Vowles, 2007; Vowles, McCracken, & Eccleston, 2008; McCracken & Velleman, 2010) 
chronic low back pain (Mason, Mathias, & Skevington, 2008), and fibromyalgia (Yu, Norton, 
Almarzooqi, & McCracken, 2017). Preliminary evidence of this type has led in turn to successful 
treatment trials of ACT in these conditions (Hann & McCracken, 2014). We simply do not know 
whether the results from studies of PF in the context of chronic musculoskeletal pain will be 
replicated in the context of PDN, again, a condition for which there are very few psychological 
studies, and none focused on PF. 
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The complex and particularly intractable qualities of PDN are important as motivators for research 
into the role of PF. The prospects for pain control are practically very limited, even when compared 
to other pain conditions, and hence an approach that supports the capacity to function without pain 
control, and in the midst of multiple co-morbid symptoms, appears relevant to this condition. 
However, no published studies have yet explored either the suitability of ACT or the applicability of 
PF to individuals with PDN. 
Finally, there is one more motivation for the study of PDN in a context of many studies of other pain 
conditions. It appears that neuropathic pain conditions in clinical practice are implicitly mainly 
regarded as mainly a physical problem with relatively little psychological input (Kioskli et al., 2019), 
possibly because that pathology underlying the pain appears undeniable. This conclusion is 
supported by evidence from large cohorts of people seeking specialty treatment for chronic pain 
where few, if any, report diagnosis of neuropathic pain (Mason et al., 2008; McCracken & Velleman, 
2010; Yu et al., 2017). We argue that, in order to overcome this bias against access to psychosocial 
thinking and treatment development for PDN, evidence for the role of psychological factors must be 
shown in this condition specifically. 
Neuropathic pain has different physiology from non-neuropathic pain, otherwise called nociceptive 
pain. This distinction is also sometimes called pathophysiological versus physiologic (Akter, 2019). 
Neuropathic pain is caused by damage to either the central or the peripheral nervous system or 
both. This type of pain is generally never useful for the individual - it never serves a useful purpose, 
such as to warn about a potential injury or to support healing. Also, neuropathic pain is more likely 
to be chronic. The basic characteristics of nociceptive or physiologic pain are that it is caused by 
activation of nociceptors, alerts the individual in order to avoid injury and passes over time (Pasero, 
2004). Even though there are a large number of studies examining psychosocial factors in general 
pain conditions that are predominantly nociceptive this is not the case for neuropathic pain. 
The purpose of the present study is to survey people with PDN and examine the role of PF in relation 
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to their daily functioning, including emotional functioning. Our research question is whether PF, here 
including acceptance, cognitive defusion, committed action, and self-as-context, is relevant and 
potentially beneficial for people with PDN. We measure only 4 out of 6 PF processes, not including 
values-based actions and present-moment awareness, because these facets sample from each of the 
broader categories of “openness,” “awareness,” and “engagement,” dimensions of PF, and at the 
same time leave out the facets that we felt are least well assessed at the time the study was 
planned. Two “openness” facets were included: acceptance because it is the most studied and 
easiest to compare with other studies, and cognitive defusion because it was deemed important to 
include a cognitive component in the study due to the high importance placed on cognitive 
processes in all current psychological models of chronic pain. We predicted that each process 
measured here would be relevant and that a potentially important role would be shown significant 
correlations between measures of PF and measures of pain and daily functioning in this group, and 
significant increments of explained variance in multivariate analyses.  
2. Methods 
2.1 Study design and participants 
The current study was a cross-sectional survey of adults with Type 1 and Type 2 diabetes and PDN. 
Participants were included regardless of any treatment they were receiving. The sample was 
recruited from pain and diabetes hospital services, from Diabetes UK (DUK), other websites designed 
to support people with pain, and via social media (i.e. Twitter). The recruitment started on 6 of 
February 2018 and finished on 6 of May 2018. 
2.2 Sample size 
A priori estimation was used to determine the required sample size based on several considerations.  
First, for multiple regression analyses, we based our estimate on similar studies (Billingham, 
Whitehead, & Julious, 2013; Chilcot et al., 2015). We also based it on modelling a regression 
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equation with 12 predictors and an effect size (Muller & Cohen, 1989) of f2=0.15 (medium effect), 
with power set at 0.80. This suggested a need for a sample size of at least 127.  Finally, we also 
considered possible missing data, and the need for an adequate sample size for secondary validity 
analyses of the instruments being used, as well as sensitivity analyses based on the mode of 
recruitment. We thus aimed to recruit a minimum of 200 participants. 
2.3 Procedure 
Ethical approval was gained for this study (Surrey Research Ethics Committee, 29/1/2018. Ref: 
17/LO/2047). Informed consent was obtained from all participants, described below in more detail. 
The inclusion criteria for this study were having an age of 18 years or more, living in the UK, having 
either a confirmed or self-reported diagnosis of diabetes mellitus (DM), having suffered from self-
reported PDN for the last three months or more, having the ability to take part in the study, and the 
ability to provide informed consent. Diabetes diagnosis was assessed, using one participant self-
report question. We also screened for possible neuropathic pain by one self-report question and the 
validated screening questionnaire, Douleur Neuropathique 4 (DN4). DN4 was not administered to 
the whole sample, but to a subgroup of participants, as it was not initially a high priority concern to 
obtain this kind of screening data, and in order to reduce the length of the survey. Also, the study 
did not have the resources to contact participant’s general practitioners and diabetes specialists for 
further information for those recruited online. We assume that people would only self-identify as 
having PDN if they had actually been given that diagnosis, and any exceptions to this would be rare. 
Participants recruited from the hospital services also had a physician’s diagnosis for DM and PDN. 
Potential participants who were not able to understand verbal explanation or written information in 
English were excluded from the study, as no resources were available to translate the survey or to 
produce and validate the standardized measures being used in other languages. 
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Participants were recruited either online or face-to-face through hospital services. In particular, 
within the hospital services, participants were identified by diabetes and pain clinical care teams. A 
member from our research team (KK) then approached the potential participants, in the relevant 
outpatient clinics, explained the study and answered questions. Participants who agreed to take part 
then gave consent and received the recruitment pack.  
A total of 120 participants were initially approached in person. Of the 120 invited this way, 60 did 
not meet the inclusion criteria (N=25 not being diagnosed with diabetes, N=35 suffering from 
neuropathy due to other causes than diabetes), and 38 declined to take part. Reasons for non-
participation included, the length of the questionnaires (N=16), not being able to understand written 
information in English (N=10), and some eligible participants declined to give a reason (N=12). A 
total of 14 completed the pen-and-paper version of the presented survey. Two out of the 14 
participants did not adequately complete the questionnaire and were excluded. In total 12 
participants were recruited from hospital services. 
Online recruitment was conducted through sending targeted online invitations to diabetes 
organisations with an online presence and through social media. An email was sent to the charity 
Diabetes UK (DUK), explaining the study and the inclusion criteria of participants and asking to 
publicise it through any available means, such as special interest forums and their website. Within 
the email, there was also a link to the online version of the survey. DUK posted the link on the 
recruitment page (https://www.diabetes.org.uk/research/take-part-in-research) and forum. 
Recruitment was also done via  Twitter and two discussion forums sponsored by charity supported 
websites,  ‘Pain Support’ (https://painsupport.co.uk/) and ‘Pain Concern’ 
(http://painconcern.org.uk/how-we-help/forum/). Particularly, 130 people were recruited from 
DUK’s website, 40 from DUK’s forums, 7 from Twitter, 17 from Pain Support forum and 19 from Pain 
Concern forum. In total 213 participants were recruited from online sites. This dual method of 
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recruitment, in clinic and online, aimed to include a wider sample of people suffering from PDN and 
achieving the targeted sample size. 
2.4 Measures 
The participants who agreed to take part in the survey completed a series of psychometrically 
validated assessment measures. The following additional variables were assessed through self-
report questions: age, gender, ethnicity, education, work status, marital status, type of diabetes, 
presence of neuropathy, duration of pain, and specific pain locations. The survey was administered 
via paper or a widely available survey platform, Bristol Online Survey (BOS, 
https://www.onlinesurveys.ac.uk/). This is an easy to use portal to create a survey and used by many 
institutions. BOS is flexible and does not require any technical knowledge to set-up the survey or 
collect the data. 
2.4.1 Chronic Pain Acceptance Questionnaire (CPAQ-8) 
The CPAQ-8 is a measure of acceptance of chronic pain. It includes engagement in activities while 
experiencing pain and willingness to experience pain without trying to control or avoid it (McCracken 
et al., 2004; McCracken, & Velleman, 2010). CPAQ-8 is based on the 20-item questionnaire, and this 
version consists of 8 items and has also been fully validated (Fish, McGuire, Hogan, Morrison, & 
Stewart, 2010). Items are rated on a scale from 0 (never true) to 6 (always true). Higher scores 
reflect greater acceptance of pain. In the current sample, the CPAQ-8 demonstrated good internal 
consistency (Cronbach’s α =0.87). 
2.4.2 Cognitive Fusion Questionnaire (CFQ-7) 
The CFQ-7 is a measure of cognitive fusion (Gillanders et al., 2014). Cognitive fusion refers to a 
domination of cognitive influence over direct experiential influence on behaviour, and a lack of 
separation between the content of the thoughts and the situations or people to which they refer. 
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Cognitive defusion, on the other hand, is the ability to see thoughts as just thoughts, and not as 
essential reflections of events as they are directly experienced. The CFQ-7 consists of seven items 
rated on a 1 (never true) to 7 (always true) point scale. An early version of the CFQ has been 
validated in chronic pain samples based on significant predicted correlations with acceptance and 
daily functioning in people with chronic pain (McCracken, DaSilva, Skillicorn, & Doherty, 2014). The 
updated version was used in the present survey. In the current sample, the CFQ-7 demonstrated 
good internal consistency (Cronbach’s α =0.95). 
2.4.3 Committed Action Questionnaire (CAQ-8) 
The CAQ-8, is an eight-item measure of committed action, a facet of PF (McCracken, 2013; 
McCracken, Chilcot, & Norton, 2014). Committed action is the ability to persist with actions that are 
guided by goals, including when this runs into discouraging experiences and to change these actions 
when they are shown to be ineffective. Responses to the items were rated from 0 (never true) to 6 
(always true).  Out of the eight items four are positively keyed and four negatively keyed. Scores 
from the CAQ-8 have demonstrated relations with measures of acceptance, and of emotional, 
physical, and social functioning in people with chronic pain, supporting construct validity 
(McCracken et al., 2014). In the current sample, the CAQ-8 demonstrated good internal consistency 
(Cronbach’s α =0.81). 
2.4.4 Douleur Neuropathique 4 (DN4)  
Presence of neuropathic pain was assessed with a screening measure called DN4. It consists of four 
interview questions and has also been psychometrically validated as a self-report measure 
(Bouhassira et al., 2005). It has a specificity of 83% and sensitivity of 90% (Spallone et al., 2012). In 
the current sample, the DN4 demonstrated adequate internal consistency (Cronbach’s α = 0.75). This 
questionnaire was only administered to a subsample (N=75), to reduce the length and burden of the 
survey. The subsample was selected from their response to a question at the end of the survey 
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asking if they would be willing to take part in further research, if they answered ‘yes’, we contacted 
them and asked them to respond to the DN4. The purpose was to give evidence to support, or 
essentially validate, the self-report method which was used in the full sample.  
2.4.5 Pain Scale 
Pain intensity and pain-related distress were assessed through four validated questions using 0 (no 
pain/distress) to 10 (worst possible pain/distress) numerical ratings. Participants were asked to rate 
their pain right now and in the past week, and how distressing their pain is right now and in the past 
week (Jensen, Turner, Romano, & Fisher, 1999; Von Korff, Ormel, Keefe, & Dworkin, 1992). In the 
current sample the reliability of the pain intensity and pain distress scale was calculated with the 
Spearman-Brown formula, due to the fact that each scale has only two items and is was r= 0.86 in 
each case (Eisinga, Grotenhuis, & Pelzer, 2012). 
2.4.6 Patient Health Questionnaire (PHQ-9) 
The PHQ-9 is a widely used, reliable and validated, measure used as an index for depression severity. 
It includes ten items based on DSM-IV. The first nine items reflect severity of depression symptoms 
and each is rated on a scale from 0 (not at all) to 4 (nearly every day). The last item, item ten, is a 
measure of impact of depression and is rated from ‘not difficult at all’ to ‘extremely difficult’ - this 
item was used as an additional variable to study here because within the psychological flexibility 
model the impact of symptoms of functioning is regarded as a particularly important potential 
outcome in treatment. The higher score for the sum of the nine items indicates higher levels of 
depression severity (Kroenke, Spitzer, & Williams, 2001). In the current sample, the PHQ-9 
demonstrated good internal consistency (Cronbach’s α =0.84). 
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2.4.7 Self Experiences Questionnaire (SEQ) 
The SEQ is a 15-item self-report measure of self-as-context, within the PF model (Yu, McCracken, & 
Norton, 2016). This “contextual self” is defined as a sense of self that is not based upon self-
evaluations and is separate from one’s thoughts and feelings. This could also be referred as, taking a 
point of view on one’s psychological experiences, seeing oneself as distinct from one’s psychological 
experiences, or as “perspective taking”. All items are rated on a scale from 0 (never true) to 6 
(always true). All items are positively keyed, and higher scores indicate higher PF. The construct 
validity of the SEQ has been supported in demonstrated significant expected correlations with 
acceptance, committed action, and decentring, and with depression and daily functioning in people 
with chronic pain (Yu et al., 2016). In the current sample, the SEQ demonstrated good internal 
consistency (Cronbach’s α =0.98). 
2.4.8 Work and Social Adjustment Scale (WSAS) 
The WSAS is a five-item, reliable and validated self-report measure of impairment in work and social 
functioning, or as we label here, “functional impairment” (Mundt, Marks, Shear, & Greist, 2002). 
WSAS items refer to work, home management, social and private leisure, and relationships. Each 
item is rated from 0 (no impairment) to 8 (very severe impairment).  The validity of the WSAS is 
supported by significant correlations with measures of psychiatric symptoms and it is shown to be 
sensitive to the effects of treatment (Mundt et al., 2002). In the current sample, the WSAS 
demonstrated good internal consistency (Cronbach’s α =0.93). 
2.5 Statistical Analyses 
The collected data were analysed with the Statistical Package for Social Science (version 18.0 IBM, 
SPSS). Limited missing data in the standardized inventories were substituted by mean imputation. 
The total sample size was 225 participants. Descriptive statistics, including means and standard 
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deviations (SDs) for continuous variables and frequencies and percentages for categorical variables, 
were calculated for the sample. 
All standardized measures were scored according to their standard instructions. The variables 
consisting the PF facets were: acceptance of chronic pain (CPAQ-8), cognitive fusion (CFQ-7), 
committed action (CAQ-8), and self-as-context (SEQ). The dependent variables of the study were 
pain and pain-related distress (pain scale), functional impairment (WSAS), depression (PHQ-9), and 
depression impact (PHQ-9 item 10). Preliminary analyses included t-tests and correlation analyses 
examining relations between the pain outcomes and functioning variables and the PF variables with 
individual’s background characteristics.  
Three sets of analyses were conducted to address the main purpose of this study. The first set 
included correlation analyses between the four PF variables, with pain, functional impairment, and 
depression variables. These analyses were conducted to first identify significant unadjusted 
relationships between these variables in order to then proceed to a multivariate approach with 
linear, hierarchical, multiple regressions. Multiple regression analyses were designed both to 
consider and statistically control the role of age, education, sex, pain duration, and pain intensity, 
and to examine the proportion of variance accounted by acceptance of chronic pain, cognitive 
fusion, committed action, and self-as-context, uniquely and combined, in relation to the measures of 
participant’s functioning.  
3. Results 
3.1 Sample Characteristics 
A total of 225 people participated in this survey. The mean age of all participants was 52.05 (SD= 
12.06) years. Women represented 64.9% of the sample and white ethnicity 82.2%. The mean years 
of education was 14.98 (SD=3.76) and mean years of pain duration was 7.16 (SD=9.02). Employment 
status was categorized as follows: full-time employment (24%), employed part-time due to pain 
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(22%), employed part-time due to other reasons (13%), retired (24%), unemployed due to pain 
(10%), and full-time student (7%). The mean DN4 score was 7.15 (SD =2.39) and 92.7% exceeded the 
cut-off, an overall score of 4, for neuropathic pain. The 12 participants recruited from hospital 
services and 213 from online did not differ on background variables or the measures of psychological 
flexibility or pain outcome measures and were treated as one sample. 
3.2 Preliminary analysis 
Each primary variable was examined for normality by using histograms, Q-Q plots, and indices of 
skewness and kurtosis. None of the primary measures in this study produced significantly skewed 
distributions or outliers expected to adversely affect correlation-based analyses. The total scores of 
all measures were considered normally distributed. See Table 13 for means, ranges and standard 
deviations for the primary study variables. 
Pain intensity and distress variables differed significantly by gender, with men reporting higher 
scores of pain intensity, t = -3.09, p < 0.01, and pain-related distress, t = -2.86, p < 0.01. Participants 
of white ethnicity reported lower scores in terms of committed action, t = -2.64, p < 0.01, functional 
impairment, t = -2.96, p <0.01, and self-as-context, t = -3.82, p < 0.01, than the non-white group of 
participants. Employed participants scored significantly lower in terms of committed action, t = -
2.73, p < 0.01, functional impairment, t = -2.97, p <0.01, and self-as-context, t = -3.44, p < 0.01 
variables than those who are not employed.  
Preliminary correlation analysis showed that age was correlated with committed action, depression 
severity, and self-as-context, r = -0.23, p < 0.01; r = 0.19, p < 0.01, and r = -0. 24, p < 0.01 
respectively. Years of education was found to be correlated with all primary variables except 
cognitive fusion, including pain intensity: r = 0.20, p < 0.01; acceptance of pain: r = -0.16, p < 0.05; 
committed action: r = -0.20, p < 0.01; depression severity: r = 0.21, p < 0.05; functional impairment: r 
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= 0.21, p < 0.01; self-as-context: r = - 0.14, p <0.05. Duration of pain was not significantly correlated 
with any of the variables. 
Table 13: Means and standard deviations for standardized psychological flexibility variables, health 
and functionality outcome variables (N = 225) 
 
3.3 Correlation analyses 
The four primary PF variables were not found to be correlated with each another at a level that 
would suggest problems of multicollinearity in regression analyses (r < .80, Grewal, Cote, & 
Baumgartner, 2004). In fact, the highest correlation between these variables was r =.54. Please see 
Table 14. 
Correlations between acceptance of pain, cognitive fusion, self-as-context, and committed action 
and pain intensity with pain-related distress, functional impairment, depression severity, and 
depression impact are included in Table 15. Pain intensity positively correlated with pain distress, 
r=0.87, p<0.01, functional impairment, r=0.57, p<0.01, depression severity, r=0.51, p<0.01, and 
 Possible Range Sample Mean Standard Deviation 
Pain intensity (Rating Scales) 0-10 4.31 2.24 
Pain distress (Rating Scales) 0-10 4.52 2.43 
Functional impairment (WSAS) 0-40 17.67 11.48 
Depression severity (PHQ-9 items 1-9) 0-27 12.05 7.00 
Depression impact (PHQ-9 item 10) 0-3 1.83 0.64 
Acceptance of pain (CPAQ-8) 0-48 25.01 4.88 
Cognitive fusion (CFQ) 7-49 24.33 11.06 
Committed action (CAQ-8) 0-48 21.08 8.16 
Self-as-context (SEQ) 0-90 40.98 21.17 
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depression impact, r=0.40, p<0.01. Acceptance of pain negatively correlated with pain intensity r=-
0.21, p<0.01, pain distress, r=-0.25, p<0.01, functional impairment, r=-0.38, p<0.01, depression 
severity, r=-0.41, p<0.01, and depression impact, r=-0.41, p<0.01. Cognitive fusion positively 
correlated with pain intensity r=0.14, p<0.05, functional impairment, r=0.24, p<0.01, depression 
severity, r=0.44, p<0.01, and depression impact, r=0.20, p<0.01. Additionally, committed action 
negatively correlated with functional impairment, r=-0.22, p<0.01, depression severity, r=-0.43, 
p<0.01, and depression impact, r=-0.21, p<0.01. Lastly, self-as-context negatively correlated only 
with depression severity, r=-0.31, p<0.01. 




* p < .05, two-tailed 
** p < .01 two-tailed 
  
 1 2 3 4 
1. Acceptance of pain -    
2. Cognitive fusion -.25*    
3. Committed action .40** -.42**   
4. Self-as-context .27** -.20** .54** - 
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Table 15: Correlations between psychological flexibility variables, health and functioning, and pain 
* p < .05, two-tailed 
** p < .01 two-tailed 
 
3.4 Multiple regression analyses  
Multiple regression analyses were conducted to examine the unique and combined role of PF 
variables, after adjusting for individuals’ characteristics and pain intensity, in relation to the 
measures of health and functioning: pain-distress, functional impairment, depression severity, and 
depression impact. Hence four regression equations were conducted. 
The potential predictors were tested hierarchically in each of these equations. Participants’ age, 
gender, education and duration of pain were firstly tested and retained in the equations when 
significant (first block, p < 0.05 to enter, p > 0.10 to remove). Afterwards, the pain intensity average 
score was entered to control its contribution to the prediction of each criterion variable (second 
block). Finally, acceptance of pain, cognitive fusion, committed action, and self-as-context scores 
were entered together in a single block to examine their contribution. The regression results are 
shown in Table 16. 
Education was entered and retained as a significant predictor at entry into all the equations. 












Pain intensity - .87** .57** .51** .40** 
Acceptance of pain -.21** -.25** -.38** -.41** -.41** 
Cognitive fusion .14* .12 .24** .44** .20** 
Committed action -.05 -.12 -.22** -.43** -.21** 
Self-as-context -.05 -.07 -.07 -.31** .00 
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the regression equations. It should be noted that education accounted for modest increments of 
variance at entry, no more than 7.7%. Gender and duration of pain were not significant predictors at 
entry in the equation for depression impact, depression severity or functional impairment. Gender 
was a significant predictor of pain distress, with men experiencing more pain distress than women, 
explaining 3.1% of the variance. Gender did not remain significant in the final step of the regression 
equation. Finally, age was a significant predictor of both depression impact and depression severity 
and accounted for a 3.0% and a 2.3% increment of variance, respectively. As age increased, 
depression impact and depression severity also increased. Age remained significant only in the final 
step of depression impact regression equation. 
The pain intensity variable was a significant predictor at entry and remained significant in all the 
equations. In the equation for functional impairment, pain intensity had the largest regression 
coefficient and the ΔR2 (change in variance or R2) value, higher than that of the four PF variables 
combined, reflected 32.2% of the variance. In the equation for depression severity, pain intensity 
once again had the largest regression coefficient and the ΔR2 value, close to that of the four PF 
variables combined, reflected 23.3% of the variance. In the equation for pain distress, pain intensity 
had the largest regression coefficient and the ΔR2 value, higher than that the four PF variables 
combined, reflecting 67.1% of the variance. In the equation for depression impact, pain intensity had 
the largest regression coefficient and the ΔR2 value, close to that of the four PF variables combined, 
reflected 13.2% of the variance. 
The combination of the four variables representing PF variables accounted for a significant 
increment of variance in all the equations except in the case of pain distress. In the equation for 
functional impairment, PF variables accounted for 4.5% of the variance, although only the coefficient 
for acceptance of pain was significant. In the case of depression severity, acceptance of pain, 
cognitive fusion and committed action had significant regression coefficients and the variance 
accounted for was 7.5%. In the case of pain distress, no significant regression coefficient was found 
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from among the PF variables. In the case of depression impact, acceptance of pain and self-as-
context had significant regression coefficients and the variance accounted for was 11.4%. 
Standardized regression coefficients and the squared semi-partial correlation coefficients reveal the 
relative role of the four separate processes when considered together. Mean proportions of unique 
variance contributed (sr2) from all the equations were as follows: acceptance of pain, 0.033, 
cognitive fusion, 0.011, committed action, 0.008, pain intensity, 0.294, and self-as-context, 0.011.  
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Table 16: Multiple regression analyses of psychological flexibility variables with measures of health 
and functioning 
* p < .05, two-tailed, ** p < .01, two-tailed  
Block Predictor Beta (final) ΔR2 (block) sr2 Adjusted total R2 
Pain distress 
1 Duration of education .100** .061** .009  
2 Gender -.015 .031* .000  
3 Pain intensity .851** .671** .642  
4 Acceptance of pain -.012 .003 .000  
 Cognitive fusion -.027  .001  
 Committed action -.072  .003  
 Self-as-context .034  .001 .757** 
Functional impairment 
1 Duration of education .081 .045** .006  
2 Pain intensity .532** .322** .264  
3 Acceptance of pain -.218** .068** .037  
 Cognitive fusion .062  .003  
 Committed action -.075  .003  
 Self-as-context .053  .002 .417** 
Depression severity 
1 Duration of education .061 .042** .003  
2 Age .079 .030* .006  
3 Pain intensity .436** .233** .178  
4 Acceptance of pain -.158** .187** .019  
 Cognitive fusion .228**  .041  
 Committed action -.165*  .015  
 Self-as-context -.064  .003 .473** 
Depression impact 
1 Duration of education .173** .077** .027  
2 Age .131* .023* .015  
3 Pain intensity .314** .132** .092  
4 Acceptance of pain -.313** .126** .075  
 Cognitive fusion .000  .000  
 Committed action -.136  .010  
 Self-as-context .237**  .039 .334** 




PDN is a complex condition and one of the most distressing complications of DM (Galer et al., 2000; 
Selvarajah et al., 2014). Despite this, existing studies of psychological variables mainly focus on pain 
intensity as an outcome in relation to depression and anxiety without exploring the other potentially 
therapeutic psychological processes. For the first time in a study of PDN, facets of PF were carefully 
assessed, using validated questionnaires, and examined in relation to standard measures of pain and 
functioning.  
This study demonstrated significant correlations between PF variables and functional impairment, 
depression severity, and depression impact in people with PDN. These results are consistent with 
the results of previous studies that support the role of PF in people with general, usually 
musculoskeletal, pain, including studies particularly focused on acceptance of pain (Mason et al., 
2008; McCracken, 1998; Nicholas & Asghari, 2006; Viane et al., 2003), cognitive defusion (McCracken 
et al., 2014), mindfulness (McCracken, MacKichan, & Eccleston, 2007) and value-based action 
(McCracken et al., 2007), and committed action (McCracken, 2013).  
In this study, we found mostly small correlations between PF and the dependent variables, 
functional impairment, depression severity, and depression impact, and relatively larger correlations 
between pain and some of these same variables, particularly so for functional impairment, less for 
the depression variables. While PF appears as a plausible contributor, pain severity generally 
appears to play a more important role in relation to daily functioning in PDN. This result is different 
in this sense from studies of other populations where the role of PF facets in daily functioning and 
wellbeing appears greater and the role of pain itself appears smaller, including studies of mixed pain 
conditions (McCracken & Velleman, 2010; McCracken & Zhao-O'Brien, 2010), low back pain (Mason 
et al., 2008), fibromyalgia (Wicksell et al., 2012; Yu et al., 2017) and headache (Almarzooqi, Chilcot, & 
McCracken, 2017; Foote, Hamer, Roland, Landy, & Smitherman, 2015). Taking into account that the 
role of PF is smaller than expected, this could be due to as yet unidentified differences in the 
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experience of neuropathic pain. There are so few psychological studies in neuropathic pain, 
however, it is too soon to confirm the current results or propose an explanation.   
Studies investigating outcomes following treatment have demonstrated a moderate-sized negative 
relationship between changes in PF variables and pain interference (Wicksell, Ahlqvist, Bring, Melin, 
& Olsson, 2008) and pain-related anxiety, depressive symptoms, physical and psychosocial disability 
(McCracken & Gutiérrez-Martínez, 2011; McCracken & Jones, 2012; Vowles, McCracken, & O’Brien, 
2011). These results suggest that if PF is increased this would lead to the improvements in a wide 
range of outcomes. It remains to be seen if this would happen in PDN.  
Regression analyses here show that PF variables may play a significant role in functional impairment, 
depression severity and depression impact, even when other relevant factors are considered, 
including background variables and pain intensity. Acceptance of pain appeared to contribute the 
greatest proportion of variance among the PF variables. In general, this suggests that these variables 
may afford a route toward improved functioning that is independent of pain severity in this 
population. 
It may be worth mentioning that compared to previous pain research our sample was older (by 
approximately 10 years) (i.e. McCracken & Velleman, 2010), but it was consistent with PDN research 
(i.e. Geelen et al., 2017). This might suggest that the added challenges that can come with ageing 
(i.e. co-morbid conditions, polypharmacy, cognitive impairment) need to be better addressed within 
an ACT based programme for older people (Scott et al., 2017). Participants in the current study were 
more likely to be employed either part-time or full-time, and they reported a lower level of 
acceptance of pain than other studies. The sample recruited from hospital services and online did 
not appear to differ. It remains the case, however, that the applicability of the current results to 
specific subpopulations with PDN will need to be further examined. 
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As far as we are aware, only four studies of psychological treatments have been conducted including 
individuals with PDN, most of them were either small in scale or produced limited results (Otis et al., 
2013; Nathan et al., 2017; Pfammatter, 2010; Teixeira, 2010). Clearly more research needs to be 
done, including into the structure and mode of delivery and into the choice of treatment methods. It 
appears reasonable, based on present findings, to next incorporate the components of PF into a 
pilot or feasibility trial.  
ACT has been applied successfully to individuals with chronic pain and has growing support (Hann & 
McCracken, 2014; McCracken & Morley, 2014; Veehof et al., 2016). We know that online treatment 
in particular, is increasingly used. A brief online treatment for chronic pain in general, based on ACT, 
has been demonstrated feasible within a mixed specialty pain treatment population in the UK (Scott 
et al., 2018b). This type of delivery format and similar content could provide efficient means for 
further treatment development for PDN.  
This study addresses new questions and produces new findings. At the same time, it has a number of 
limitations. Because of the cross-sectional design and reliance on self-report measures, it can include 
biases. Self-reports may include some participants not reporting their actual behaviour and views, 
which may compromise the accuracy of the results. Also, it did not include either analysis of 
variables over time or an experimental manipulation. No conclusions about causal relations between 
PF and functioning are possible. Furthermore, the questionnaire was also accessed online 
anonymously. This means diagnoses could not be verified. This also makes it possible for participants 
to access it more than once, although the length of the questionnaire certainly would discourage 
participants from doing this. Also, recruitment among those seeking treatment in the hospital 
services was limited (10%). It is possible that results may have been different if that type of 
recruitment had been more successful. Lastly, our results cannot be automatically generalised to any 
specific groups within the larger population of people with PDN, groups characterised by specific 
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ethnicity, age, comorbidities, and other factors. If the sample had been different in any of these 
ways, the results could have been different. 
In conclusion, based on the collected data of this cross-sectional observational study, facets of PF are 
associated with pain, emotional experiences, and difficulties experienced in daily life activities of 
individuals with PDN. Meanwhile, the unexpected relatively larger role that pain intensity appears to 
play in the PDN population calls for replication. If a significant role for pain itself is confirmed as 
reliable, perhaps we need to search more vigorously for effective remedies for pain itself. Further 
study of psychological factors in general in the context of PDN is encouraged to support the design 
and evaluation of psychological treatments for individuals suffering from PDN, a condition that has 
been the subject of very few psychological treatment studies. A psychological treatment focusing on 
psychological flexibility, rather than on symptom control, may represent an important new option, 
an addition to the current almost complete reliance on analgesic medication only.  
4.3 Summary 
This was a cross-sectional survey of PF facets in adults with PDN. Key results suggested that 
compared to previous chronic pain studies, PF seems to play a smaller role in the daily functioning of 
people with PDN while pain intensity is a stronger contributor. At the same time the correlations 
observed appear statistically significant in most of the instances tested, and the size of the relations, 
mostly small on average, are similar to the size achieved by measures of variables included in 
previous generations of psychological treatments, particularly measures of coping and beliefs 
(Jensen & Turk, 2014). 
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4.4 Rationale for Proceeding with the Online ACT Treatment  
The cross-sectional survey demonstrated that pain intensity (accounting for 32.2% of the variance) 
plays a more important role than PF (accounting for 6.8% of the variance) in people with PDN. 
However, it was decided to proceed with the online ACT treatment for people with PDN targeting PF 
for the following reasons: 
• Pharmacological interventions target pain reduction (Griebeler et al., 2014), and therefore pain 
intensity, while psychological treatments target other aspects, such as behaviour change, to improve 
coping with pain. Therefore, PF is still potentially relevant to this population. 
• This study demonstrated that face to face recruitment from NHS clinics was less successful than 
from online advertisements. An explanation for this is that it is difficult to identify people with PDN 
attending diabetes clinics due to the lack of adequate coding of PDN diagnosis. Therefore, given 
online recruitment was successful an online treatment was deemed appropriate. 
• The online ACT treatment that was available, through the platform ACT4PAIN, has been successfully 
delivered to people with general chronic pain (Scott et al., 2018b). The results suggested small 
effects for decentring, functioning, medication, committed action and healthcare use, medium for 
mood and large for acceptance.   
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Chapter 5: Feasibility Single-Cohort Study of Online Acceptance and 
Commitment Therapy for People with Painful Diabetic Neuropathy in the 
United Kingdom 
5.1 Chapter Overview  
The study in this chapter was underpinned by the theory and philosophy of the PF model and ACT, 
the available data to support the efficacy of ACT, and the findings from the earlier described 
systematic review and cross-sectional survey. The systematic review identified the lack of research 
into psychological interventions for the treatment of pain for people with PDN compared to the 
general chronic pain population. This chapter examines the feasibility of an online version of ACT-
based treatment for the PDN population in the UK and investigates whether a larger RCT is justified. 
The design and content of the ACT treatment will be described in detail and the main treatment 
materials, including experiential exercises and metaphors, and programme schedule are presented. 
This chapter is published in the following article at Pain Medicine journal (Appendix Q): 
Kioskli, K., Scott, W., Winkley, K., Godfrey, E., & McCracken, L. M. (2019). Online Acceptance and 
Commitment Therapy for people with painful diabetic neuropathy in the United Kingdom: A single-
arm feasibility trial. Pain Medicine (Accepted/In Press). 
Chapter naming and numbering are presented as they are in the published article. 
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5.2 Published Article 
Manuscript Number: PME-ORR-Sep-19-797 
Title: Online Acceptance and Commitment Therapy for people with painful diabetic neuropathy in 
the United Kingdom: A single-arm feasibility trial 
Article Type: Research Article 
Corresponding Author: Lance M McCracken, PhD 
Corresponding Author's Institution: King's College London 
Authors: Kitty Kioskli, MSc; Whitney Scott, PhD; Kirsty Winkley, PhD; Emma Godfrey, PhD 
Funding sources This study is funded via a PhD fellowship grant awarded from Diabetes UK (Ref: 
16/0005540). Also, this research is independent work partly supported by the National Institute for 
Health Research (NIHR Postdoctoral Fellowship, Dr Whitney Scott, PDF-2015-08-059). The views 
expressed in this publication are those of the authors and not necessarily those of the National 
Institute for Health Research or Diabetes UK. 
Conflicts of interest: None declared. 
Note: This is the author’s accepted copy. 
  




Objective: This study aimed to assess the feasibility of online ACT for PDN in the United Kingdom 
and to determine if a larger randomised controlled trial testing treatment efficacy is justified. 
Methods: Participants with PDN were recruited online and from hospital services. This was a single-
arm study in which all participants received online ACT. Participants completed questionnaires at 
baseline and 3-month post-treatment. Primary feasibility outcomes were recruitment, retention, 
and treatment completion rates. Secondary outcomes were pre- to post-treatment effects on pain 
outcomes and psychological flexibility (PF). 
Results: From 225 potentially eligible participants, 30 took part in this study. Regarding primary 
feasibility outcomes, the treatment completion and follow-up questionnaire completion rates were 
40% and 100%, respectively. Generally, at baseline those who completed the treatment, compared 
to those who did not, had better daily functioning and higher PF. With respect to secondary 
outcomes, results from the completers group showed clinically meaningful effects at post treatment 
for 100% of participants in pain intensity and pain distress, 66.7% in depressive symptoms, 58.3% in 
functional impairment, 41.7% in cognitive fusion, 66.7% in committed action, 58.3% in self-as-
context, and 41.7% in pain acceptance.  
Conclusions: This preliminary study suggests feasibility of recruitment and follow-up questionnaire 
completion rates supporting planning for a larger randomised control trial. However, treatment 
completion rates did not achieve the pre-specified feasibility target. Changes to the treatment 
content and delivery may enhance feasibility of ACT for people with PDN on a larger scale, however 
this needs further investigation.  
Keywords: painful diabetic neuropathy, acceptance and commitment therapy, feasibility study 
  




PDN is a complex pain condition and a known complication of diabetes with a prevalence of 25-30% 
(Daousi et al., 2004; Geelen et al., 2017). The main symptoms are tingling and burning sensations in 
hands and feet that can have a significant impact on daily functioning (Geelen et al., 2017; Kioskli et 
al., 2019). Psychosocial factors, such as depression, anxiety and sleep are significantly associated 
with PDN (Kioskli et al., 2019). At the same time current treatment options are mainly 
pharmacological, which appear to produce limited benefits (Finnerup et al., 2016). The experience of 
pain, and how pain is viewed by others, may differ in this population compared to other populations 
suffering from chronic pain of mainly musculoskeletal origin (Coghill, 2010; Kioskli et al., 2019).  
ACT is a newer, contextual form of CBT that incorporates acceptance, mindfulness, and values-based 
behaviour change (Hayes et al., 1999). It specifically focuses on increasing psychological flexibility 
(PF) (Hayes et a., 2011), which includes six processes: acceptance, cognitive defusion, awareness of 
the present moment, self-as-context, committed action, and values-based actions (Hayes et al., 
2006).  
Systematic reviews show that CBT is effective for chronic pain in general (Williams et al., 2012). ACT 
has a growing evidence base for the treatment of chronic pain and appears to produce outcomes 
similar to traditional CBT (McCracken & Vowles, 2014; Veehof et al., 2016). Furthermore, ACT may 
produce better results post-treatment regarding pain-related disability in comparison to alternative 
treatments, such as relaxation (Kemani et al., 2015).  
ACT has not previously been evaluated in PDN (Kioskli et al., 2019). It is designed to be broadly 
applicable to different types of psychological and physical problems and may be particularly suited 
to multi-problem cases. Therefore, ACT may be a good fit to address the multiple impacts of pain 
and the range of physical and psychosocial comorbidities that people with PDN can experience 
(Dindo, Van Liew, & Arch, 2017; Kioskli et al., 2019). Additionally, ACT assumes that targeting a core 
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set of behavioural processes (i.e. PF) can lead to improved functioning and quality of life generally 
across these different problem areas. Thus, ACT for chronic pain may also help people with PDN 
without requiring specific adaptations. 
A current challenge is that access to CBT and ACT for pain management is limited outside of 
specialist centres (Scott et al., 2018b). However, online treatments may address this, and they may 
be cost-effective, time-efficient, more acceptable, and less stigmatizing, than face-to-face 
treatments (Andersson, Cuijpers, Carlbring, Riper, & Hedman, 2014; Eccleston et al., 2014). Several 
studies have investigated online CBT and ACT for chronic pain, all yielding moderate to large 
improvements in pain and disability compared to waitlist controls or other psychological treatments 
(Andersson et al., 2014; Buhrman et al., 2013; Eccleston et al., 2014; Scott et al., 2018b; Trompetter, 
Bohlmeijer, Veehof, & Schreurs, 2014; Yang, Moss-Morris, & McCracken, 2017). 
No studies have examined online ACT for PDN, despite the clear need, potential to enhance access 
and potential for cost-effectiveness. Therefore, the current study aimed to test the feasibility of 
online ACT for people with PDN, within the context of a single-arm study to identify if a larger RCT is 
possible and justified. The feasibility questions were whether online ACT would be acceptable to the 
PDN population, as reflected by adequate recruitment, follow-up questionnaire completion, and 
treatment completion rates. For each of these questions a priori criteria were set against which to 
determine feasibility. In terms of secondary feasibility questions, effect sizes were calculated to 
determine whether participants who received ACT treatment improved in terms of on pain 
outcomes and PF.  
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2. Methods  
2.1 Study design  
This study was an online single-arm (non-randomised) feasibility study. The treatment being tested 
was originally designed for individuals with chronic pain in general. NHS ethical approval was 
obtained from Surrey Research Ethics Committee (29/1/2018, Ref: 17/LO/2047). All participants 
gave informed consent and the protocol was registered at https://www.clinicaltrials.gov 
(NCT03700528). The study followed the ethical standards of the Declaration of Helsinki (1964) and 
its later amendments. 
Participants completed assessment at baseline and 3-month follow-up through a secure survey 
platform (Bristol Online Survey; BOS). Even though the literature recommends RCT designs 
(Eccleston et al., 2014), the National Institute for Health Research highlights that not all feasibility 
trials should be randomised. The study’s focus was on recruitment, retention for follow-up 
questionnaires, and treatment completion rates, which are aims that do not necessarily require 
randomisation. 
The total sample size was calculated to allow reliable estimation of retention and completion rates, 
assuming a retention rate of 80%. The estimated sample size would allow for estimation of the true 
population consent rate with an 11% margin of error (95% CI) for eligible participants. Past research 
in chronic pain, conducted by the team, suggests consent rates between 50-70%, assuming a more 
conservative uptake of 40%, and that approximately 30% will meet the eligibility criteria. 
Additionally, a sample of 30 participants is in line with recommendations for feasibility study 
(Billingham et al., 2013). 
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2.2 Recruitment and Participants  
The case definition was adults with PDN. The main inclusion criteria were (1) >18 years old; (2) 
diabetes and PDN diagnosis, which were identified through self-report questions, the Douleur 
Neuropathique 4 interview (DN4i), and a physician’s diagnosis, when available; (3) verbal and 
written proficiency in English; and (4) computer literacy. Potential participants were excluded if their 
primary pain was not PDN. Please see Figure 14 for recruitment details. The 225 participants, initially 
approached, were participants from a previously conducted survey by the same authors (Kioskli et 
al., 2019). However, wider efforts for recruitment took place to reach the initial target. More 
specifically, participants were recruited via Guy’s and St Thomas NHS Foundation Trust and online 
advertisements. Online invitations were sent and resulted in recruitment as follows: ‘Diabetes UK’ 
(https://www.diabetes.org.uk/research/take-part-in-research) (n=15), ‘Pain Support’ forum 
(https://painsupport.co.uk/) (n=8), ‘Pain Concern’ forum (http://painconcern.org.uk/how-we-
help/forum/) (n=4) and Twitter (n=1). Final post-treatment questionnaires were collected in April 
2019.  
  




Figure 14: Study Flow Diagram 
2.3 ACT Online Treatment 
The purpose of this online therapist-supported treatment was to increase participants’ PF - namely, 
their willingness to experience pain, awareness of experiences in the present moment, and 
engagement in committed and values-based actions (McCracken & Vowles, 2014). ACT was 
considered appropriate for this study, since PF is a transdiagnostic model and can be applied to 
various conditions with no need for any alterations (Dindo et al., 2017). ACT is theoretically well 
suited to a range of problem areas and, on average, people with a range of conditions benefit.  
Online treatment procedures and content were based on the online version of ACT developed and 
initially tested by Scott et al. (2018b). The treatment involved one 30-45-minute Skype session with 
the therapist, at the beginning of treatment, to explain the treatment processes and set therapeutic 
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goals. The online treatment platform which was used was called ACT4PAIN 
(https://www.act4painonline.co.uk/#/), initially created by LM and WS. In the current study, the first 
author (KK) acted as the therapist. The therapist’s experience level was Master’s-level in health 
psychology, 6 months certified training on third wave CBT from the British Psychological Society 
(BPS), and further training from LMM and WS who are registered clinical psychologists, with 
experience providing ACT for chronic pain. WS provided ongoing supervision to discuss participants’ 
engagement and challenging responses as they arose. Since KK acted as the therapist and analysed 
the collected data, direct data entry from each participant and remote/online assessment were used 
to reduce the influence of the researcher on the assessment. 
Following the first Skype session, eight online sessions were provided in a 5-week period. This 
standardized package was delivered, two times per week, for the first 3 weeks, and one time per 
week for the final two weeks. The delivery was conducted according to the originally developed 
treatment by Scott et al. (2018b). Twice weekly sessions were chosen earlier in the treatment to 
keep participants focused on the treatment and practicing new skills. This was based loosely on a 
previously designed treatment (McCracken, Sato, & Taylor, 2013). Frequency of treatment sessions 
tapered off in final two weeks to foster greater independence in preparation for self-management 
after treatment completion. The sessions consisted of video and audio recordings that guided 
participants through experiential exercises, mindfulness practice, metaphors, values clarification and 
values-based goal setting (see examples in Figures 15 and 16). Online sessions included video and 
audio content that was between 12 and 35 minutes in duration (see Tables 17 and 18 for more 
details on treatment content). The total approximate time for the content delivered from the system 
was approximately 150 minutes. 
  




Figure 15: Example of video recording as shown in ACT4PAIN platform 









Table 17: Summary of ACT psychological treatment sessions 






Session 1: Skype one-to-one Introducing the treatment Goal setting & Identify barriers - - 
Session 2: Online Living with pain: Shifting your focus Passengers on the bus metaphor & Notice 5 things exercise 
 
6.16  10.86  
Session 3: Online Open: Letting go of the struggle with 
pain 
Unwanted party guest & Connect, breathe, open up exercise 
 
3.99  12.16  
Session 4: Online Open: Responding differently to 
thoughts 
Mind experiments & Labelling thoughts exercise 
 
7.01  17.63  
Session 5: Online Engaged: Choosing your values and 
goals 
Choosing your focus & 80th Birthday exercises & Values 
assessment form 
6.32  10.52  
Session 6: Online Aware: Focusing on the present 
moment 
Tracking thoughts in time 7.23  27.08  
Session 7: Online Engaged: Committing to your goals The swamp metaphor, Small steps exercises & goal setting form 3.84  8.06 
Session 8: Online Aware: A different point of view  ‘Observer self’ exercise 4.94  17.32  
Session 9: Online Building wider patterns of success ‘Brief observer self-exercise’, Your kind friend exercise, & goal 
setting form 
4.16  10.87  
Session 10: Skype one-to-one Committed action & Debriefing Goal setting & Evaluation - - 




Table 18: Overview of study procedures and treatment schedule 
Note: Rows follow the order of actions undertaken per week. 
 
Week (0) Week (1) Week (2) Week (3) Week (4) Week (5) Week (6) Week (7) Week (12) 
Participants give 
informed consent 




Skype session with the 
therapist, to help the 
navigation within the 
platform, set goals, 
identify barriers and 
answer any questions 
 
Completion of 




sessions 4 and 






sessions 6 and 

























receive an e-mail 
linked to a post-
treatment 
questionnaire 
Arrange the first 
Skype session 
Participants gain 



































At the start of each session participants provided ratings of their developing skills in the categories of 
openness, awareness, and engagement, on a scale from 0 (never) to 6 (always) in reference to the 
past three days (see Figure 17). These ratings were seen by the therapist who could then use the 
information to tailor feedback. During each session, participants were asked about their experience 
with the material and received individual written feedback from the therapist within 24 hours 
through secure in-site messaging. The feedback was meant to be individualized, to incorporate any 
particular challenges specific to PDN, and aimed to encourage engagement and to enhance PF. 
Participants received weekly reminders to complete sessions through messages generated by the 
website. When a participant expressed that they wished to drop-out, the therapist would ask the 
reason for discontinuation via in-site messaging, and whether the participant had any suggested 
refinements for the treatment which would encourage them to complete all the sessions When 
sessions were completed the therapist could see this, however, data on how frequently/for how long 
participants practiced the exercises between sessions were not collected. Collecting practice time 
information would be useful in a larger trial. However, therapist messages served to prompt practice 
and discuss any barriers or challenges around practicing skills between sessions. At the end of the 
online sessions there was a final Skype session, with the therapist, to encourage participants to set 
long-term goals, discuss the treatment, and suggestions for improvements. Thus, there was a total of 











2.4 Assessment procedures 
During baseline assessment, participants responded to self-report questions about diabetes and 
neuropathy duration, medication, comorbidities, age, sex, education, occupation, domestic status, 
and ethnicity. The participant self-report on the DN4i was used as a screen to support the potential 
diagnosis of PDN (Bouhassira, Lantéri-Minet, Attal, Laurent, & Touboul, 2008). The DN4i is a 
psychometrically validated tool used to screen for the possible presence of neuropathic pain. It 
includes seven interview questions, and a positive screen is indicated by the score of >3. The 
questions include (a) pain characteristics (e.g., burning, electric shocks) and (b) associated symptoms 
(e.g., tingling, numbness) (Bouhassira et al., 2008). This measure demonstrated good internal 
consistency in the current sample (Cronbach’s α= 0.72). For participants recruited from the NHS 
there was also physicians’ diagnosis for diabetes and PDN. 
2.5 Primary feasibility outcomes 
The primary feasibility outcomes for this study included recruitment, retention, treatment 
completion rates, and data completeness. Feasibility thresholds for these were defined a priori. The 
targeted sample to recruit was 30 participants. The aim was to achieve a follow-up questionnaire 
completion rate of 80% and a treatment completion rate of 70% (Scott et al., 2018b). The online 
treatment completion was calculated as the proportion of participants who completed the 
treatment, defined beforehand, based on Scott’s at al. (2018) feasibility study, as participants 
completing at least 7 out of 10 sessions. Thus, recruitment of 30 participants, and achieving 80% 
follow-up questionnaire completion and 70% treatment completion would support the feasibility of 
a fully powered RCT.  
2.6 Secondary outcomes 
Secondary to the primary feasibility aims outlined above, this study aimed to produce estimates of 




preliminary assessment of potential efficacy. All clinical outcomes were assessed with 
psychometrically validated and reliable instruments. 
2.6.1 Standard Pain Outcomes 
Pain intensity and Pain distress: Pain Scale  
Participants rated their average overall pain intensity and distress now and during the past week on 
a 0-(no pain/distress) 10 (worst possible pain/distress) numerical scale (Von Korff et al., 1992). This 
measure has been validated in people with general chronic pain (Jensen et al., 1999). 
Depression Symptoms: Patient Health Questionnaire (PHQ-9) 
The PHQ-9 is a widely used measure of depression symptoms. It is a 9-item questionnaire rated on a 
0-3 numerical scale, with the last item rated from ‘not difficult at all’ to ‘extremely difficult’. A higher 
score for the sum of the 9 items indicates higher levels of depression severity (Kroenke et al., 2001). 
This measure demonstrated good internal consistency (Cronbach’s α= 0.88) in the current sample. 
Functional Impairment: Work and Social Adjustment Scale (WSAS) 
The WSAS is a five-item questionnaire assessing functional impairment related to one’s health 
condition. It has been previously used in chronic pain trials (Scott et al., 2018b) and focuses on 
domains of functioning such as work and hobbies that might be targeted within the treatment. Each 
item is rated on a 0 (no impairment) to 8 (very severe impairment) scale (Mundt et al., 2002). This 
measure demonstrated good internal consistency (Cronbach’s α= 0.94). 
Patients' Global Impression of Change (PGIC) 
The PGIC is a single-item scale assessing participants’ overall perception of change after treatment 




minimally improved, no change, minimally worse, much worse, or very much worse. It is routinely 
used in trials for chronic pain (Scott & McCracken, 2015). 
2.6.2 Theoretically-relevant treatment process variables 
Chronic Pain Acceptance: Chronic Pain Acceptance Questionnaire (CPAQ-8) 
The CPAQ-8 is a reliable measure of chronic pain acceptance on a scale from 0 (never true) to 6 
(always true). The measure reflects pain willingness and activity engagement in the context of pain 
(Fish et al., 2010; McCracken et al., 2004). This measure demonstrated good internal consistency in 
the current sample (Cronbach’s α= 0.81). 
Cognitive Fusion: Cognitive Fusion Questionnaire (CFQ-7) 
The CFQ-7 is a measure of cognitive fusion or defusion with items rated on a 1 (never true) to 7 
(always true) point scale (Gillanders et al., 2014). Cognitive defusion, is the capacity to experience 
thoughts as just thoughts, and not as events as they are directly experienced. This measure 
demonstrated good internal consistency (Cronbach’s α= 0.97). 
Committed Action: Committed Action Questionnaire (CAQ-8) 
The CAQ-8 is a measure of committed action as defined in the PF model (McCracken et al., 2015).  Its 
items are rated on a 0 (never true) to 6 (always true) scale and they reflect the level of flexible 
commitment in the pursuit of meaningful goals, and plans. This measure demonstrated good internal 
consistency (Cronbach’s α= 0.86). 
Self-as-context: Self-Experiences Questionnaire (SEQ) 
The SEQ, assesses self-related processes in the PF model, mostly including the capacity to see oneself 




rated on a 0 (never true) to 6 (always true) numerical scale (Yu et al., 2016). This measure 
demonstrated good internal consistency (Cronbach’s α= 0.95). 
3. Statistical Analyses 
Data was analyzed with the Statistical Package for Social Science for Windows (version 18.0 IBM, 
SPSS). Descriptive statistics, including means and standard deviations (SDs) for continuous variables 
and frequencies and percentages for categorical variables, were calculated for participant 
characteristics and primary feasibility outcomes.  
For the clinical outcomes and process variables, including pain distress and pain intensity (pain 
scale), depression symptoms (PHQ-9), functional impairment (WSAS), chronic pain acceptance 
(CPAQ-8), cognitive fusion (CFQ-7), committed action (CAQ-8), and self-as-context (SEQ), t-tests were 
conducted to determine whether there were differences on the baseline scores for these variables 
between completers and non-completers of the treatment. The secondary aim of the study was 
addressed via effect size calculations and paired t-test analyses to examine the magnitude of the 
effect over time on these measures within the single group receiving treatment. In exploratory 
analyses, mixed between groups and repeated measures ANOVA were used to examine whether 
treatment completion status was associated with any effects on the measures. The final set of 
frequency analyses addressed descriptively the participant’s perception of treatment change (PGIC).  
Clinically meaningful changes were also calculated following the IMMPACT recommendations, which 
includes the convention of applying a threshold of 1/2 SD (Dworkin, McDermott, Farrar, O’Connor, & 
Senn, 2014). The value for 1/2 SD was calculated for each outcome for the whole sample at baseline 
(pre-treatment). A clinically significant effect was identified where the change observed for a 






4.1 Sample Characteristics 
The mean age of participants was 51.23 (SD= 13.30) years. Men represented 56.7% of the sample 
and the sample was predominantly white (67%). Equal proportions of the sample were either in full-
time employment (30%), or unemployed due to pain (30%), while about a quarter were retired 
(23.3%).The median DN4i score of all participants was 4.00 and all participants scored higher than 
the cut-off (an overall score of at least 3) for neuropathic pain (Timmerman et al., 2017). The mean 
duration of PDN was 6.97 years (SD= 1.04). Please see Table 19 and 20 for detailed demographic and 






















Note: N is the number of participants, % is the percentage the number of participants represents in the 
sample, M is the mean and SD is the standard deviation. Range reveals the lowest and highest value, 
respectively. 
  
 N (%) or M (SD) or Median (Range) 
Age (years) 51.23 (13.30) 
Age range 21 to 50 years 15 (50%) 
Age range 51 to 80 years 15 (50%) 
Education (years) 15.20 (4.92) 
Gender  
Male 17 (56.7%) 
Female 13 (43.3%) 
Ethnicity  
White 26 (86.6%) 
Asian  2 (6.7%) 
Mixed 2 (6.7%) 
Living status  
Alone 5 (16.7%) 
With partner 10 (33.3%) 
With child/children 2 (6.7%) 
With partner and child/children 8 (26.7%) 
With other relatives 3 (10%) 
With friends/flatmates 2 (6.6%) 
Employment status  
Employed full time 9 (30%) 
Employed part time 3 (10%) 
Unemployed - due to pain 9 (30%) 
Unemployed - unrelated to pain 1 (3.3%) 
Student/Training - full time 1 (3.3%) 
Retired 7 (23.3%) 
Diagnosis of type 1 Diabetes 12 (40%) 
Diagnosis of type 2 Diabetes 18 (60%) 
DN4i 3.5 (0.00-7.00) 




















Note: N is the number of participants, % is the percentage the number of participants represents in the 
sample, M is the mean and SD is the standard deviation. 
  
 N (%) or M (SD) 
Diabetes diagnosis (years) 15.50 (2.39) 
Painful diabetic neuropathy duration (years) 6.97 (1.04) 
Analgesic Medication  
Non-steroidal anti-inflammatory drugs 4 (13.3) 
Anticonvulsants 3 (10.0) 
Anti-depressants 14 (46.7) 
Anti-epileptics 7 (23.3) 
Opioids  8 (26.7) 
Other 6 (20.0) 




Retinopathy/Vision impairment 11 (36.7) 
Cardiac infarction 2 (6.7)  
Angina pectoris 1 (3.3) 
Coronary stent 2 (6.7) 
Coronary bypass 2 (6.7) 
Diabetic nephropathy 13 (43.3) 
Dialysis  1 (3.3) 
Leg/Foot ulcer 3 (10.0) 
Operation on legs 3 (10.0) 
Amputation 1 (3.3) 
Sleeping disorders 13 (43.3) 
Micturition and defecation disorder 2 (6.7) 




4.2 Primary Feasibility Outcomes 
In total of 225 people were referred or expressed initial interest in the study and 30 of these 
consented to participate (24.6% recruitment) during a three-month recruitment period. 122 (54%) 
declined to participate and 73 (32%) were not eligible. Participants were recruited from Guy’s and St 
Thomas NHS Foundation Trust (n=2) and online advertisements (n=28), between October 2018 to 
December 2018. Twelve (40%) participants completed the online treatment sessions as per the 
specified completion definition. All participants were retained in the study (100%), in the sense that 
they completed all measures, and data completeness was 100%. Reasons for discontinuing 
treatment can be found in Figure 14. For the 18 people who did not complete treatment the most 
frequent reasons were no adequate time (44.4%, n=8), other health problems (22.2%, n=4), 
computer problems (10.5%, n=2), or other (22.9%, n=4). 
Analyses of pre-treatment data for pain intensity and pain distress variables revealed no significant 
differences between treatment completers and non-completers. However, comparison of pre-
treatment scores for depression symptoms, functional impairment, chronic pain acceptance, 
cognitive fusion, committed action, and self-as-context variables showed large differences between 
completers and non-completers. It is notable that, at pre-treatment, treatment completers 
demonstrated lower cognitive fusion and functional impairment, and higher levels of committed 





Table 21: Baseline scores on study variables for treatment completers and non-completers 
Note: On pain intensity, pain distress, depression symptoms variables a higher score means worse well-
being/functioning, while higher scores on process variables (except cognitive fusion measure) indicate higher 
PF. 
 
4.3 Secondary Feasibility Outcomes: Clinical Outcomes 
At post-treatment, all of the 18 treatment non-completers (60% of the overall sample) reported “no 
change” in their health and functioning compared to before treatment. Amongst treatment 
completers (N=12) all reported that they felt ‘improved’ (N=10) or ‘very much improved’ (N=2).  
Each of the variables from the clinical outcome and process measures was examined for normality 
using histograms, Q-Q plots, skewness and kurtosis. None of these showed significantly skewed 
 Completer 
N Mean SD 
t d 
p-value 
Pain intensity (Rating Scales) 
 Yes 12 6.50 1.58 
0.497 0.19 0.623  No 18 6.13 2.15 
Pain distress (Rating Scales) 
 Yes 12 6.16 2.50 
-0.334 -0.13 0.741  No 18 6.47 2.43 
Depression symptoms (PHQ-9) 
 Yes 12 11.16 7.28 
-2.341 -0.87 0.027  No 18 17.00 6.27 
Functional impairment (WSAS) 
 Yes 12 15.92 12.29 
-2.033 -0.76 0.052  No 18 25.44 12.76 
Cognitive fusion (CFQ-7) 
 Yes 12 11.83 9.31 
-2.133 -0.80 0.042  No 18 21.17 13.08 
Committed action (CAQ-8) 
 Yes 12 33.17 8.48 
2.368 0.88 0.025  No 18 25.17 9.42 
Self-as-context (SEQ) 
 Yes 12 64.33 16.77 
1.942 0.72 0.062  No 
18 52.28 16.58 
Chronic pain acceptance 
(CPAQ-8) 
 Yes 12 26.08 5.40 




distributions or outliers expected to adversely affect the analyses. See Table 21 for each group 
means and standard deviations on study variables. 
Effect size calculations and paired t-test analyses of pre- and post-treatment scores for the full 
sample revealed small effects over time for depression symptoms and functional impairment, and 
medium effects for pain intensity and pain distress, chronic pain acceptance, cognitive fusion, 
committed action, and self-as-context. These results include a mix of improvements in some 
variables and deterioration in others, owing particularly to deterioration in the larger treatment non-
completers (Table 21). However, the majority of the sample did not complete treatment and, 
therefore, an improvement in the full sample analysis was not necessarily expected. The analysis of 
time by completer, which was conducted, shows that some of these variables improved among the 
completers. 
4.4 Exploratory Analyses of Treatment Completion and Clinical Outcomes 
Large interaction effects between time point and treatment completion were observed across all 
variables examined except for chronic pain acceptance where the effect was very small. The large 
effects included pain intensity, pain distress, depression symptoms, functional impairment, cognitive 
fusion, committed action, and self-as-context.  
This was confirmed when data was split into completers and non-completers of the treatment. For 
completers there were significant improvements within group over time, including a large effect for 
pain intensity and pain distress, depression symptoms, and functional impairment. These results 
appear superior to those who did not complete the treatment who generally deteriorated.  
Over time completers improved and demonstrated a large effect for committed action compared to 
non-completers who had lower scores and a similarly large effect in the opposite direction. 
Completers showed a medium effect for cognitive fusion and self-as-context. On the other hand, 




self-as-context. There were medium effects for completers and non-completers for chronic pain 
acceptance. Please see Table 22 for more details. 
4.5 Clinically Meaningful Changes  
The percentage of completers and non-completers who experienced clinically meaningful changes 
can be found in Table 23. At post-treatment, the majority of treatment completers showed 
meaningful improvements for 7 out of 8 of the outcome variables. The exception was chronic pain 
acceptance, where 41.7% meaningfully improved while 50% did not meaningfully change. Very few 
of the completers deteriorated meaningfully, for 4 of the outcomes this was none, and for the others 
this was one participant. For the non-completers the picture of meaningful change was more mixed, 
in 6 of 8 outcomes 72% or more of the participants showed either no meaningful change or they 
meaningfully deteriorated. For just two outcomes the majority meaningfully improved, for 
committed action and self-as-context, which was unexpected. For pain intensity, pain distress, and 






Table 22: Paired t-test uncontrolled analysis and repeated measures ANOVA examining psychological 
flexibility variables (N=30) 
Note: *dppc2 (pretest-posttest-control): according to Morris (2008). 
  
Paired t-test uncontrolled analysis  
 Pre-treatment scores Post-treatment scores     
 Mean SD Mean SD t d p-value 
Pain intensity  6.28 1.92 5.05 3.64 1.59 0.42 0.124 
Pain distress  6.35 2.42 5.28 3.88 1.29 0.32 0.208 
Depression symptoms 14.67 7.187 14.27 9.00 0.26 0.05 0.795 
Functional impairment 21.64 13.24 22.67 15.91 -0.34 -0.07 0.736 
Cognitive fusion 17.43 12.44 24.87 15.15 -2.58 -0.53 0.015 
Committed action 28.37 9.76 22.50 15.71 2.23 0.44 0.034 
Self-as-context 57.10 17.43 39.53 29.37 3.41 0.72 0.002 
Chronic pain 
acceptance 
22.20 6.58 24.00 4.15 -1.74 
-0.32 0.092 
Time*Completer interaction effects 
  Pre-treatment 
scores 
Post-treatment 
scores     
 Completer Mean SD Mean SD MS F dppc2* p-value 
Pain intensity Yes 6.50 1.58 0.83 0.72 
196.54 82.89 3.76 0.000 
No 6.13 2.15 7.86 1.17 
Pain distress Yes 6.16 2.50 0.75 0.45 
189.23 48.29 2.93 0.000 
No 6.47 2.43 8.31 1.19 
Depression symptoms Yes 11.16 7.28 4.08 3.23 
446.67 21.94 -1.65 0.000 
No 17.00 6.27 21.06 3.06 
Functional 
impairment 
Yes 15.92 12.29 3.92 3.32 
1698.68 20.55 -1.71 0.000 
No 25.44 12.76 35.17 3.33 
Cognitive fusion Yes 11.83 9.31 7.17 2.62 
1464.10 19.19 -1.08 0.000 
No 21.17 13.08 36.67 4.33 
Committed action Yes 33.17 8.48 40.25 5.15 
1677.03 35.26 2.36 0.000 
No 25.17 9.42 10.67 5.78 
Self-as-context Yes 64.33 16.77 73.42 7.90 
7102.23 44.44 2.64 0.000 
No 52.28 16.58 16.94 8.98 
Chronic pain 
acceptance 
Yes 26.08 5.40 28.33 2.27 
2.03 0.12 -0.13 0.729 




Table 23: Percentages of completers and non-completers who made clinically meaningful improvements, showed no change and deteriorated at post-treatment 
 
 
Completers (N = 12)  Non-completers (N = 18) 
 
Improved (%) No change (%) Deteriorated (%)  Improved (%) No change (%) Deteriorated (%) 
Pain intensity 12 (100.0) 0 (0.0) 0 (0.0)  2 (11.1) 4 (22.2) 12 (66.7) 
Pain distress 12 (100.0) 0 (0.0) 0 (0.0)  3 (16.7) 4 (22.2) 11 (61.1) 
Depressive symptoms 8 (66.7) 4 (33.3) 0 (0.0)  2 (11.1) 6 (33.3) 10 (55.6) 
Functional impairment 7 (58.3)  5 (41.7) 0 (0.0)  1 (5.6) 10 (55.6) 7 (38.9) 
Cognitive fusion 5 (41.7) 6 (50.0) 1 (8.3)  1 (5.6) 4 (22.2) 13 (72.2) 
Committed action 8 (66.7) 3 (25.0) 1 (8.3)  16 (88.9) 0 (0.0) 2 (11.1) 
Self-as-context 7 (58.3) 4 (33.3) 1 (8.3)  18 (100.0) 0 (0.0) 0 (0.0) 
Chronic pain acceptance 5 (41.7) 6 (50.0) 1 (8.3)  5 (27.8) 7 (38.9) 6 (33.3) 
 





5. Discussion and Conclusions 
The aim of this study was to assess the feasibility of conducting a larger RCT of online ACT for people 
with PDN. The targeted sample size was recruited (N= 30), all participants were retained in the study 
and completed follow-up questionnaires. However, the treatment completion rate was 40%, which 
was below the prespecified feasibility target of 70%. Hence, partial feasibility was found for the 
research and treatment methods for evaluating online ACT for PDN in a larger RCT. However, the 
treatment completion rate here is considered inadequate to justify proceeding to a full-scale trial 
until some modifications to enhance treatment engagement are designed and demonstrated. 
The treatment completion rate for the current treatment was 40%, which is lower than a Dutch trial 
(72%) (Trompetter et al., 2014), a German trial (60%) (Lin et al., 2017), and a UK trial (61%) (Scott et 
al., 2018b) of online ACT for general chronic pain. In the current study, there were differences at 
baseline between treatment completers and non-completers, even though the sample was largely 
self-selected online, and these differences may underline the high drop-out rate. Particularly, non-
completers had relatively higher levels of cognitive fusion, depressive symptoms, functional 
impairment, and lower levels of committed action, pain acceptance and self-as-context. This appears 
not to have been found in other similar studies (Lin et al., 2017; Scott et al., 2018b; Trompetter et al., 
2014) and may be unique to the PDN population, perhaps due to the complexity or nature of 
neuropathic pain, or it could be due to some unique aspect of the setting or methods used here. As 
this is a one time finding in a small sample it is too soon to determine what it means. 
If further research again shows that factors such as higher levels of cognitive fusion, depressive 
symptoms, functional impairment, and lower levels of committed action, pain acceptance and self-
as-context, are associated with inadequate treatment completion, then they could be used either in 




basis for redesign of the treatment methods or content. Presumably selecting participants with 
relatively lower depression or functioning impairment as a group may show better completion rates. 
It may be that participants with particularly low levels of PF, or severe depression and high pain 
interference, may require more intensive psychological therapy, such as that delivered in a face-to-
face setting (individual or group). However, it is known from previous studies that online treatment 
completion rates can be low, apparently due to problems with the use of technology, barriers due to 
poor health, or low motivation (Simblett et al., 2018). Based on the current data, it is not known 
whether it was the ACT approach itself, aspects of online delivery, requirements inherent in any 
psychological treatment, or all the above, that were unacceptable to participants. Most of those who 
did not complete treatment reported a lack of time. Another possible explanation represented in 
supplemental background information was that 11/30 participants reported some degree of visual 
impairment, which would make it difficult for them to complete treatment which mainly consisted of 
videos. Each of these possibilities deserves further consideration. 
Future research may also explore treatment engagement through a qualitative study to investigate 
PDN participants’ preferences for delivery format and views about ACT as a treatment approach. The 
model underlying ACT suggests a core set of behavioural processes underlie the treatment impact 
and that a standard package of this treatment ought to be generally applicable. However, the 
current data suggest that the treatment may need to be better tailored in a PDN context. This could 
be achieved by providing specific case examples of PDN throughout and orienting participants to 
problem areas specific to PDN such as fear of falling (Geelen et al., 2017; Kioskli et al., 2019). 
Treatment might also focus more explicitly on improving sleep. Given that 13/30 of the participants 
reported significant sleeping problems, this could be a motivating element if added to the treatment. 
A qualitative study could help to further identify specific problems area within PDN for which to 
apply ACT skills. This could contribute to better tailoring the treatment for this population and 




Another way to potentially enhance treatment engagement is to allow the treatment to be more 
dynamically customizable around each individual. This could include remotely assessing each case 
intensively over time, supporting the selection of treatment modules that are personalized, 
delivering only the modules particular participants need and not the ones they do not, leading to 
more rapid and efficient benefits from treatment (Fisher et al., 2019). In theory, a customized 
modular treatment guided by daily data gathering could pick up on, and intervene with, engagement 
lapses to promote better completion rates. The treatment components delivered here could 
certainly be repackaged to operate in this fashion. 
The observed uncontrolled effect sizes on the clinical outcomes and process measures ranged from 
small to large at 3-months, favouring a decrease of depression symptoms, functional impairment, 
pain intensity and pain distress and an increase of chronic pain acceptance, and committed action, in 
treatment completers. Although clinical outcome results are highly preliminary, the large reduction 
in pain differs from other ACT trial results. This may be relevant to the observation in a recent cross-
sectional survey which suggested that PF may play a smaller role, compared to pain intensity, in 
relation to distress and disability in the PDN population (Kioskli et al., 2019). It could also be related 
to the severity of participants’ PDN, and this is not adequately measured in this study.  
The rate of clinically meaningful results for treatment completers, across outcomes, are encouraging. 
At post-treatment, all treatment completers showed meaningful improvement in at least 3 variables, 
83.3% in at least 4 variables, 41.7% in at least 5, 33.3% in at least 6, 25% in at least 7 and 16.7% in 8. 
On the other hand, all non-completers showed a meaningful deterioration in at least 2 variables, and 
half of non-completers deteriorated in at least half (4 of 8) of the outcomes. These results may 
provide “proof of concept” that ACT can benefit people suffering effects of PDN provided that they 
can be supported to complete the treatment sessions. On the other hand, support for applying ACT 




A notable result is the number of clinical outcome and process measures on which those who did not 
complete treatment worsened during the three-month interval examined.  In fact, on every measure 
with the exception of pain acceptance, the non-completers were worse at the end of the study 
compared to the beginning. In several cases these declines were significant and large, and in all cases 
this was unexpected. This perhaps reflects natural variability in PDN, and perhaps this contributed in 
some way to non-completion, but this is only speculation (Simblett et al., 2018; Soucy et al., 2018). 
Another possible explanation might be that the treatment did not adequately target key areas of 
need for participants. For example, depression is highly prevalent in people with diabetes and in 
those with diabetes complications as well. Therefore, not only does this population have significant 
levels of pain, but also have co-morbid disability because of PDN, like balance and mobility problems, 
and associated micro-vascular comorbidity, such as retinopathy and nephropathy (Anderson et al., 
2001). These co-morbidities were not adequately measured or reported for this sample. Qualitative 
interviews with the non-completers would have allowed us to determine the reason of these 
changes and the main reason for discontinuing treatment. Also, a revised version of treatment might 
help participants to practice applying these skills more broadly to other diabetes related problems, 
which might be considered to have a larger impact on their functioning and quality of life. 
Possibly, non-completers were experiencing symptoms of PDN during their engagement in this 
treatment, became more conscious of their experienced difficulties, and were willing to report them. 
Additionally, it is possible that the nature of neuropathic pain is responsible for non-completion of 
treatment. It may be relevant that neuropathic pain is different pathophysiologically, compared to 
other chronic pain conditions, with the dominant component of neuroplastic changes within the 
nervous system (Costigan et al., 2009). These speculations deserve study. 
In this study, the most commonly suggested refinements by the non-completers, coming from 
comments in the experiential exercises or the last Skype session with the therapist, were to shorten 




neuropathy, and provide additional printed materials to supplement the online content. We note 
however that the total time for all online content was just 150 minutes, or an average of less than 19 
minutes for each online session. Nonetheless, it could be possible to provide choices around longer 
exercises, by more clearly alerting participants regarding the length and providing them with 
scheduling options (now or later when there is more time available), or by providing a choice for 
several shorter exercises in the place of a lengthy one. A missed opportunity here, to investigate 
treatment non-completion, would have been to include in-depth exit interviews with participants 
who dropped out. Unfortunately, these methods were not possible in the current study due to lack 
of resources. Such a study could provide more detailed feedback on reasons for dropping out or 
losing interest. 
This study has several limitations. Firstly, the study design does not allow for causal interpretations 
for observed changes in outcomes since this was not an RCT. Secondly, even though the recruitment 
was reached target (N=30), this is a small sample with high drop-out rates (60%),  which may lead to 
limited reliability and precision of our estimates, and limited power for all of the mean comparisons. 
The sample was also too small to conduct meaningful analyses to identify characteristics associated 
with a favourable response to treatment responses. Thirdly, the fact that participants were self-
selected to take part in the treatment means that results may not generalise to the wider population 
of people with PDN in need of treatment. Also, since the majority of participants were recruited from 
online portals, and even though we used the DN4i and self-reported questions for diabetes and PDN 
diagnosis, there is the possibility that participants did not fulfil more stringent diagnostic criteria for 
PDN. It is worth noting that this treatment applied here was designed for people with chronic pain in 
general. This is possibly not an ideal test for the specific feasibility for people with PDN, and a more 
tailored version of treatment may be ultimately more feasible. Unfortunately, at the time of this 




interest here. Finally, it is recognised that a different sample and longer follow-up may yield different 
results. The generalisability and reliability of the results still need to be established. 
Despite these limitations, this is the first feasibility study of online ACT in people with PDN. Based on 
low completion rates a larger RCT testing efficacy is not feasible for the current online ACT treatment 
as examined here. Future research is encouraged to specifically address the problem of low 
treatment completion, possibly including active patient involvement and qualitative work. Further 
tailoring of research methods and treatment to specifically fit PDN may be needed. Another avenue, 
at the same time, is simply greater individualization. This could include identifying the defining 
features of individuals who will both engage and achieve clinically meaningful benefits from 
treatment model here, and those who will not. It could also include making this treatment more 
sensitive to whoever encounters it by breaking it into modules and personalizing the delivery of 
these based on assessment data. 
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This study tested the feasibility of online ACT in people with PDN in the United Kingdom and 
evaluated whether a full-scale trial would be justified. In this single-arm trial, all participants were 
offered the online ACT program, and completed questionnaires at baseline and 3-month follow-up. 
Primary outcomes were recruitment, treatment completion, and retention rates. Secondary 
outcomes were within-groups effects on pain outcomes and PF evaluated through repeated 
measures ANOVA. Thirty participants took part in this study and 12 of them completed the 
treatment (40%), while all of them completed the baseline and follow-up questionnaires. Treatment 
completers reported lower levels of pain intensity, pain distress, depression symptoms and 
functional impairment and higher levels of committed action scores, compared to non-completers, 
at post-treatment. Results suggest that online ACT is only acceptable to a minority of participants, as 
indicated by low completion rates. However, among those willing to complete it, they may achieve 




Chapter 6: General discussion 
6.1 Chapter Overview 
The purpose of this PhD project was to gain an understanding of Painful Diabetic Neuropathy (PDN), 
particularly from the perspective of the Psychological Flexibility (PF) model and, relatedly, examine 
the potential usefulness of Acceptance Commitment Therapy (ACT) for the treatment of PDN. 
Three studies were carried out to this end: 1) a systematic review, 2) a cross-sectional survey, and 3) 
a small online feasibility intervention study. This research ultimately aimed to preliminarily test a 
prototype ACT-based treatment for people with PDN. The main research question was to determine 
whether the PF model and ACT could be used to improve the wellbeing of people with PDN. 
This chapter will provide a general discussion of this set of studies and the wider implications of this 
work. This will be achieved through summarising the main results and evidence of each study, 
discussing the contribution of each study to the literature, and determining the potential theoretical 
and clinical implications. Furthermore, this chapter will discuss the limitations of the project as a 
whole and provide suggestions for future research.  
6.2 Research Aims of the Thesis 
This PhD thesis targeted to address the following research aims: 
• Aim 1: To identify and systematically evaluate the evidence for the relationship between PDN and 
psychosocial factors (i.e. depression, anxiety) and the available psychological treatment trials in PDN 
(Study 1).  
• Aim 2: To examine the relevance of PF to a sample of people with PDN in the UK (Study 2). 
• Aim 3: To assess the feasibility of an online therapist-supported ACT treatment as applied to people 




6.3 Summary of Main Findings  
6.3.1 Study 1: A Systematic Review of the Literature of Psychosocial Factors and Psychological 
Interventions for Painful Diabetic Neuropathy 
The first study of this thesis (study 1) systematically reviewed RCTs and observational studies and is 
described in Chapter 3. The study investigated the relationship between PDN and psychosocial 
factors (i.e. depression, anxiety) and synthesised the available evidence from psychological 
treatment trials in PDN. To date, there has been only one literature review investigating 
psychological factors in PDN. This earlier review focuses on the role of physical activity and coping 
strategies in relation to pain outcomes (Davies et al., 2015). The updated review reported here, was 
the first systematic review reviewing the status of psychosocial factors more broadly, including 
psychological treatments studies, in people with PDN. Despite the intended broader reach of the 
current review, results showed that the psychosocial factors investigated in the current studies 
remain limited, the evidence gathered is inconsistent, and there is a lack of high-quality RCTs. This 
led to the conclusion that there is an urgent need for the investigation of psychosocial factors in the 
context of PDN and for more psychological interventions to be tested, given that pharmacological 
treatments are in general of limited efficacy for the PDN population. 
In this review, twenty-seven studies reflecting a mixture of cross-sectional and prospective studies 
(n=24) and RCTs (n=3) were included. There was moderate quality evidence with low risk of bias in 
15, medium in 5 and high in 6 studies. Results revealed evidence of mostly consistent positive 
correlations between depression, anxiety, sleep disruption, low quality of life and pain outcomes in 
people with PDN with effect sizes ranging from small to large. Only one study examined fears (fear of 
hypoglycaemia, pain, fatigue, falling, negative evaluation and kinesiophobia) in relation to PDN and 
two additional studies measured acceptance of pain. Despite the number of studies, there was a lack 




coping and PF. A need for more high-quality psychological research in PDN is evident. Particularly 
required are studies including trials of interventions with larger samples, better reporting, more 
robust trial designs, longer follow-up and higher treatment intensity. The absence of data from such 
studies currently limits our understanding of the role of psychosocial factors related to wellbeing and 
functioning in people with PDN. 
A significant limitation of the current literature is that the variables examined in the previous studies 
lack a guiding and integrating a theoretical model. As a result, there is no sense of progress and our 
understanding is not developing. Further investigation of the understudied psychosocial factors of 
current theoretical interest, such as acceptance and PF more broadly, was suggested for future 
research. The potential value in the theoretical model of PF and ACT is that they are underpinned by 
clear assumptions and principles, include a model of wellbeing and performance, and link directly to 
a set of treatment methods already widely tested and gaining evidence (Ciarrochi, Bilich, & Godsell, 
2010; Wersebe, Lieb, Meyer, Hofer, & Gloster, 2018). Hence, the PF model could contribute to the 
examination of psychosocial factors and application of an ACT-based treatment which may be of 
benefit for people with PDN.  
The systematic review that was conducted for this PhD, to identify psychosocial factors, revealed 
findings which are partially consistent with the general chronic pain literature. More specifically, the 
most commonly identified factors were depression, anxiety, poor sleep, and low quality of life as in 
most studies of chronic pain conditions (Edwards, Dworkin, Sullivan, Turk, & Wasan, 2016; Jensen, 
Moore, Bockow, Ehde, & Engel, 2011). There is a wealth of evidence that these factors strongly 
contribute to long-term effects of pain such as mortality (Kadam, Thomas, & Croft, 2005; Smith, 
Wilkie, Uthman, Jordan, & McBeth, 2014), disability (Hall et al., 2011; Hung, Liu, & Fu, 2015) and 
increased healthcare costs (Baumeister, Knecht, & Hutter, 2012). However, factors commonly 
assessed in the chronic pain literature such as coping, beliefs, and social factors have not been 




6.3.2 Study 2: A Cross-Sectional Survey of People Suffering from Painful Diabetic Neuropathy 
To build on the results from the systematic review (Chapter 3), a quantitative cross-sectional survey 
study (study 2) was undertaken, as described in Chapter 4. This study was designed to examine the 
relevance of PF in a sample of people with PDN in the UK (n=225). The sample was recruited from 
online advertisements (n=213) and hospital services (NHS; n=12). Recruitment was more successful 
from online advertisements and less successful from the NHS clinics, although overall the 
recruitment target (n=200) was achieved and surpassed (n=225). Results from correlational analysis 
suggested that acceptance of pain was negatively correlated with pain intensity, pain distress, 
functional impairment, depression severity, and depression impact. Cognitive fusion was positively 
correlated with pain intensity, functional impairment, depression severity, and depression impact. 
Committed action was negatively correlated with functional impairment, depression severity, and 
depression impact. Results from regression analyses suggested that the variables representing PF 
accounted for significant variance in all the equations for key outcomes except for pain distress. 
However, pain intensity demonstrated larger correlations with these same outcomes. These results 
suggest that PF does play a role (accounting for 6.8% of variance), however, it may not play such a 
significant one, as pain intensity (accounting for 32.2% of variance) in people with PDN compared to 
the general chronic pain population. However, it is important to note that psychological treatments 
do not directly target the reduction of pain intensity, but behaviour change or emotional regulation, 
which can affect perceptions of pain, and therefore addressing PF through ACT treatment seemed 
appropriate. Reliability and generality of these results remain to be determined, and it is possible 
these results could differ if recruitment from NHS settings was more successful. 
To date, this is the first and only investigation which has provided preliminary evidence for the 
relevance and potential applicability of the PF model in a PDN sample. Therefore, treatments aimed 
to enhance PF (i.e. ACT) may be suitable and require testing. Results of this survey should facilitate 




6.3.3 Study 3: Internet-Based Feasibility Study of Online Acceptance and Commitment Therapy for 
People with Painful Diabetic Neuropathy 
Based on the findings of the systematic review and cross-sectional survey, a previously developed 
online therapist-supported ACT treatment was provided to people with PDN, as described in Chapter 
5. This single-arm study (study 3) tested the feasibility of treatment and trial methods and 
investigated the impact of ACT on pain and functioning in people with PDN. The recruitment for this 
study was conducted online and from hospital services (NHS), and it was successful overall since the 
targeted sample size was achieved (n=30). However, online advertisements proved much more 
successful (n=28) than NHS recruitment (n=2). All participants completed follow-up assessments. 
Thus, study retention was 100%. On the other hand, treatment completion was only 40%, which was 
below the prespecified feasibility target of 70%, suggesting limited feasibility in this regard.  
This was the first study applying ACT in a PDN population and currently one of the six studies, in 
total, applying any type of psychological intervention to people with PDN. Since the publication of 
the systematic review that was conducted for this PhD, two additional studies have been identified 
(Hussain & Said, 2019; Nathan et al., 2017). None of these psychological interventions involved ACT. 
Both of the recent additional studies showed that participants who completed the psychological 
treatments (including Mindfulness-based stress reduction, Mindfulness-based meditation, 
Progressive Relaxation Meditation) reported improvement in pain interference, among other 
outcomes. These results are concordant with the secondary outcomes results from the feasibility 
study conducted for this PhD.  
This feasibility study provided preliminary evidence for the potential benefit of ACT treatment in 
people with PDN. However, the small sample size means the results lack generalisability. More 
specifically, all treatment completers reported that they felt ‘improved’ or ‘very much improved’, 




completers at baseline, it is not certain that this improvement was attributable to the treatment 
received. Future studies are required to develop a treatment more specific to people with PDN, to 
make refinements in the delivery method and materials used or test other approaches as well. 
Further investigation on ways to reduce drop-out rates and how to tailor the intervention more 
precisely to this population is needed. 
6.4 Theoretical Implications 
This project informs potential future developments of the PF model. The cross-sectional survey 
indicated that for people with PDN, PF processes explained much less of the variance in predicting 
functional impairment than pain intensity did. This contrasts with studies investigating the PF model 
in other pain conditions. More specifically, a study of 384 people with general chronic pain, aiming to 
explore the relative magnitude of change in PF processes associated with ACT, showed that in 
regression analyses the change in PF processes explained 6-27% of the variance in depression and 
functioning changes (Scott, Hann, & McCracken, 2016). Other studies (McCracken et al., 2015; Scott 
& McCracken, 2015; Vowles & McCracken, 2008) have demonstrated that changes in pain 
acceptance are associated with improvements in treatment outcomes, which was not evident in our 
study. It appears that the variance accounted for, by PF, in terms of pain-related functioning is 
smaller in PDN than other pain samples.  
It should be taken into consideration that neuropathic pain differentiates mechanistically, compared 
to other chronic pain conditions, due to its domination of the maladaptive plasticity within the 
nervous system (Costigan, Scholz, & Woolf, 2009). Pain hypervigilance could be the reason that pain 
intensity plays a more important role than PF. Hypervigilance has been defined as “a behaviour 
involving enhanced or exaggerated search of environmental stimuli or scan for threatening 
information (pp.183-184)” (Rollman, 2009). It has been suggested that pain-related information may 




people with fibromyalgia, that a context of pain or threat lead to hypervigilance and patients may 
experience more pain (Rost, Van Ryckeghem, Schulz, Crombez, & Vögele, 2017).  
This could also be due to biomedical features, for example, the unique burning pain associated with 
PDN which may be more important. On the one hand, there is the possibility that features of 
neuropathic pain, and how it is experienced psychologically, may modify the role of other 
psychological processes and their relationship with physical functioning. It should also be noted that 
people with DM experience many comorbidities and PF may not suffice, so a broader range of 
factors should be examined. On the other hand, the discrepancies between the results of this thesis, 
and the role of PF in other pain samples, may have occurred because a selected or non-
representative sample of participants was obtained.  
Furthermore, the impact of diabetes self-management should also be considered. An RCT delivered 
ACT or education alone to 81 participants with diabetes (Gregg, Callaghan, Hayes, & Glenn-Lawson, 
2007). Results showed that participants who received ACT were more likely to cope with stressful 
diabetes-related thoughts and keep their HbA1c within the target range. This may indicate that the 
stability of diabetes management might influence the PF model’s applicability to PDN outcomes. For 
example, if a person’s diabetes is poorly managed (high glucose levels) this could be the biggest 
driver of pain and disability (Wagner, Reiser, & Lotz, 2006; Won, Park, Park, & Riew, 2009). However, 
once glycaemic levels are stable, it might be that psychological factors and the PF model are more 
relevant for PF outcomes. Of course, PF might play a role in a person’s willingness to engage in 
behaviour patterns, such as lifestyle changes and glucose monitoring (Lindholm-Olinder et al., 2015).  
PDN could also differ from other pain populations, due to the stabbing, stinging, burning sensation 
which results in sleep disruption and lower quality of life in general. There may also be the 




microvascular complications, retinopathy and nephropathy which add to their level of disability 
(Colloca et al., 2017; Marchettini, Lacerenza, Mauri, & Marangoni, 2006). 
PF is a transdiagnostic model and can be applied to various conditions with no need for any 
alterations (Dindo et al., 2017; Levin et al., 2014). PF has a core set of processes assumed to 
contribute to health and function across a wide range of health problems (Kashdan, 2010). Even 
when these PF processes are applied, this model does not always assure continuous healthy actions. 
The main criticism that the PF model and ACT have received is that there is not a distinctive 
difference with other psychological approaches, like CBT (Scott, McCracken, & Trost, 2014). It has 
also been indicated that ACT is not as developed and methodologically advanced as traditional CBT 
(Öst, 2008).    
Besides the strengths and limitations of the PF model, the third study of this PhD project 
demonstrated that the completion rates were low and one of the main reasons may have been that 
the treatment was not specifically tailored for the PDN population, as it was developed for the 
general chronic pain population. The restriction of using a previously designed generic treatment is a 
limitation of this PhD project. Of course, it is also a legitimate path towards treatment development 
in the absence of resources to test a fully tailored version. 
6.5 Clinical Implications 
Much more could and should be done to enhance the development and application of psychological 
treatments for PDN in the UK and worldwide, as there are no effective treatments for pain in this 
population (Davies et al., 2015; Finnerup et al., 2015). The clinical implications emerging from this 





1. There is evident difficulty to identify people with a diagnosis of PDN. This was demonstrated in 
studies 2 and 3 where NHS recruitment was challenging. Similar to other conditions PDN is not easily 
identifiable via electronic patient record systems. Although clinical codes exist, they are not 
necessarily routinely applied, which means it is more difficult to conduct electronic record searches 
(Hall, Morant, Carroll, Gabriel, & McQuay, 2013). This raises questions as to whether there is under-
diagnosis of this condition. 
2. This project suggests that psychological interventions designed to enhance PF for people with PDN in 
the UK may facilitate pain management and encourage better health and wellbeing. However, the 
results must be treated with caution due to the limitations of this project. It is possible that tailoring 
ACT in a pragmatic way may provide more benefits to participants with PDN. Specific treatment 
content alterations could be applied to refine the content of the audio and video recordings in a way 
that applies specifically to experiences of people with PDN. This could include information on 
prevention and treatment options and the main physical challenges these people face, such as 
diabetic foot, muscle cramps and weakness, pain in the extremities and sexual dysfunction 
(Belapurkar et al., 2018). This information could be delivered within ACT experiential exercises and 
metaphors (Shayeghian, Hassanabadi, Aguilar-Vafaie, Amiri, & Besharat, 2016), which would 
facilitate the treatment process (Hayes et al., 1999). More specifically potential adaptations could 
be, supplementary reading material at the end of each session related to the condition’s and 
treatment’s issues and age-related problems (Schmidt, van Loon, Vergouwen, Snoek, & Honig, 2018), 
modifying the language in the experiential exercises within the videos targeting individuals with 
diabetes, and/or add a session regarding the management of diabetes distress to achieve optimal 
results. Of course, qualitative work would be firstly recommended, prior to any adaptations, to 
explore the views and preferences of people with PDN. 
3. This project did not investigate the potential impact of glycaemic control on pain in people with PDN. 




within the treatment, specifically focused on providing information about monitoring glucose levels. 
Patient education is of great importance to manage and control PDN (Bril, 2012; Javed et al., 2015). 
Managing blood glucose levels and investigating how they might interact with psychosocial factors to 
influence pain/disability in PDN seems to be relevant for future research, especially in terms of 
improving the effectiveness of an intervention. The design of such treatment may particularly fit the 
UK because of the difficulty in accessing pain management specialty centres, the lack of available 
trained psychologists, and the stigma that might be associated with psychological therapy (Knaak, 
Mantler, & Szeto, 2017; Lake, 2017).  
4. Finally, whilst this project has highlighted the potential benefits of psychological treatments for PDN, 
a challenge here is that there may not be a large enough workforce that is adequately skilled to 
deliver tailored psychological treatments for this population. Therefore, online treatments such as 
ACT may help address this issue. Alternatively, first-line treatment providers, for example nurses and 
GPs, could enhance their training and education by becoming more psychologically skilled and use 
psychologically informed interventions (i.e. ACT, CBT, DBT, MBSR) to improve the functioning and 
wellbeing of patients.  
It is recognised that some of the clinical implications of this research depend upon making changes in 
policy, health care and education systems and it is difficult to make recommendations based on 
these preliminary results. However, smaller changes may start from the initial consultation within 
the primary care service and referral process. There is limited psychological treatment and support 
available and little that is specifically for people with diabetes (DUK, 2008). The Improving Access to 
Psychological Treatment (IAPT) service is the most widely available, but this focuses on common 
psychological problems such as anxiety and depression. However, an issue for this PhD project is the 
need to improve treatment engagement and completion. This could be achieved by considering 
making changes to the online ACT treatment by: 1) using different recruitment methods to identify 




treatment content to be specific and applicable to people with PDN, and 3) incorporating a longer 
follow-up. 
6.6 Limitations 
This PhD thesis has a number of limitations.  
• In the systematic review (study 1) there was the potential for publication bias, since it was possible 
that some studies were not identified because they may have not been published, not written in 
English, or not have been indexed in the searched databases. It would be worth including non-
English studies and grey literature and updating the systematic review. Furthermore, two recent 
studies were not included. 
• Recruitment for the cross-sectional survey (study 2) and the feasibility study (study 3) was conducted 
mainly online, which means it cannot be deemed to have produced a sample representative of the 
general PDN population. Even though there were efforts to recruit from hospital secondary care 
services, these attempts were not very successful. There are generally few people with PDN 
attending diabetes clinics, therefore, accessing this population by conventional approaches to trial 
recruitment is a challenge. It is recommended that people with PDN should be referred to specialised 
pain clinics (Pop-Busui et al., 2016), but even in these clinics relatively few people with PDN attend. It 
is recognised that if participants had been recruited in a different way the results may have differed. 
Further research is encouraged to investigate this and identify the best method of recruitment, such 
as recruiting over a larger geographical area and involving primary care settings. 
• In the cross-sectional survey (study 2), the PF measures used included pain acceptance, cognitive 
fusion, committed action, and self-as-a-context. These measures have not been validated in the PDN 
population, even though they have been validated in other chronic pain populations. Therefore, it is 




participants’ responses may have been different if the measures had been developed and validated 
specifically for them. 
• In study 3, a single treatment group design was conducted, and the intervention has thus not been 
fully tested against a control condition in an RCT. Therefore, different study designs are needed, such 
as a large scale RCT, to investigate the causal impact of ACT and the mediating role of PF, or as an 
alternative single case experimental designs (SCEDs).  
• Treatment completion rates were lower than expected (40%) (in study 3), which warrants further 
investigation. To improve completion, changes may be needed in research methods, in treatment 
delivery, including the therapist support component, or in the treatment content. However, as the 
studies presented were conducted as part of a PhD project, time and resources were limited. 
• This PhD project did not employ qualitative methods. Qualitative methods would have been useful 
for hypothesis generation, in-depth data collection, process evaluation, and the input from people 
with PDN might have made the treatment more accessible and effective. Conducting interviews with 
participants could have taken place at the following time-points: before the survey in order to get 
feedback on the content, wording, and length of the questionnaires; before the delivery of the 
psychological intervention to assess the acceptability of the mode and content and, perhaps most 
importantly, after the intervention to identify reasons for continuation or discontinuation of the 
treatment. This type of data collection can be time intensive and may be influenced by multiple 
factors, including the interviewer’s own presence and beliefs, as well as interviewing skill set, 
location of the interview and ability of the interviewee to express and articulate their experiences 
(Sutton & Austin, 2015). The reason why these interviews were not conducted was because this PhD 
aimed to look at the practical feasibility of an ACT-based intervention. In retrospect, looking at the 
high drop-out rate (60%) in the feasibility study, future research would benefit from using qualitative 




• This project would have benefitted from ongoing patient and public involvement (PPI) from people 
with diabetes and/or PDN. PPI was obtained prior to the research being funded by Diabetes UK but it 
was not continued in a structured way. The treatment delivery platform (ACT4PAIN) originally 
included a PPI group which guided the final version. PPI could have provided clear and effective 
benchmarks from patients, staff, carers and HCPs for subsequent treatment development and could 
have made the treatment more relevant and inclusive (Holmes et al., 2019). It is worth noting that 
while online delivery is advantageous to increase access, it is relatively costly to develop up front, 
which was a barrier to tailoring the feasibility study that was conducted as part of this PhD. As 
expected, the methods used, and studies conducted both provide some progress and suggest future 
work that can be done. However, the importance of this set of studies is that they provide some 
indication of the next steps required in the development of treatment for people with PDN. 
• A framework to inform the implementation of this intervention was not used. However, the 
originally developed treatment (ACT4PAIN) used the Medical Research Council’s framework (MRC; 
Craig et al., 2008), for development and implementation. The MRC framework recognises the 
importance of interventions being tailored to the context and not standardised (Campbell, Donner, & 
Klar, 2007), and the greater use of theoretical insights in development and evaluation (Hardeman et 
al., 2005; Shiell, Hawe, & Gold, 2008). The recently updated framework, provided by the MRC and 
NIHR, recognises that completion of all the stages is a lengthy, iterative process. The implementation 
and evaluation plan should be considered from the beginning of an intervention’s conceptualisation 
(O'Cathain et al., 2019; Skivington, Matthews, Craig, Simpson, & Moore, 2018), and could have 





6.7 Future Work 
This set of studies investigated psychological factors in PDN and empirically examined the role of PF 
within ACT in people with PDN. These studies have added new knowledge regarding the experience 
of pain and responses to treatment from people with PDN. The cross-sectional survey and the online 
feasibility study were early attempts to empirically and clinically investigate PF in people with PDN. 
Further investigations are needed to establish the generalisability of the results. The application of 
different techniques, measurements and methodologies are required for the evaluation of the PF 
processes. Further modifications of the ACT-based psychological treatment may be necessary. 
Studies including qualitative, RCTs, longitudinal designs, or SCEDs, building on evidence from the 
above conducted studies, could be useful. The studies presented in this thesis are unique and novel 
and there is hope that they will further the existing knowledge and contribute to the development of 
better, more accessible, treatments for people with PDN.  
In general, different research methods may be used in the future to further elucidate the role of the 
PF model and ACT for people with PDN. For example, SCEDs or n-of-1 designs would allow more 
intensive observation and report of participants’ proposed changes and specific treatment 
refinements. SCEDs can evaluate the effect of an intervention on a single person and a study can 
include multiple single cases, potentially each replicating the same or similar result based on designs 
using repeated measurements where each person provides their own baseline for comparison 
(Krasny-Pacini & Evans, 2018; Tate et al., 2013). N-of-1 designs including multiple crossover 
randomised and blinded trials conducted with one patient would enhance the internal validity 
(Kravitz, Duan, & Braslow, 2004; Kravitz et al., 2008). The feasibility study that was conducted only 
collected data at two time points (pre and post treatment). Single case designs or n-of-1 methods 
would provide more data points on fewer people (McDonald et al., 2017; Morley, 2017). As 
mentioned, this more intensive following of each individual case, can more rapidly reveal useful 




Future studies are particularly encouraged to pursue qualitative work. Qualitative research has 
several benefits for theory and treatment development. It can uniquely expose features of the pain 
experience in ways that quantitative methods cannot. It can obtain input from the participants’ own 
words and thus yield information the researcher did not or could not expect. The epistemological 
assumptions that qualitative research adopts reveal different information than quantitative work, 
and it can be used in parallel with quantitative research and provide a more holistic result (Osborn & 
Rodham, 2010). Qualitative studies provide a comprehensive understanding of the key factors that 
may influence behaviours (Bartholomew et al., 2016; Kok, 2014), which ultimately inform targeted 
intervention development. The use of qualitative methods has increased in informing healthcare 
decisions. Interviews are a powerful way to generate personal descriptions and understand 
someone’s world. Purposive sampling of a chosen population allows for the exploration of the 
experiences and beliefs of the respondent and this can then guide intervention development (Al-
Busaidi, 2008). 
There are currently limited studies reporting qualitative work in participants following their 
participation in ACT-based treatments in chronic pain (Casey, Smart, Hearty, Lowry, & Doody, 2019; 
Thompson, Vowles, Sowden, Ashworth, & Levell, 2018). However, these studies are useful in 
providing a unique insight regarding peoples’ views and perceptions of their pain and treatment 
experience. Adding qualitative work to this project could have achieved a better tailored 
psychological treatment before delivery, enhanced treatment completion, and could offer useful, 
detailed feedback for future alterations following treatment delivery. Qualitative work could also 
help to disentangle whether it was the treatment content itself or the online delivery format that led 
to inadequate treatment completion. This can inform whether change is needed to the content or 
delivery level (e.g., group-based, different treatment provider), or both.  
Future research needs to assess the acceptability and improve the uptake of psychological 




psychological interventions for people with PDN in the UK.  A holistic framework such as the 
Theoretical Framework of Acceptability (TFA), in which participants’ acceptability can be quantifiable 
via the overall rating of ethicality, affective attitude, burden, opportunity costs, perceived 
effectiveness, self-efficacy and intervention coherence could be used to guide this process (Sekhon, 
Cartwright, & Francis, 2017). 
Furthermore, clinical and health psychologists with expertise in chronic pain management and health 
researchers will be required. Personalised adaptations of ACT-based treatments which will make the 
treatment tailor-made for each person, encourage engagement, reduce drop-out rates and improve 
overall outcomes appear to be needed. It may also be necessary to involve diabetes specialists to 
advise on modifications which address the potential impact of glycaemic control on PDN. Lastly, it 
would be useful to repeat the 3 studies presented in this PhD thesis in different healthcare settings. 
The data presented here has added knowledge regarding the application of psychological treatments 
in people with PDN in the UK. The availability of these studies will help to clarify the applicability and 
acceptability of psychological interventions for the PDN population in different settings and to 
provide a starting point for future investigation of treatment needs and preferences for individuals 
with PDN. 
6.8 Epistemological Assumptions  
This study aimed to explore the perspectives of individuals on PDN, by using a social constructionist 
epistemological position. Social constructivism stresses out the importance of social context and 
culture. The social and cultural construction of knowledge is evident, while individuals create 
meaning through relationships with others and there are several ways to understand a situation. It 
argues that societies have a significant influence on the interpretation of experiences, resulting in 
influencing the physical and emotional states (Kim, 2001). This project was not only set out to 




research programme adopts a social constructionist epistemological position by accepting that the 
experiences of individuals are constructed by their beliefs, thoughts, and social world. It is 
significantly important to avoid judging when participants describe the pain management strategies 
they have tried or the physical and psychological impacts.  
6.9 Researcher Reflections 
In order to contribute to the body of PDN knowledge, I started this PhD aiming to work on a series of 
well-designed studies which would provide clear answers to the set research questions. The 
experience and skills I gained through this project will be invaluable in my future research career.  
By spending a lot of time at diabetes and pain clinics at Guy’s and St Thomas Hospital, I was able to 
develop my understanding of diabetes and PDN. Observing both the HCPs and the patients helped 
me gain an insight into the patients’ experience, NHS procedures and PDN management. Delivering 
the online treatment, with the guidance and support from my supervisory team, I was able to have 
hands-on experience in ACT treatment, develop my skills as a therapist by managing expectations, 
setting goals and providing feedback on the experiential exercises.  
Before starting this PhD, my attention to detail, critical appraisal of the literature and manuscript 
preparation were limited with room for improvement. Written feedback and comments and face-to-
face meetings with my supervisory team helped me develop these important skills and encouraged 
me towards precision. Additional skills which I have gained are project management, data analysis, 
and presentation skills.  
I wish I could have included an additional qualitative study, to interview the participants after their 
participation in the ACT treatment. This would give my project a more holistic approach. While 
delivering the treatment I got to know the participants better and I would really like to have more 




would have required an additional researcher’s time, as I was involved in delivering the intervention, 
and conducting the exit interviews myself would introduce researcher bias.  
6.10 Overall Conclusions  
This thesis successfully addressed and provided evidence for the possibility of applying the PF model 
and ACT treatment to people with PDN in the UK. Three studies were conducted with the following 
conclusions drawn: 
• Depression, anxiety, poor sleep and low quality of life are positively associated with pain outcomes 
in PDN. The evidence of the existing research is of moderate quality. 
• PF may be relevant in the context of PDN. However, pain intensity appears more salient and more 
research is required to investigate these factors. 
• The results of this thesis must be treated with caution due to the limitations described. However, 
online ACT only appears to be acceptable to a minority of participants with PDN. Among those willing 
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Appendix B: Systematic Review Quality Assessment Tool for Observational Studies (Downs 
& Black, 1998) 
Modified Downs and Black checklist for the assessment of the methodological quality of both 















X Individually-randomized parallel-group trial 
 Cluster-randomized parallel-group trial 
 Individually randomized cross-over (or other matched) trial 
 
For the purposes of this assessment, the interventions being compared are defined as 
Experimental:  Comparator:  
 
Specify which outcome is being assessed for risk of bias  
 
Specify the numerical result being assessed. In case of multiple alternative 
analyses being presented, specify the numeric result (e.g. RR = 1.52 (95% CI 
0.83 to 2.77) and/or a reference (e.g. to a table, figure or paragraph) that 
uniquely defines the result being assessed. 
 
 
Is the review team’s aim for this result…? 
 to assess the effect of assignment to intervention (the ‘intention-to-treat’ effect) 





If the aim is to assess the effect of adhering to intervention, select the deviations from intended intervention that should be addressed (at least one 
must be checked):  
 occurrence of non-protocol interventions 
 failures in implementing the intervention that could have affected the outcome 
 non-adherence to their assigned intervention by trial participants 
Which of the following sources were obtained to help inform the risk-of-bias assessment? (tick as many as apply) 
 Journal article(s) with results of the trial 
 Trial protocol 
 Statistical analysis plan (SAP) 
 Non-commercial trial registry record (e.g. ClinicalTrials.gov record) 
 Company-owned trial registry record (e.g. GSK Clinical Study Register record) 
  “Grey literature” (e.g. unpublished thesis) 
 Conference abstract(s) about the trial 
 Regulatory document (e.g. Clinical Study Report, Drug Approval Package) 
 Research ethics application 
 Grant database summary (e.g. NIH Reporter or Research Councils UK Gateway to Research) 
 Personal communication with trialist 






Risk of bias assessment  
Responses underlined in green are potential markers for low risk of bias, and responses in red are potential markers for a risk of bias. Where questions 
relate only to sign posts to other questions, no formatting is used. 
Domain 1: Risk of bias arising from the randomization process 
 
  
Signalling questions Comments Response options 
1.1 Was the allocation sequence random?  Y / PY / PN / N / NI 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to 
interventions? 
Y / PY / PN / N / NI 
1.3 Did baseline differences between intervention groups suggest a problem with the 
randomization process?  
 Y / PY / PN / N / NI 
Risk-of-bias judgement  Low / High / Some concerns 
Optional: What is the predicted direction of bias arising from the randomization process?  NA / Favours experimental / Favours 





Domain 2: Risk of bias due to deviations from the intended interventions (effect of assignment to intervention) 
  
Signalling questions Comments Response options 
2.1. Were participants aware of their assigned intervention during the trial?  Y / PY / PN / N / NI 
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention 
during the trial? 
Y / PY / PN / N / NI 
2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of 
the trial context? 
 NA / Y / PY / PN / N / NI 
2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?  NA / Y / PY / PN / N / NI 
2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?  NA / Y / PY / PN / N / NI 
2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?  Y / PY / PN / N / NI 
2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse 
participants in the group to which they were randomized? 
 NA / Y / PY / PN / N / NI 
Risk-of-bias judgement  Low / High / Some concerns 
Optional: What is the predicted direction of bias due to deviations from intended interventions?  NA / Favours experimental / Favours 
comparator / Towards null /Away 




Domain 2: Risk of bias due to deviations from the intended interventions (effect of adhering to intervention) 
  
Signalling questions Comments Response options 
2.1. Were participants aware of their assigned intervention during the trial?  Y / PY / PN / N / NI 
2.2. Were carers and people delivering the interventions aware of participants' 
assigned intervention during the trial? 
Y / PY / PN / N / NI 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol 
interventions balanced across intervention groups? 
 NA / Y / PY / PN / N / NI 
2.4. [If applicable:] Were there failures in implementing the intervention that 
could have affected the outcome? 
 NA / Y / PY / PN / N / NI 
2.5. [If applicable:] Was there non-adherence to the assigned intervention 
regimen that could have affected participants’ outcomes? 
 NA / Y / PY / PN / N / NI 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis 
used to estimate the effect of adhering to the intervention? 
 NA / Y / PY / PN / N / NI 
Risk-of-bias judgement  Low / High / Some concerns 
Optional: What is the predicted direction of bias due to deviations from 
intended interventions? 
 NA / Favours experimental / Favours comparator / 




Domain 3: Missing outcome data 
 
  
Signalling questions Comments Response options 
3.1 Were data for this outcome available for all, or 
nearly all, participants randomized? 
  Y / PY / PN / N / NI 
3.2 If N/PN/NI to 3.1: Is there evidence that the 
result was not biased by missing outcome data? 
 NA / Y / PY / PN / N 
3.3 If N/PN to 3.2: Could missingness in the outcome 
depend on its true value? 
 NA / Y / PY / PN / N / NI 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in 
the outcome depended on its true value? 
NA / Y / PY / PN / N / NI 
Risk-of-bias judgement  Low / High / Some concerns 
Optional: What is the predicted direction of bias due 
to missing outcome data? 
 NA / Favours experimental / 
Favours comparator / 
Towards null /Away from 




Domain 4: Risk of bias in measurement of the outcome 
 
  
Signalling questions Comments Response options 
4.1 Was the method of measuring the outcome inappropriate?  Y / PY / PN / N / NI 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?  Y / PY / PN / N / NI 
4.3 If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention received by study 
participants? 
 NA / Y / PY / PN / N / NI 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of 
intervention received? 
 NA / Y / PY / PN / N / NI 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of 
intervention received? 
 NA / Y / PY / PN / N / NI 
Risk-of-bias judgement  Low / High / Some concerns 
Optional: What is the predicted direction of bias in measurement of the outcome?  NA / Favours experimental / Favours 
comparator / Towards null /Away 




Domain 5: Risk of bias in selection of the reported result 
  
Signalling questions Comments Response options 
5.1 Were the data that produced this result analyzed in accordance with a pre-specified analysis 
plan that was finalized before unblinded outcome data were available for analysis? 
 Y / PY / PN / N / NI 
Is the numerical result being assessed likely to have been selected, on the basis of the results, 
from... 
  
5.2. ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within 
the outcome domain? 
 Y / PY / PN / N / NI 
5.3 ... multiple eligible analyses of the data?  Y / PY / PN / N / NI 
Risk-of-bias judgement  Low / High / Some concerns 
Optional: What is the predicted direction of bias due to selection of the reported result?  NA / Favours experimental / 
Favours comparator / 







Overall risk of bias 
 
Risk-of-bias judgement  Low / High / Some 
concerns 
Optional: What is the overall predicted 
direction of bias for this outcome? 
 NA / Favours 
experimental / Favours 
comparator / Towards null 





Appendix D: Systematic Review Data Extraction Form 
 
Reviewer Name  
Authors  
Publication Year  
Journal  
Publication Type Full text peer-reviewed article:  
Published Thesis: 
Study Details Description as 
stated in paper 
Location in text 
(page and 














Geographic Location of Study    
Recruitment Sites  






Inclusion/Exclusion Criteria   
Sample Size  





Age (mean, SD, & range)  





(if case-control or group comparison, report this for each 
group) 











Time since PDN Diagnosis (mean & SD; or median & range) 
(if case-control or group comparison, report this for  
each group, if reported) 
  
Taking Pharmacological Medication 
(if case-control or group comparison, report this for each 




Medication Type  
(list type and % of participants taking that type) 
(if case-control or group comparison, report this for each 
group, if reported) 
  
Co-morbidities  
List type and frequency (%) 
(if case-control or group comparison, report this for each 












PDN Duration (mean & SD; or median & range)   
Pain Assessment:  
list measures used and aspects of pain/functioning/QoL that 
were measured)  
i.e.: BPI (pain intensity and interference); EQ-5DL (quality of life) 
Note: If multiple items of pain intensity are assessed and 
presented separately in the analyses (e.g., present, average, 
least, worst), extract data only from the average pain intensity; 
if average is not reported, extract worse pain intensity) 
 
  




Psychosocial Assessment:   
list measures used and psychosocial aspects 
i.e.: PHQ-9 (depression symptoms) 
  
Effect Size (mean):  
Note: Some relevant measures of association/ effect sizes: 
Pearson’s r correlation (i.e., for correlational studies looking at 
association between pain and a psych variable); Within a 
multivariate regression model, the measure of association 
would be Beta and RSquared change and their tests of 
significance. 
Odds Ratios (unadjusted or adjusted) predicting a dichotomous 
outcome (e.g., a psych variable predicting the presence of PN or 
no PN); Also, tables with frequencies (also called ‘event data’) 
and chi-square analyses—for example, a table with the number 
of depressed people in the PN group versus the number of 







Tables might also report the means and SD of continuous 
variables for a between groups comparison (i.e. they might 
compare the severity of depression symptoms between the PN 
and no PN groups). Here, extracting the mean and SD for each 




Appendix E: Systematic Review Supplementary Material for Published Paper in Chapter 3 
TableS1: Sample Search Strategy (EMBASE) 
Painful Diabetic Neuropathy search terms  
1.  Painful Diabetic Neuropath* 
2.  Diabetic Neuropath* 
3.  Painful Diabetic Polyneuropath* 
4.  Diabetic Polyneuropath* 
5.  Diabetic neuropath* pain 
6.  Diabetes 
7.  Peripheral Nervous System Diseas* 
8.  Peripheral Nervous System Disorder* 
9.  Painful Diabetic Peripheral Neuropath* 
10.  Diabetic Autonomic Neuropath* 
11.  ((neuropathic or nerve*) adj3 pain*).tw. 
12.  (Neuropath* or Polyneuropath*).tw. 
13.  sensory neuropath* 
14.  OR/1-13 
Psychological Interventions search terms 
15. exp psychotherapy/  
16. behavior therapy/ or cognitive therapy/  
17. exp Biofeedback, Psychology/  
18. behavio#r therap*.tw.  
19. cognitive therap*.tw.  




21. (relax* adj3 (technique* or therap*)).tw.  
22. meditat*.tw.  
23. psychotherap*.tw.  
24. (psychological adj2 (treatment* or therap* or intervention*)).tw.  
25. group therapy.tw.  
26. self-regulation training.tw.  
27. coping skill*.tw.  
28. pain-related thought*.tw.  
29. (behavio#r* adj3 rehabilitat*).tw.  
30. (mind and body relaxation technique* or mind-body relaxation technique*).tw.  
31. exp mind-body therapies/ or relaxation therapy/  
32. Mindfulness.tw.  
33. (Mindfulness-based stress reduction or MBSR).tw.  
34. (Mindfulness-based cognitive therapy or MBCT).tw.  
35. (Acceptance-based or acceptance based).tw.  
36. (Acceptance and commitment therap* or Acceptance and commitment intervention* or 
Acceptance and commitment treatment*).tw.  
37. Or/ 15-36 
Psychosocial search terms 
38. Psycholog$.mp  
39. Psychosocial factors/  
40. Psychological factors.mp  
41. Adjustment.mp  
42. Depression.mp  




44. exp mood/  
45. exp Social adjustment/  
46. Social function$.mp  
47. exp Quality of Life/  
48. Coping.mp  
49. Belief$.mp  
50. Cognition.mp  
51. Perception.mp  
52. Fear avoidance.mp  
53. Interference.mp  
54. Catastrophi?ing.mp  
55. Acceptance.mp  
56. Willingness.mp  
57. Mindfulness.mp  
58. Endurance.mp  
59. Biopsychosocial  
60. Or/ 38-59 
Combined Search 
→Limit to humans 1981-Current 





TableS2: Psychosocial variables and pain outcomes 







Summary of Main Findings 
AL-Mahmood et al. 
(2018)  
Subjective & objective 
measurement of PDN 
symptoms, reported 
DN4 - QOL (ADDQOL) 27.8% of participants reported the negative impact of 
diabetes on their QOL, and 37.8% reported the belief that 
their QOL would have been higher if they were not 
diagnosed with diabetes. 
 Benbow et al. 
(1998)  
Subjective 
measurement of PDN 
symptoms, reported 
MPQ Pain Severity 
(VAS) 
QOL (NHP) Patients with neuropathy had higher scores in 5/6 NHP 
domains (showing impaired QOL) compared to diabetic 
patients with no pain (p<0.01) and the non-diabetic group 
(p<0.001).  
Bouhassira et al. 
(2013)  
Subjective & objective 





- QOL, sleep, 
depression, anxiety 
(MOS SF-12, SF-36, 
MOS, HADS) 
Prevalence of chronic neuropathic pain was 20.3% [95% CI 
17.4–23.1]. MNSI revealed that pain was related to 
polyneuropathy in 80.1% of these participants. Patients with 
pain had a poorer quality of life, reduced sleep quality, and 
anxiety and depression were more present compare to 
patients without pain. Neuropathic characteristics acted as 
predictors for these impairments.  
Currie et al. (2006)  Subjective & objective 





- QOL (EQ-5D, SF-36, 
QoL-DN) 
For patients with a clinically confirmed diagnosis of DPN, the 
mean NTSS-6-SA score was 6.16 vs 3.19 in patients without 
DPN (p<0.001). All quality of life measures showed a 
deterioration between these groups: the SF36 general 
health profile fell from 59.9 to 25.5 (p<0.001) and the QoL-





Dobrota et al. 
(2014)  
Subjective & objective 
measurement of PDN 
symptoms, reported 
LANSS, EFNS, NE Presence of pain 
(VAS) 
QOL, depression, sleep 
(SF-36, BDI) 
The most significant differences between the groups were in 
sleeping disorders, impaired QOL, problems regarding 
defecation and micturition and medication which were more 
expressed in PDPN subjects than the patients without 
painful DPN. 
 
Galer et al. (2000)  Subjective 
measurement of PDN 
symptoms, reported 
NPS Pain Interference 
(mBPI) 
QOL (mBPI) Participants reported major interference of pain in sleep and 
enjoyment of life resulting to a substantial impact on QOL.  
Geelen et al. 
(2016;2017 
Subjective 








y (VAS, PDI) 
Fears, QOL (QOL-DN, 
HFS, PASS-20, TSK, 
TSF, FES-I, BFNE) 
Fears were independently associated with QOL-DN and PDI 
(p < 0.001). Pain intensity, duration and FES-I were strongly 
associated with QOL-DN (R2 = 0.603). Pain intensity, gender 
(male) and FES-I were also strongly associated with PDI (R2 = 
0.526).  
Gore et al. (2005; 
2006)  
Subjective & objective 





- Sleep, anxiety, 
depression, QOL 
(MOS, HADS, SF-12v2)  
) 
Average and worst pain scores (BPI-DPN) were 5.0 + 2.5 and 
5.6 + 2.8. 71.4% reported moderate-to-severe average and 
75.3% reported worst pain intensity.  
Hoffman et al. 
(2009)  
Subjective 








(MOS, HADS, EQ-5D 
UK Index, EQ-5D Japan 
Index) 
Subjects reported at least moderate levels of pain severity. 
Mean + SD scores for average pain: Asia 5.9 + 1.8, Latin 
America 6.7 + 1.6, Middle East 6.6 + 1.7. Mean + SD scores 
for mBPI-sf: Asia 4.7+2.3, Latin America 5.6+2., Middle East 
5.5+2.3. All subjects reported difficulties with sleep, health 
and functioning, sleep resulting in increasing pain severity.  
 
Jacovides et al. 
(2014) 
Subjective & objective 
measurement of PDN 
symptoms, reported 
DN4 - Sleep, QOL (DSIS, EQ-
5D) 
Prevalence of DPNP was 30.3%. EQ-5D scores (mean, +SD) 
were 0.84 + 0.16 for subjects without DPNP and 0.64 + 0.25 
for subjects with DPNP. DSIS scores (mean + SD) were 0.83 






al. (2013)  
Subjective & objective 






QOL (SF-36) In NPS, sharp pain was the most common reported symptom 
while itching the lesser one. VAS had a mean of 53mm. SF-36 
showed that physical functioning was the most affected 
domain while social functioning the least. 
Levterova et al. 
(2018)  
Subjective & objective 
measurement of PDN 
symptoms, reported 
DN4 - QOL (SF-36) Overall, the prevalence of DPN was 43% among all 
participants. DPN with pain was 14% among all participants 
with DPN. Participants with DPN with pain (group 1) had 
statistically lower QOL compared to participants with DPN 
without pain (group 2). 
 
Lewko et al. (2007)  Subjective 
measurement of PDN 
symptoms, reported 
Self-reports - Acceptance of illness, 
QOL (AIS, HRQOL, SF-
36) 
QOL was significantly reduced in subjects with PDN and also 
was related to the levels of illness acceptance. Factors 
influencing illness were feelings of being a burden (p≤0.05) 
and the belief that people around them are becoming 
anxious by their illness (p≤0.05)  
Mai et al. (2015)  Subjective & objective 











POMS, PCS, PGS) 
At 12-month follow-up, 37.2% of patients achieved pain 
reduction of ≥30%, 51.2% of patients achieved functional 
improvement of ≥1 on the BPI and 30.2% of patients 
achieved both pain reduction and functional improvement.  
Otis et al. (2013)  Subjective 









The CBT group showed decreases in pain severity (B = -0.54) 
and pain interference (B = -0.77) from pre-treatment to 4-
month follow-up. No significant differences were shown on 
the control group on pain severity (B = 0.00) and pain 
interference (B = -0.09). Depressive symptoms did not 
change for any group.  
Pfamatter (2012) Subjective & objective 






Control of pain (SOPA) No significant associations were produced. The effect sizes 
suggest that the experimental group experienced less pain 




Sadosky et al. 
(2013)  
Objective measurement 









3, MOS, HADS, WPAI-
SHP) 
The pain severity score was 5.2 (mean), and 79.5% of the 
participants reported moderate or severe pain. Overall, the 
function and pain interference scores were 5.0 (mean) 
overall. The mean overall activity impairment across all 
participants was 52.3%. Participants with severe pain had 
worse pain interference with sleep, function and health 
status (P<0.0020).  
Selvarajah et al. 
(2014)  
Subjective & objective 
measurement of PDN 
symptoms, reported 
NDS, NPS - QOL, catastrophizing, 
acceptance, anxiety, 
depression (QOL-DN, 
CPA-Q, PCS, HADS) 
Overall, the prevalence of emotional distress was 51.4%. 
Catastrophic thinking, pain-related restriction of QOL, age, 
marital status and employment acted as independent 
contributors to increase symptoms of anxiety and 
depression.  
Teixeira (2010)  Subjective 
measurement of PDN 
symptoms, reported 
NPS - QOL, sleep, 
mindfulness 
(NeuroQol, PSQI) 
The results suggested no significant statistical difference 
between the intervention and control group. 
Themistocleous et 
al. (2016)  
Subjective & objective 











insomnia (SF-36, PCS, 
PASS, DAPOS, ISI) 
Participants with PDPN scored higher on DN4 and 
painDETECT and correlated well with the mean score 
obtained from the 7-day pain intensity diary. Participants 
with moderate/severe PDNP scored higher on PCS, DAPOS, 
PASS-20, ISI, BPI and SF-36. Hence, these participants had 
poorer quality of life. 
Tölle et al. (2006)  Subjective & objective 





Presence of pain 
(mBPI-SF) 
QOL (EQ-5D) Pain severity was strongly associated with greater pain 




Van Acker et al. 
(2009) [44] 
Subjective & objective 
measurement of PDN 
symptoms, reported 
Neuropen, DN4 Pain Intensity 
(VAS) 
QOL (SF-12) The prevalence of DPN was 43% (95% CI 40.1–45.9). The 
prevalence of DPN-P was 14% (95% CI 12.1–16.2). 
Nephropathy, obesity, low HDL cholesterol and high 
triglyceride levels were independently associated with DPN 
and/or DPN-P. Physical and mental components of QoL were 
significantly altered by DPN-P. Only half of the DPN-P 
patients were using analgesic treatment, while 28% were 
using anticonvulsants or antidepressants.  
 Vileikyte et al. 
(2005)  
Subjective & objective 




- Depressive symptoms 
(HADS, IPQ-R) 
NDS and VPT were strongly associated with HADS. The 
relationship between foot ulceration and depression was 
non-significant.  
Vileikyte et al. 
(2009)  
Subjective & objective 




- Depressive symptoms 
(HADS, IPQ-R) 
NDS at baseline predicted increased HADS-D over 18 
months. Increased pain, unsteadiness and ADL restrictions 
from baseline to 9 months predicted increased HADS-D over 
18 months. Change in social self-perception from baseline to 
9 months predicted increased HADS-D. 
Wickramasinghe et 
al. (2016)  
Subjective & objective 
measurement of PDN 
symptoms, reported 
DN4 - QOL (NeuroQoL) 74% of the participants suffered from DPN while 97.1% were 
asymptomatic. 40% of the patients with diagnosed DPN 
reported that they have a poor quality of life. 74% 
mentioned that their symptoms reduced with 
pharmacological treatment.  
 Zelman et al. 
(2005)  
Subjective & objective 







QOL (EQ-5D, SF-12v2) Mean BPI-DPN Interference was 2.1 (SD=2.1) for mild pain, 
4.9 (SD=1.9) for moderate pain and 7.4 (SD=1.6) for severe 
pain. These categories of DPN pain severity are based on 
interference with daily function. 
Zelman et al. 
(2006)  
Subjective 
measurement of PDN 
symptoms, reported 
BPI-PDN - Sleep, Anxiety (MOS, 
HADS) 
Individuals with painful DPN reported impaired sleep 
compared to postherpetic neuralgia patients, the general 




Note: “-”: not reported, ADDQOL: Audit of Diabetes-Dependent Quality Of Life, AIS: Acceptance of Illness 
Scale, BDI: Beck Depression Inventory, BFNE: Brief Fear of Negative Evaluation Scale, CPA-Q: Chronic Pain 
Acceptance Questionnaire, CPPN: Chronic Painful Peripheral Neuropathy, DAPOS: The Depression Anxiety and 
Positive Outlook Instrument, DFNS: German research network of neuropathic pain, DN4: Douleur 
Neuropathique 4, DNSS: Diabetic Neuropathy Symptom Score, DPN: Diabetic Peripheral Neuropathy, DPNP: 
Diabetic Peripheral Neuropathic Pain, DSIS: Daily Sleep Interference Scale, EFNS: European Federation of 
Neurological Societies, EQ-5D: EuroQol, FES-I: Falls Efficacy Scale-International, FS: rating scale for current 
feelings, HADS: Hospital Anxiety and Depression scale, HFS: Hypoglycaemia Fear Survey, IENFD: Intraepidermal 
Nerve Fibre Density, IPQ: Illness Perceptions Questionnaire, ISI: Insomnia Severity Index, LANSS: Leeds 
Assessment of Neuropathic Symptoms and Signs, mBPI: modified Brief Pain Inventory, MNSI: Michigan 
Neuropathy Screening Instrument, MOS: Medical Outcomes Study-sleep scale, MOS SF –12: Medical Outcomes 
Short Form 12 scale, MPI: Multidimensional Pain Inventory, MPQ: McGill Pain Questionnaire, NCT: Nerve 
Conduction Tests, NDS: Neuropathy Disability Score, NE: Neurological Examination, NeuroQol: Neuropathy and 
Foot Ulcer-specific Quality of Life Instrument, NHP: Nottingham Health Profile, NPS: Neuropathic Pain Scale, 
NPSI: The Neuropathic Pain Symptom Inventory, NRS: Numeric Rating Scale, NSS: Neuropathy Symptom Score, 
NTSS-6-SA: Neuropathic Total Symptom Score Self-Administered, PASS-20: Pain Anxiety Symptom Scale, PCS: 
Pain Catastrophizing Scale, PDI: Pain Disability Index, PDPN: Painful Diabetic Polyneuropathy, PGS: Patient 
Global Satisfaction, POMS: Profile of Mood State, PPIS: Present Pain Intensity Scale, PSMPI: Pain Severity scale 
of the Multidimensional Pain Inventory, PSS: Pain Symptom Score, PSQI: Pittsburgh Sleep Quality Index, QOL: 
Quality of Life, QOL-DN: Norfolk Quality of Life Questionnaire, SF-MPQ: Short Form, SF-12: Short Form Health 
Survey, SF-36: Short Form Health Survey, SOPA: Survey Of Pain Attitudes, TCSS: Toronto Clinical Scoring 
System, TSF: Tampa Scale of Fear of Fatigue, TSK: Tampa Scale of Kinesiophobia, VAS: Visual Analogue Scale, 
VPT: Vibration Perception Threshold, VRS: Verbal rating scale, WPAI-SHP: Work Productivity and Activity 
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The Problem of Chronic Neuropathic Pain  
Chronic neuropathic pain (CNP) is the type of pain caused by a nerve injury or disease and is 
considered as a serious issue in the UK.  There are several causes for CNP such as, pain arising in 
stroke, spinal cord injury, multiple sclerosis, post-surgical pain, diabetic neuropathy, post herpetic 
neuralgia, and facial neuralgias, among other conditions.  According to Haanpäa et al, (2011), 3.3% 
to 8.2% of the general population suffers for CNP due to various causes. As a result, this condition 
involves great suffering and disability for the individuals, while the health-care system is significantly 
burdened (Jensen et al., 2007).   
Most interventions for CNP are pharmacological, including medications such as tricyclic 
antidepressants (TCAs), anticonvulsants, and opioids.  However, a recent systematic review of 174 
randomized controlled clinical trials (RCTs) of pharmacological treatment for neuropathic pain, 
frankly, yielded disappointing results (Finnerup, Sindrup, & Jensen, 2010).  There has been a 
substantial increase in the number and quality of trials conducted in the past five years but overall 
little improvement in efficacy. For example, some of the most effective drugs are those in the class 
of TCAs.  The number needed to treat (NNT) to achieve at least 50% pain relief, ranges from 2.1 for 
painful polyneuropathy to 2.8 for post herpetic neuralgia. On the other hand, the number needed to 
harm (NNH), that is the number of patients treated for one to drop out due to adverse effects, is 
15.9.  The next best front-line drug, pregabalin, has an NNT ranging between 3.8 for mixed 
neuropathic pain to 5.6 for central neuropathic pain (Finnerup et al., 2010). Conclusively, as implied 
by Finnerup et al, (2010), even though pharmacological interventions are considered the most 
effective therapeutic option for patients who suffer from CNP, patients still experience great pain 






Psychological Treatment Methods 
Psychological treatment methods, particularly those based on Cognitive Behavioral Therapy (CBT) 
represent a viable alternative or addition for the treatment of chronic neuropathic pain.  Broadly 
considered CBT interventions, are regarded as the most effective and cost-effective methods for 
treating chronic pain when compared to a range of pharmacological, surgical, and interventional 
procedures (Gatchel & Okifuji, 2006).  There are now more than five systematic reviews that support 
the effectiveness of CBT for chronic pain (Eccleston et al., 2009; Guzmán et al., 2001; Morley et al., 
1999). These approaches are not only able to reduce pain, but, importantly, also to improve daily 
activities, emotional functioning, work status, and to reduce healthcare costs (Gatchel & Okifuji, 
2006).  However, CBT interventions are rarely applied to patients suffering from CNP. In particular, 
there is only one RCT, by Otis et al, (2013), that applied CBT to Painful Diabetic Neuropathy (PDN) 
patients, yielding promising results suggesting that CBT could improve patients’ skills to experience 
less pain and be more physically active.   
Some researchers have suggested that different types of pain may require different psychological 
interventions. However, there is little evidence to support this. The literature reveals that, 
individuals who suffer from either chronic pain or neuropathic pain experience major impact in most 
aspects of their life including mood, mobility, work, sleep, and overall quality and enjoyment of life 
(Jensen et al., 2007; Schmader, 2002). One may conclude that, the impact of pain appears the same 
regardless of the different patient groups. 
Studies that compared patients with neuropathic pain to patients with non-neuropathic pain in 
terms of psychological variables, have found the groups to be much more similar, rather than 
different.  In a cross-sectional study comparing people with post-herpetic neuralgia versus low back 
pain there were no significant differences in self-reported measures of pain, mood, fear, or pain 





neuropathic (trigeminal neuralgia) and non-neuropathic (temporomandibular disorder) orofacial 
pain.  Once again, the groups were not different on measures of depression, anxiety, 
catastrophizing, or physical and social functioning, even though they differed in some of their 
reported sensory aspects of their pain (Gustin et al., 2011). Another study showed group differences 
between patients with fibromyalgia and patients with peripheral neuropathic pain, however, the 
groups were small and were confounded by the recruitment methods used, and by gender (Gormsen 
et al., 2010). 
There have been few studies of psychological treatments for neuropathic pain.  A recent systematic 
review identified 14 studies which involved adults with neuropathic pain and cognitive or 
behavioural interventions (Van de Wetering et al., 2010). Only three of these studies were RCTs and 
only one was regarded as having good methodological quality.  Upon further inspection, however, 
this trial included patients diagnosed with “long-term non-specific spinal pain” and not neuropathic 
pain as such (Jensen et al., 2001).  Hence, it was included in the systematic review erroneously.  
Another of the RCTs tested the effect of viewing an intact limb in a mirror on phantom limb pain, 
referred to it as “viewing a virtual limb” (Brodie et al., 2007), a method that is not regarded as a 
standard cognitive or behavioural method.  The final RCT was a feasibility and acceptability study of 
CBT for HIV-related neuropathic pain (Evans et al., 2003). In this study, the CBT group showed 
significantly greater reductions than the control group in depression and general emotional distress, 
however, there was a 57% dropout rate in the CBT group.  Hence, the treatment was regarded as 
having limited feasibility and acceptability in this group.  Other treatments included in the systematic 
review included “healing touch,” reflexology,” and a method called “image imprinting” to address 
body image, none of which would be recognised as a standard method within CBT. All the above 
reveal that, the evidence for cognitive and behavioural approaches to neuropathic pain is limited 
and further studies are needed to determine efficacy of psychological interventions in this 





Acceptance and Commitment Therapy 
A relatively new and promising approach to chronic pain, within the wider range of cognitive and 
behavioural approaches, is Acceptance and Commitment Therapy (ACT) (Hayes et al., 1999, 
McCracken, 2005).  ACT is a form of CBT that focuses specifically on increasing psychological 
flexibility. Psychological flexibility is the capacity to change or continue with behaviour, depending 
on which is more effective, according to one’s goals and what the current situation affords. 
Psychological flexibility in turn includes processes of acceptance, values-based action, and other 
processes related to mindfulness.  There are now at least four RCTs that support the efficacy of ACT 
as an approach for chronic pain in general (Dahl et al., 2004; Thorsell et al., 2011; Wetherell et al., 
2011; Wicksell et al., 2008).  One of these shows that ACT is at least as effective as traditional CBT for 
chronic pain and may be preferred by patients (Wetherell et al., 2011).  There are also a number of 
larger scale effectiveness studies showing that ACT (a) is deliverable in NHS practice settings 
(McCracken et al., 2005; Vowles & McCracken, 2008), (b) is associated with a wide range of 
improvements in emotional, physical, and social functioning and reduced healthcare use (McCracken 
et al., 2005; Vowles & McCracken, 2008), (c) produces good long term results, such as at three years 
post treatment (Vowles et al., 2011) and, (d) appears to produce results specifically through changes 
in its theoretically proposed processes of change (McCracken & Gutiérrez-Martínez, 2011; Vowles & 
McCracken, 2010; Wicksell et al., 2010). 
ACT is a highly flexible and variously scalable approach.  It has been delivered in formats ranging 
from a self-directed workbook (Johnston et al., 2010), to four hours of individual treatment time 
delivered by a single treatment provider (Dahl et al., 2004), and up to 20 days of full time treatment 
in a group, residential, treatment environment, provided by an interdisciplinary team of treatment 
providers, specifically for highly complex problems of chronic pain (Vowles & McCracken, 2008). ACT 





the American Psychological Association (Society for Clinical Psychology, 2011). None of the currently 
published trials has specifically focused on neuropathic pain. 
Painful Diabetic Neuropathy 
There are nearly 3 million people in the UK diagnosed with diabetes mellitus (DM) and this is 
expected to grow to 5 million by 2025 (Diabetes UK, 2011). One of the more common forms of 
neuropathic pain is associated with DM. Approximately 25% of all patients with DM develop painful 
diabetic neuropathy (PDN) and the prevalence of painful symptoms is up to 60% (Daousi et al., 2004; 
Davies et al., 2006, Mai et al., 2017). PDN, is considered a complex, multi-dimensional condition, 
possibly affecting the physical and mental health of the patient (Barrett et al., 2007). PDN, is usually 
described as a sense of burning, stabbing, aching and/or pricking mainly affecting areas like toes, 
legs, and feet and physically interfering with mobility, sleep, mood, and generally quality of life. 
Moreover, PDN despite the physical health it also affects the mental health of the patients by 
enhancing the levels of anxiety, catastrophizing thinking and depression (Geelen et al., 2016; 
Vileikyte et al., 2005) resulting in poorer outcomes, such as worsening pain-related disabilities (Gore 
et al., 2005). Although some patients may experience temporary symptoms’ relief through 
interventions PDN is a chronic disease and a long-term suffering for most patients (Mai et al., 2017). 
The summary presented here clearly highlights the importance of improving the health and well-
being in patients with PDN by developing acceptable and potentially effective psychological 
interventions (Collins et al., 2009; Geelen et al., 2016; Vileikyte et al., 2005). This condition 
represents both a significant problem in its own right and a useful condition in which to test 
treatments that may offer wider benefits for neuropathic pain conditions in general.  There are no 
published studies of ACT for PDN and the limited available evidence indicates that a CBT-based 





People with PDN have clear treatment needs.  While ACT may help them, little is known directly 
about the relevance of different components of ACT for this condition or about how to customize it 
for them. The proposed research will include two aims: (a) to preliminarily survey people with PDN 
on relevant treatment needs and then (b) to conduct a feasibility study of the resulting treatment 
design based on these. 
Objectives 
The overarching objective of this research is to assess the feasibility, acceptability, and potential 
efficacy of the ACT treatment, via the following objectives in Table 24: 
Table 24: Research Objectives 
Research aims 
This patient’s survey and the feasibility study is a response to unmet treatment needs of people in 
the UK suffering from PDN, and to a particular lack of development of ACT-based approaches for 
these patients. Available evidence, limited as it is, suggests no reason to doubt the efficacy of 
broadly ACT-based approaches for CNP.  Well controlled studies are needed to verify this reasonable 
presumption.  There are also recent developments within ACT, that already have strong research 
support, offer flexible and highly efficient delivery options, and appear well-suited to the study 
population.  PDN is being chosen as a condition on which to pursue this treatment development 
work, as the condition is relatively common, causes patients great problems, and overlaps with the 
areas of expertise represented in the research team. 
Objective 1 Gather a more in-depth understanding of the patients’ perspectives and beliefs associated to 
neuropathic pain 
Objective 2 Examine the feasibility of such treatment by measuring recruitment and retention rates 
Objective 3 Establish the best instruments for measuring variables by examining the quality, completeness, 
and variability of the data 
Objective 4 Specify if ACT is as acceptable and credible approach for the participants 







• Assess the experience of pain from the perspective of PDN patients.  
• Examine patients’ treatment needs and preferences. 
• Assess the suitability and feasibility of ACT as an acceptable and potentially effective intervention. 
• Examine the feasibility and to pilot test a psychological treatment for PDN.   
• Assess a feasibility of such a treatment by establishing recruitment and retention rates, the 
appropriateness and sensitivity of outcome measures, and acceptability to participants, through 
conducting a small feasibility study. 
Hypothesis Being Tested 
This research is not so much hypothesis driven as it is focused on a few key research questions. 
Through the methods described we will determine treatment needs and preferences, identify 
therapeutic priorities, develop these into a prototype treatment, and then test the feasibility of this, 
particularly in terms of deliverability and acceptability. In particular we will be able to specify the 
intervention’s duration, techniques, processes emphasised, mode of delivery, and outcomes from 
phase one of this project and then test these aspects in phase two.  
Study Design 
The survey will adopt a cross-sectional design for patients who suffer from PDN and receive any type 
of treatment, pharmacological or psychological, or no treatment at all. This survey intends to include 
at least 200 participants with PDN, which will be recruited both online and face to face in order to 
achieve results that are likely to be reliable and the power to detect small correlations in the data.  
The feasibility study will be an online single cohort, which will be linked to the survey. Based on this 
survey, the research team will develop an ACT-based intervention for PDN patients that can then be 





from PDN. The total sample size is designed primarily to allow an efficient size to be conducted and 
to allow enough recruitment to observe retention rates.   
Sample Size 
For the survey, we used a regression-based a-prior estimation for required sample size based upon 
past data looking at cognitive and behavioural predictors in Multiple sclerosis. Modelling a 
regression equation with 12 predictors and an effect size of .15 (f2=medium effect) with power set at 
.80, revealed an estimated require sample size of 127. We will aim to achieve a minimum sample 
size of 200 that will achieve the power needed and also provide enough sample size for secondary 
validity analyses of the instruments being used. 
For the feasibility study, a sample size of approximately 30 participants would allow us to estimate 
the true population consent rate with a 11% margin of error (95% confidence level) for those 
meeting eligibility criteria. Past psychological research in patients with chronic pain, conducted by 
the team, suggest consent rates between 50-70%, assuming a more conservative uptake of 40%, and 
approximately 30% will meet both the inclusion and exclusion criteria. In line with recommended 
sample sizes of pilot feasibility trials (Billingham, Whitehead, & Julius, 2013; Browne, 1995; 
Viechtbauer et al., 2015) 30 patients is deemed sufficient to explore feasibility, acceptability, and 
potentially efficacy of the intervention, assuming retention rates of 80%, the true population 
consent rate will be with a margin of error of 14% (95% confidence interval). Achieving this sample 







The eligibility of the participants will be assessed through a screening pack which will include two 
self-report questions asking if they are adults and have confirmed diagnosis of diabetes and 
neuropathic pain and have the basic English reading ability and interest to participate.  
Inclusion Criteria 
Participants will have to fulfil the following criteria in order to take part to our research: 
• Aged at least 18 years. 
• Confirmed diagnosis of diabetes. 
• Presence of painful diabetic neuropathy, for the last three months or more. 
• Have full verbal and written proficiency in English. 
• Willingness and ability to take part. 
• Have computer literacy (where online procedures are involved). 
Exclusion Criteria 
Potential participants who are not able to understand verbal explanation or written information in 
English will regrettably be excluded. The measures are designed for self-administration and live 
translation would both undermine their validity and create unnecessary variability in the data. We 
do not have the resources or funding available produce and validate the standardised measures 
being used in other languages. We will monitor the number of potential participants excluded for 







Potential participant will be approached both online and face to face.  
Within the GSTT NHS site participants will be identified by the direct clinical care team. The research 
team will only approach the potential participant after the direct care team has obtained verbal 
consent for the research team to approach them about the study. The clinical care team will 
introduce the member of the research team to suitable potential participants. The member of the 
research team will explain the studies to potential participants in the waiting room of the relevant 
outpatient clinics and will answer any questions. The member of the research team will then provide 
the recruitment pack to potential participants. The recruitment pack will include: 1) Participant 
Information Sheet, 2) Consent Form and a, 3) Screening Questionnaire. All the recruitment materials 
are written in simple, easy to understand language, free of medical jargon. National Institute of 
Health Research (NIHR) guidelines have been followed when creating the Information Sheet and 
Consent Form. Participants will be encouraged to take at least 24 hours to consider their 
participation to the survey and discuss it with their family, GP, or the research team if they wish. It 
will be made clear that they may or may not be eligible to take part and their usual care will not be 
affected in any way. Also, participants can refuse to take part without giving a reason. Consent will 
be taken with the presence of a researcher either via Skype or face to face.  
Participants will also be recruited online if necessary. The researcher will contact online 
organisations with an interest in the diabetes and related conditions to disseminate the present 
research. The questionnaires will be delivered online using Bristol Online Surveys (BOS) tool and the 
intervention will also be delivered online. BOS provides a protective privacy policy regarding e-mail 
addresses and personal information that is compliant with EU and international standards as 





information. Responses will be anonymised at the point of data collection and no personal 
identifiers will be collected.  
As the BOS tool is accessed via a hyperlink we will focus on organisations with an online presence, 
like Diabetes UK. The targeted organisations will be kindly asked to add a notice to their website, a 
message on their forums and send a message to their followers that highlights the study and 
provides the URL. Via the link participants will be provide with details about the studies before they 
begin. Initial questions will collect basic demographics information, for descriptive purposes, and a 
screening questionnaire will detect their eligibility for the study.  
We anticipate that recruitment will take approximately 3 months. Also, participants will be kindly 
asked if they would also like to take part in further research, if yes, they will be asked to provide 
their contact details. Data will be analysed qualitatively in for some of the open-ended content and 
quantitatively, with SPSS, particularly for the numerical rating data and standardized measures. A 







Figure 18: Anticipated flow of the participants 
Assessment Instruments 
The following questionnaires will be used in the present studies and consent will be obtained for all 
of them: 
Demographic Questionnaire collecting the background information mentioned below: age, gender, 
ethnicity, pain history and pain location, level of education, occupation. 
Screening pack, assessing participants’ eligibility for the study: Self-report: Two questions asking the 
participants if they have a confirmed diagnosis of diabetes and neuropathy from their physician.  
The following set of questionnaires, commonly used for chronic pain studies, will be included in this 





Pain Intensity scale: 0-10 numerical ratings of pain intensity. Participants will be asked to rate 
average pain in the past week on a 0-10 numerical scale. 
Work and Social Adjustment Scale (WSAS): WSAS is a reliable self-report measure with great validity. 
It contains five-items which are rated to a 0-8 numerical scale (0=No impairment, 8=very severe 
impairment). WSAS assess “functional impairment” whith statements reffering to work, home 
management, social and private leisure, and relationships (Mundt, Marks, Shear, & Greist, 2002; Yu, 
McCracken & Norton, 2016).  
Patient Health Questionnaire (PHQ-9): PHQ-9 is a reliable and validate measure for depressive 
symptoms, according to DSM-IV. It includes 9-items, and each item is rated on a four-point scale 
between ‘not at all’ and ‘nearly every day’ (Lowe et al, 2004; Kroenke et al, 2001). 
Committed Action Questionnaire (CAQ-8): CAQ-8 intends to reveal the level of commitment 
participants have related to their goals, plans, activities and furthermore their psychological 
flexibility (McCracken, Chilcot & Norton 2015). Responses to the statements of the questionnaire 
will be rated to a 0-6 scale (0=Never True, 6=Always True). 
The Chronic Pain Acceptance Questionnaire (CPAQ): CPAQ is a validate measure which reveals 
acceptance of pain through measuring: engagement in activity in the presence of pain, and 
willingness to experience pain without trying to control or avoid it (McCracken, 2010; McCracken, 
Vowles & Eccleston, 2004). CPAQ is a 20-item questionnaire, on a 6-point scale (0 = never true, 6 = 
always true). The higher score a participant reaches the greater acceptance of pain he/she have.  
Self - Experiences Questionnaire (SEQ): The SEQ consists 29-items and aims to measure self-related 
process within the psychological flexibility model (Yu, McCracken & Norton, 2016). All items are 





The Cognitive Fusion Questionnaire (CFQ-7): The CFQ offers a psychometrically sound measure of 
cognitive fusion and consists of 7-items on a 7-point scale (1=never true, 7=always true). CFQ is 
considered very valuable for the researchers and clinicians who intend to assess psychological 
processes (Gillanders et al., 2014). 
At the end, there will also be a questionnaire which will help the research team design and 
implement an acceptable and potentially effective ACT psychological treatment. The questionnaire 
will ask for the personal views of the participants regarding the treatment delivery format.  
Treatment 
The intervention is a tailored ACT-based self-management intervention which will be delivered 
online, unless results from the feasibility survey clearly suggest another format.  The purpose of this 
intervention is to improve participant daily functioning via increased psychological flexibility.  The 
intervention’s outline can be found in Figure 19. The development of the PDN ACT-based 
intervention involved a multidisciplinary team of psychologists, health professionals and diabetes 
specialists.  
The ACT treatment package will embrace the core treatment processes of acceptance, cognitive 
defusion, mindfulness, and values-based action. Methods will include practice in contacting painful 
experiences, experiential cognitive methods to promote awareness, exercises similar to mindfulness, 
methods to increase one’s the role of goals and values in patient choice, and to help people flexibly 
stick to commitments (McCracken, 2005). 
The process will involve, two brief direct one-to-one contact sessions, one at the beginning and one 
at the end of the intervention, with convenient means according to each participant, as for example 
Skype, phone or face to face. Following the first one-to-one session there will be 8 short online 
sessions, with a duration of 20-30 minutes each. In accordance with ACT principles, participants will 





write on a diary weekly, which will include ratings for openness, awareness and engagement. Within 
the diary we will also ask participants to note changes, in medication, if any, and if the data is 
sufficient and relevant, we will include them in the final analysis. The completion of these tasks has 
been found to be predictive of CBT outcomes (Kazantzis, Whittington, & Dattilio, 2010; Mausbach, 
Moore, Roesch, Cardenas, & Patterson, 2010). 
Post Intervention Evaluation 
At the end, we will also have evaluation forms for treatment completers. They will be asked to 
answer a questionnaire on the acceptability of format, focus, and content of treatment; whether 
they found it helpful; any barriers to participation or barriers to benefits they could identify; 
acceptability of the assessment methods; and any views they might provide on maximizing access, 
participation, and effectiveness of the treatment in the future. 
 







The distribution tool for the dissemination of the questionnaires and for raw data collection will be 
the BOS platform, and statistical data analysis will be performed using the SPSS software tool, 
particularly for the numerical rating data and standardized measures. Descriptive statistics will be 
used to display demographic data of the participants and standardised measures will be scored 
according to their standard instructions.  
The final phase of the project will include calculating recruitment and retention rates and examining 
the data from the feasibility study to consider the appropriateness of measures chosen for 
examining effects of treatment. Descriptive statistics, such as frequencies and percentages of 
patients approached, screened, eligible, consented, and allocated to treatment will be computed. 
Reasons for non-consent, exclusion, and drop-out, at each stage of the study, will be recorded and 
reported. Adherence to the intervention will be reported using descriptive statistics. Acceptability 
and credibility ratings will also be examined to assure that at least 75% provide ratings above the 
midpoint on each of the relevant ratings, to indicate feasibility on this basis. 
Dissemination 
We will endeavour to publish this research in a peer-reviewed journal, present the findings at 
relevant conferences and the findings will also contribute to the doctoral thesis of the PhD student 
(Miss Aikaterini-Pinelopi Kioskli).  
Withdrawal Criteria 
Patients who consent and begin treatment but discontinue will be contacted to explore their 
reasons for discontinuing treatment or any barriers they encountered to participating.  Participants 
have the right to withdraw from the research at any time without having to give a reason for doing 





decide to withdraw. All study participants will notify the research team of their wish to withdraw, 
using the contact details provided in the Participant Information Sheet for this study. As indicated on 
the Informed Consent Form, all data collected before the point of withdrawal will be retained and 
analysed unless the participant requests otherwise. It will not be possible to withdraw a patient’s 
data after data analysis. 
Ethical Considerations  
Patients may find completing questionnaires and treatment delivery burdensome or mildly stressful. 
However, we hope that this burden will be offset by having access to the treatment which will likely 
benefit their psychological wellbeing and increase their psychological flexibility. Participants will be 
reminded that they are free to withdraw from the study at any time. Participants will be fully 
informed about the intervention using the participant information sheet and a researcher will be on 
hand to answer any specific questions.  
If participants require additional emotional support, they will be referred to their GP to consider 
possibly a psychologist or counsellor at the earliest possible time point. If there is an urgent risk to 
participant’s mental or physical health, then they will be referred to their clinical care team, their 
General Practitioner or the emergency services immediately. If the members of the research team, 
involved in the treatment delivery, feel concerned about the level of distress of a participant; with 
the participant’s permission, this will be disclosed to the clinical care team. Participants will also 
receive information on the support services of the Diabetes UK.  
Fortnightly supervision meetings will occur with the researchers involved in the delivery of the 
intervention, this will include ensuring fidelity to the treatment and to assess and discuss patient 







Risk to participants are expected to be small based on extensive experiences of the methods used 
here with other populations. Participants may find the questionnaires or treatment mildly 
distressing. However, these effects are anticipated to be short lived, as participants will learn 
psychological techniques during the intervention that can help them manage negative emotions and 
diabetes better.  
Potential Risks for Researchers 
There are no identifiable risks for the researchers.  
Regulatory Issues 
Ethic Favourable Opinion and NHS R&D Permission  
All Investigators will obtain HRA Approval, which combines the REC opinion and R&D permissions. 
The Chief Investigator will require a copy of the research team’s current CV and GCP certificates, and 
letter of NHS permission before accepting participants into the study. On obtaining a favourable 
ethical opinion, any subsequent changes to the conduct, design or management of the study will be 
notified to the original approving REC and any other relevant regulatory authority via a substantial 
amendment. Changes to the study will not be implemented until REC approval has been obtained. 
NHS R&D Amendment permission from the participating sites will be required before any changes 
can be implemented at the applicable site. The CI will submit a final report to the sponsor and the 
approving REC. The research team, which have taken part in the development of the treatment and 
protocol, includes researchers with expertise in quantitative methods, developing and delivering 






Confidentiality and Data Management 
The Chief Investigator (CI) and all members of the research team will preserve the confidentiality of 
participants taking part in the study and will work in accordance with the Caldicott Principles, Data 
Protection Act 1998, NHS Code of Confidentiality and any relevant NHS Trust organisational policies. 
The participating NHS sites will be bound to act in accordance with these applicable regulations. 
Research team members who are not part of the direct care team will not have access to patients’ 
identifiable records without consent at any stage of research, including identification of eligible 
participants. All participants will be assigned an identification number (ID) and all collected data will 
be identified by the ID number. The consent form will contain patient identifiable information, 
including the name, contact details, and GP information. This information will be necessary to 
maintain contact with the participants throughout the feasibility study, in particular to arrange 
treatment delivery, and also to notify the GP of their participation in the study. A secure database of 
participants’ Study ID, names and contact details will be maintained by the research team, accessed 
by a password and stored in a secure, restricted access folder at King’s College London. The 
demographic, clinical, and psychological data will be stored in a separate database from the 
identifiable data.  
All electronic data will be anonymised and stored in a restricted access folder on a password-
protected computer at King’s College London. Secure password-controlled access is restricted to the 
research team only. All identifiable data stored in paper files (signed consent forms) will be managed 
securely in restricted access, lockable cabinets at King’s College London. Consent forms, containing 
identifiable information, will be stored separately from non-identifiable data. When the study is 
completed, all non-identifiable data will be archived at King’s College London and held for seven 







The study is sponsored by King’s College London, providing insurance for the study, through its own 
professional indemnity for research involving human participants and no-fault compensation and 
the Trust having a duty of care to patients via NHS indemnity cover, in respect of any claims arising 
as a result of clinical negligence by its employees, brought by or on behalf of a study patient. 
Sponsor  
KCL will act as the main sponsor for this study and will adhere to the Research Governance 
Framework for Health and Social Care 2005 (2nd Edition), and any amendments or subsequent 
replacements. The study will be co-sponsored by GSTT. 
Funding 
This study is part of a PhD, funded by the Diabetes UK to Aikaterini-Pinelopi Kioskli. The views 
expressed are those of the authors and not necessarily those of the NHS or Diabetes UK. Participants 
will not receive any financial incentive. 
Audits and Inspections 
The study may be subject to inspection and audit by King’s College London under their remit as 
sponsor and other regulatory bodies to ensure adherence to GCP and the NHS Research Governance 
Framework for Health and Social Care (2nd edition). The participating NHS sites are required to 
comply with any requests for audit by the sponsor or applicable site R&I Office and ensure that the 
study documentation and information is available in the relevant site file. Copies of audit / 







There are no anticipated amendments to the study conduct, management and activities at this stage 
(pre-study preparation and planning June-September 2017). Authorisation will be sought from the 
study sponsor for any future substantial and non-substantial amendments arising during the course 
of the study, prior to submission to the HRA. Advice on amendments will be sought via: 
http://www.nres.npsa.nhs.uk/applications/after-ethical-review/notification-of-amendments/ 
Intellectual Property 
Any intellectual property arising from the development, conduct and completion of this study will be 
owned by the study sponsor. 
Study Management 
The day-to-day management of the study will be co-ordinated by the CI and the trial management 
team. The team will also meet regularly, once a month, to discuss the overall running of the study 
including: rates of recruitment, adherence to the protocol, safety and confidentiality of patients. All 
serious adverse events related to the study will be reported to the study sponsor, ethics committee 
and relevant NHS R&I departments. The monitoring and auditing of the conduct of the research 
within the Trust lies with the R&I Office. The R&I Office, on behalf of the Sponsor, may monitor and 
conduct random audits on a selection of studies in its clinical research portfolio, or may conduct for-
cause monitoring visits following an incident or a breach or GCP or protocol. 
Deviations and Breaches 
In the case of study deviations or serious breaches of protocol, study deviation forms will be 
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Appendix G: Participants’ Information Sheet for Survey 
 
 
Information Sheet for Participants 
Title of Project: The Development of Contextual Cognitive Behavioural Approach to painful 
diabetic neuropathy; revealing patients’ perceptions and beliefs 
We would like to invite you to participate in a study. This study seeks a more in-depth understanding 
of the patients’ experiences and perspectives related to painful diabetic neuropathy (PDN), to 
further develop an acceptable and effective psychological treatment for this condition. Before you 
decide whether to take part in this study, it is important that you understand why the research is 
being conducted and what is involved. Please take time to read the following information and feel 
free to ask if there is anything that is not clear or if you would like more information.  
What is the purpose of this project? 
This is part of a PhD project at King’s College London. It is hoped that this study will improve our 
understanding of PDN. PDN is usually managed with medication. There has been little development 
or research into psychological treatments for neuropathic pain, in general, including PDN. However, 
existing evidence demonstrates that psychological treatments applied to chronic pain are beneficial, 





we assess the experience of pain from the perspective of people with PDN and examine their 
treatment needs and preferences. 
Who is eligible to take part?  
Participants will have to fulfil the following criteria to take part in the study: 
• Confirmed diagnosis of diabetes. 
• Presence of painful diabetic neuropathy. 
• Aged at least 18 years. 
• Willingness and ability to take part. 
Why have I been invited? 
You have been identified as a potential participant by your doctor because you have a confirmed 
diagnosis of diabetes and you suffer from neuropathic pain due to diabetes.  
What will I have to do if I agree to take part?  
Participants will have to answer ten short questionnaires, which overall will help the research team 
to collect demographic data, and assess pain intensity, certain attitudes toward pain, mood, and the 
impact of pain on participants’ daily physical, social and work activities.  
How much of my time will participation involve? 
Participation should take no more than 45 minutes.  
Will my participation in the project remain confidential?    
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. You will be given this information sheet and a signed consent form to keep, if you wish. 





questionnaires will be used for the purpose of this project only. The results from the analyses of the 
combined data will be summarized and submitted for publication in an academic journal and also be 
presented in scientific conferences. No participants’ identity will be included in these reports. The 
research team will only have access to patients’ identifiable records after the participants have 
provided informed consent. KCL and GSTT, acting as sponsor and co-sponsor to this study, may also 
have access to the collected data for monitoring purposes. If data is transferred through optical 
media, it will be encrypted through password protection during transfer. When data will be stored 
on University computers, password-controlled access to the secure network will be restricted to the 
research team members only. The collected data will be kept for a maximum of 5 years. Any 
identifiable information from questionnaires will be removed. An ID number will be assigned to each 
completed questionnaire to ensure that data cannot be traced back to an individual. Participant data 
in paper (without identifying information) and consent forms in paper (with identifying information 
and contact details) will be stored separately and securely in restricted access, lockable cabinets at 
KCL. Your anonymised data will be shared with other researchers and may be used for other 
research purposes. At the end of the present survey you will be kindly asked if you like to take part 
to further research, if yes you will be asked to provide your contact details which will be stored from 
6-12 months. Your contact details will only be used to help the research team get in touch with you 
for a future study. Nobody else will have access to your contact details.  
What are the advantages of taking part?  
You will have opportunity to share your thoughts of diabetes and neuropathy. The results from this 
survey will provide valuable input and will help in the development of an acceptable and potentially 






Are there any disadvantages of taking part?  
We do not foresee any disadvantages of participating in this study, except that it does require some 
time.  You do not have to answer any questions if you do not wish to.  
Do I have to take part in the study? 
No. It is entirely your decision as to whether you take part in this study. If you decide to take part, 
you will be asked to complete a consent form. Please note the deadline to request withdrawal of 
your data from the study will be four weeks after the end of data collection. It will not be possible to 
withdraw your data after analysis. If you wish you are free to withdraw at any time during the study 
period without giving a reason, even if you initially decided to take part without affecting your 
quality of treatment or medical care. 
Will my GP and clinical care team be involved? 
The research team is in no way connected with the team involved in your treatment and your 
decision to participate or not will in no way affect the standard of care you receive. Your personal GP 
will not be involved in the study, but they will be informed of your participation with your 
permission. Any contact with the research team will be logged in your medical history file, for 
example, on the day a member of the research team approaches you about the study, it will be 
recorded as ‘approached for participation and given participant information sheet’.  Additionally, you 
will receive a copy of the signed consent form and another copy will be added to your medical file, if 
you decide to take part in the study.   
What will happen to the results of the research study?  
The study will be presented at scientific conferences and be written up for publication in scientific 





Who should I contact for further information? 
If you have any questions or require more information about this study, please contact me using the 
following contact details: Name: Miss Aikaterini-Pinelopi Kioskli (PhD candidate), Email: 
aikaterini.kioskli@kcl.ac.uk, Telephone: +44 (0) 2071880188  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions [Professor Lance M. McCracken, Email: 
lance.mccracken@kcl.ac.uk, Telephone: +44 (0) 207 188 5410, Health Psychology Section, 
Psychology Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), Guy’s Campus, 
London, SE1 9RT]. If you remain unhappy and wish to complain formally, you can do this through the 
Guy’s and St Thomas’ Patients Advice and Liaison Service (PALS) on 020 7188 8801, 
pals@gstt.nhs.uk. The PALS team are based in the main entrance on the ground floor at St Thomas’ 
Hospital and on the ground floor at Guy’s Hospital in the Tower Wing. In the event that something 
does go wrong and you are harmed during the research you may have grounds for legal action for 
compensation against Guy’s and St Thomas’ NHS Foundation Trust and/or King’s College London but 
you may have to pay your legal costs. The normal National Health Service complaints mechanisms 
will still be available to you (if appropriate). 






Appendix H: Participants’ Consent Form for Survey 
 
CONSENT FORM 
Title of Project: The Development of Contextual Cognitive Behavioural Approach to painful 
diabetic neuropathy; revealing patients’ perceptions and beliefs 
                    Please initial box  
1. I confirm that I have read the information sheet dated 8.1.2018 version 2 for the 
above study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that the information collected about me will be used to support 
other research in the future and may be shared anonymously with other researchers. 
 
4. I understand that relevant sections of my medical notes and data collected during the study  
may be looked at by individuals from King’s College London, regulatory authorities or from  
the NHS Trust, where it is relevant to my taking part in this research. I give permission for  
these individuals to have access to my records. 
 
5. I agree to my General Practitioner being informed of my participation in the study.  
 
6. I agree to take part in the above study.  
 
 
            
 Name of Participant              Date    Signature 
 
 
            
Name of Person                           Date    Signature 





Appendix I: Questionnaire Pack for Survey and Feasibility Study 
Please read each question carefully. We kindly ask you to answer the questions as honestly and as 
quickly as possible. There are no right or wrong answers to these questions. We are mostly 
interested in your own experiences and circumstances. The information that you provide in this form 
is completely confidential and anonymous and will not be shared with anyone outside the clinical or 
research team without your expressed consent. Your participation is voluntary, and you are free to 
withdraw at any time without giving any reason. If you have any difficulty completing these 
questionnaires or any further questions, please contact a member of the research team. 
Screening Questions 
Do you have a confirmed diagnosis of diabetes from your physician? Yes/No  
Do you have a confirmed diagnosis of neuropathy (or nerve pain or painful diabetic neuropathy or 
neuropathic pain or polyneuropathy) from your physician? Yes/No  
Pain History 
Duration of pain (please state):  ______Years _________ Months 
Pain location 
Where is the main or worst pain (i.e. legs, hand)? _______________ 
Demographic Questionnaire 
 (Please tick/circle the answer of your choice or provide information required) 
What is your sex? Female/Male/Other 






How many years of education have you completed? 
(Please provide total years completed counting from primary school-not school “leaving age”) 
_____years  
 











Irish  African  Other  
Other  Other  
Mixed  






White and Black 
African  Pakistani  
White and Asian  Bangladeshi  
Other  











alone   
with partner   
with child/children   
with partner and 
child/children 
  
with other relatives   





What is your present work status? Please tick ONE box: 
Employed Full time   
 Part time due to pain   
 Part time by choice/other reasons   
 Volunteer/unpaid   
 Carer   
 Homemaker   
Unemployed Because of pain   
 Unrelated to pain problems/other   
Student/Training Full time   
 Part time due to pain   
 Part time by choice/other reasons   
Retired    
Other (please 
state) 







Douleur Neuropathique 4 (DN4) – Questionnaire 
To estimate the probability of neuropathic pain, please answer yes or no for each item of the 
following four questions. 
Does the pain have one or more of the following characteristics?  
Burning .................................................................... ❏   
Painful cold .............................................................. ❏   
Electric shocks ......................................................... ❏  
Is the pain associated with one or more of the following symptoms in the same area?  
Tingling .................................................................... ❏   
Pins and needles ...................................................... ❏   
Numbness ................................................................ ❏  
Itching .......................................................................❏  
Is the pain located in an area where the physical examination may reveal one or more of the 
following characteristics? 
Hypoesthesia to touch ...............................................❏  
Hypoesthesia to pinprick ............................................❏  
In the painful area, can the pain be caused or increased by:  







Please indicate on the scale below the number between 0 and 10 that best describes your pain. 0 
indicates no pain at all and 10 indicates the worst possible pain. 
 
How intense is your pain right now? 
  0           1           2           3           4            5            6           7           8            9          10 
  □           □          □           □          □            □            □           □           □           □          □  
none                    as bad as you can imagine  
How intense was your pain on average last week?       
  0           1           2           3           4            5            6           7           8            9          10 
  □           □          □           □          □            □            □           □           □           □          □  
none                    as bad as you can imagine  
How distressing is your pain right now? 
  0           1           2           3           4            5            6           7           8            9          10 
  □           □          □           □          □            □            □           □           □           □          □  
none                                                              as bad as you can imagine 
How distressing was your pain on average last week? 
  0           1           2           3           4            5            6           7           8            9          10 
  □           □          □           □          □            □            □           □           □           □          □  






Work and Social Adjustment Scale (WSAS) 
Rate each of the following questions on a 0 to 8 scale: 0 indicates no impairment at all and 8 
indicates very severe impairment. 
1. Because of my condition, my ability to work is impaired. 
 
  0           1           2           3           4            5            6           7           8 
 
No Impairment                  Very Severe Impairment 
 
2. Because of my condition, my home management (cleaning, tidying, shopping, cooking, looking after 
home or children, paying bills) is impaired. 
 
0           1           2           3           4            5            6           7           8 
 
No Impairment                  Very Severe Impairment 
 
3. Because of my condition, my social leisure activities (with other people, such as parties, bars, clubs, 
outings, visits, dating, home entertainment) are impaired. 
 
0           1           2           3           4            5            6           7           8 
 
No Impairment                  Very Severe Impairment 
 
4. Because of my condition, my private leisure activities (done alone, such as reading, gardening, collecting, 
sewing, walking alone) are impaired. 
 
0           1           2           3           4            5            6           7           8 
 
No Impairment                  Very Severe Impairment 
 
5. Because of my condition, my ability to form and maintain close relationships with others, including those 
I live with, is impaired. 
 
0           1           2           3           4            5            6           7           8 
 






Patient Health Questionnaire (PHQ-9) 
Over the last 2 weeks, how often have you been bothered by any of the following problems (please 
circle your answer)? 
 
10. If you checked off any problems, how difficult have these 
problems made it for you to do your work, take care of things at 
home, or get along with other people (please circle your 
answer)?  
 
    Not difficult at all  
 
    Somewhat difficult 
 
    Very difficult  
 
    Extremely difficult  
  
PHQ-9 is adapted from PRIME MD TODAY, developed by Drs Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke, and 
colleagues, with an educational grant from Pfizer Inc. For research information, contact Dr Spitzer at rls8@columbia.edu. 
Use of the PHQ-9 may only be made in accordance with the Terms of Use available at http://www.pfizer.com. Copyright 





Not at all Several days 
More than 




1 Little interest or pleasure in doing things.  
0 1 2 3 
2 Feeling down, depressed, or hopeless.  0 1 2 3 
3 Trouble falling or staying asleep, or sleeping too much. 0 1 2 3 
4 Feeling tired or having little energy.  0 1 2 3 
5 Poor appetite or overeating.  0 1 2 3 
6 Feeling bad about yourself—or that you are a failure or 
have let yourself or your family down. 
0 1 2 3 
7 Trouble concentrating on things, such as reading the 
newspaper or watching television. 
0 1 2 3 
8 Moving or speaking so slowly that other people could 
have noticed. Or the opposite—being so fidgety or 
restless that you have been moving around a lot more 
than usual. 
0 1 2 3 
9 Thoughts that you would be better off dead, or of hurting 
yourself in some way. 





Committed Action Questionnaire 
 
Below you will find a list of statements. Please rate the truth of each statement as it applies to you by selecting a 
number. Use the following rating scale to make your choices. For instance, if you believe a statement is “Always 






0 1 2 3 4 5 6 
Never true Very rarely true Seldom true Sometimes true Often true Almost always true Always true 
1 I can remain committed to my goals even when there are times that I fail to 
reach them. 
 
0 1 2 3 4 5 6 
2 When a goal is difficult to reach, I am able to take small steps to reach it.  
0 1 2 3 4 5 6 
3 I prefer to change how I approach a goal rather than quit.   
0 1 2 3 4 5 6 
4 I am able to follow my long terms plans including times when progress is 
slow. 
 
0 1 2 3 4 5 6 
5 I find it difficult to carry on with an activity unless I experience that it is 
successful. 
 
0 1 2 3 4 5 6 
 6 If I feel distressed or discouraged, I let my commitments slide.  0 1 2 3 4 5 6 
 7 I get so wrapped up in what I am thinking or feeling that I cannot do the 
things that matter to me. 
 
0 1 2 3 4 5 6 
 8 If I cannot do something my way, I will not do it at all.   









0  1  2  3  4  5  6 
Never true  
Very rarely 
true 
 Seldom true  
Sometimes 
true 
 Often true  
Almost 
always true 
 Always true 
Below you will find a list of statements. Please rate the truth of each statement as it applies to you by selecting a 
number. Use the following rating scale to make your choices. For instance, if you believe a statement is “Always 
True”, you would select number 6 next to that statement.  
1. I am getting on with the business of living no matter what my level 
 1.I am getting on with the business of living no matter what my level of pain is. 
00 11 22 33 44 55 66 
2. Although things have changed, I am living a normal life despite my chronic 
pain. 
0 1 2 3 4 5 6 
3. I lead a full life even though I have chronic pain. 0 1 2 3 4 5 6 
4. Keeping my pain level under control takes first priority whenever I am doing 
something. 
0 1 2 3 4 5 6 
5. Before I can make any serious plans, I have to get some control over my pain. 0 1 2 3 4 5 6 
6. When my pain increases, I can still take care of my responsibilities. 0 1 2 3 4 5 6 
7. I avoid putting myself in situations where pain might increase. 0 1 2 3 4 5 6 





Self-Experiences Questionnaire (SEQ) 
Below you will find a list of statements. Please rate the truth of each statement as it applies to you. 
Use the following rating scale to make your choices. For instance, if you believe a statement is 
‘Always True,’ you would select number 6 next to that statement.  
 
0  1  2  3  4  5  6 
Never true  
Very rarely 
true 
 Seldom true  Sometimes true  Often true  
Almost always 
true 
 Always true 
1. Although I can get caught up with my 
own thoughts, emotions and sensations, 
I can also separate myself from them. 
0 1 2 3 4 5 6 
2. I am able to step back from my 
emotions and observe them from a 
separate point of view. 
0 1 2 3 4 5 6 
3. I am able to separate myself from my 
thoughts and feelings. 
0 1 2 3 4 5 6  
4. I have thoughts and feelings but am not 
defined as just my thoughts and 
feelings. 
0 1 2 3 4 5 6  
5. I can experience a distinction between 
my experiences and the “I” who notices 
these experiences. 
0 1 2 3 4 5 6  
6. I can actually see that I am not my 
thoughts. 
0 1 2 3 4 5 6  
7. I experience myself as more than my 
thoughts and feelings. 
0 1 2 3 4 5 6  
8. The health, appearance, and feelings of 
my body change, but the sense of 
myself who is aware of these changes is 
the same. 
0 1 2 3 4 5 6  
9. When I feel distressed, I can notice what 
is happening without being 
overwhelmed. 
0 1 2 3 4 5 6  
10. I can notice what I am thinking and 
feeling without getting too caught up in 
these experiences. 







11. Above all my experiences, there is a 
sense of myself who is noticing them. 
0 1 2 3 4 5 6  
12. I can notice that my mind is thinking 
from moment to moment. 
0 1 2 3 4 5 6  
13. I can observe experiences in my body 
and mind as events that come and go. 
0 1 2 3 4 5 6 
14. I am able to remain aware of my 
experiences from moment to moment. 
0 1 2 3 4 5 6 
15. My roles change depending on time, 
place and setting, but the sense of 
myself who has the roles stays the 
same. 





Cognitive Fusion Questionnaire (CFQ7) 
Below you will find a list of statements. Please rate how true each statement is for you by circling a 
number next to it. Use the scale below to make your choice.  
 
If you would also like to take part in further research, please provide your contact details below: 
 
 
Thank you for taking part in this survey! Your input is very much valuable to us. 
 
  













       
1. My thoughts cause me distress or emotional pain. 1 2 3 4 5 6 7 
2. I get so caught up in my thoughts that I am unable to do the 
things that I most want to do. 
1 2 3 4 5 6 7 
3. I over-analyse situations to the point where it’s unhelpful to me. 1 2 3 4 5 6 7 
4. I struggle with my thoughts. 1 2 3 4 5 6 7 
5. I get upset with myself for having certain thoughts. 1 2 3 4 5 6 7 
6. I tend to get very entangled in thoughts. 1 2 3 4 5 6 7 
7. It’s such a struggle to let go of upsetting thoughts even when I 
know that letting go would be helpful. 





Appendix J: Participants’ Information Sheet for Feasibility Study 
 
 
IRAS No 243486; REC Reference Number: 17/LO/2047 
INFORMATION SHEET FOR PARTICIPANTS 
The Development of Contextual Cognitive Behavioural Approach to painful diabetic neuropathy: A 
feasibility study 
You are being invited to take part in a research study. Please read this information carefully to 
understand why this research is being done and what your participation will involve. Discuss this 
information with family members or friends or your doctor if you wish. Do not hesitate to contact 
the research team if anything is unclear or if you would like more information. If you are happy to 
participate please complete the consent form and screening questionnaire and return them to the 
researcher via the freepost envelope or Skype or in-person.  
Who is conducting the study?  
This study is being conducted as part of the main researcher’s (Miss Aikaterini-Pinelopi Kioskli) 
doctoral studies and supervised by Professor Lance M. McCracken and Dr. Kirsty Winkley at King’s 
College London, the Institute of Psychiatry, Psychology and Neuroscience (IoPPN).  
What is the purpose of the study?  
People with diabetes often experience a type of pain called Painful Diabetic Neuropathy (PDN). PDN 





This type of pain can interfere with walking, sleep, mood and overall quality of life. Although 
medication may offer some short-term improvement in this pain, this is a chronic condition for the 
majority of the patients and the pain typically remains a problem. Our research team aims to assess 
the acceptability and potential benefits of a psychological treatment for people with PDN.  
Who is eligible to take part?  
Participants will have to fulfil the following criteria in order to take part in the study: 
• Confirmed diagnosis of diabetes. 
• Presence of painful diabetic neuropathy, for the last three months or more (a screening 
questionnaire has been added to verify that you suffer from neuropathy). 
• Aged at least 18 years. 
• Willingness and ability to take part. 
• Have computer literacy. 
Why have I been invited?  
You have been identified as a potential participant by your doctor because you have a confirmed 
diagnosis of diabetes and you suffer from neuropathic pain due to diabetes. In order to ensure that 
you are eligible to take part in the study, you will need to complete a screening questionnaire to 
check that you meet the study requirements. Once you return the completed screening 
questionnaire and consent form, a member of the research team will notify you of your eligibility.  
Do I have to take part?  
No. It is entirely your decision as to whether you take part in this study. If you decide to take part, 





the deadline to request withdrawal of your data from the study will be four weeks after the end of 
data collection. It will not be possible to withdraw your data after analysis. If you wish you are free 
to withdraw at any time during the study period without giving a reason, even if you initially decided 
to take part without affecting your quality of treatment or medical care. 
What will happen to me if I take part?  
As part of this study, you will continue to receive treatment as usual from your doctor as you 
normally do. However, you will also have the opportunity for an additional psychological treatment 
called Acceptance and Commitment Therapy (ACT). The ACT treatment includes treatment processes 
of acceptance, cognitive defusion, mindfulness, and values-based action. Methods will include 
practice to deal with painful experiences, to improve awareness, to identify and work on goals, and 
to better stick to commitments. The process will involve, two, brief, one-to-one contact sessions, 
one at the beginning and one at the end of the intervention, in a way that is convenient for you, 
including Skype, phone, or face to face in person. Following the first one-to-one session there will be 
eight short online sessions, about 20-30 minutes each. You will also be asked to complete some 
tasks between the sessions, in particular to record your progress briefly and any changes at your 
medication (i.e. type of drug, dose) in a diary weekly so that you can keep track of your developing 
skills. 
Will my GP and clinical care team be involved? 
The research team is not directly connected with the team involved in your treatment and your 
decision to participate or not will in no way affect your medical care and treatment that you receive. 
Your personal GP will not be involved in the study, but they will be informed of your participation 
with your permission. Any contact with the research team will be logged in your medical history file, 
for example, on the day a member of the research team approaches you about the study, it will be 





Will you compensate me for my time? 
Unfortunately, due to limited funding, we are unable to compensate you for your time. However, we 
greatly appreciate your help and involvement and would like to thank you in advance for your time. 
At the conclusion of the study, if you are interested, we will also provide you with a summary the 
main findings when they are available.  
Are there any costs? 
There are no costs to participants associated with the project.  
What are the possible disadvantages and risks of taking part?  
We believe that the risks involved in participating are minimal. It is possible that you might find it 
mildly distressing during the study. However, this effect is anticipated to be short lived, as you will 
learn psychological techniques during the intervention that can help you manage uncomfortable 
emotions, enhance your “psychological flexibility,” and to be mindful of your thoughts and accept 
your feelings. Should you become distressed during or after the intervention, you will have the 
opportunity to notify the member of the research team (please find contact details below). At this 
time, you can be helped to contact a suitable source of support or you may be encouraged to talk 
with your clinical care team for more information in this regard. If you require additional emotional 
support, again an appropriate referral can be made. If there is an urgent risk to your mental or 
physical health, you will be referred to the clinical care team, your General Practitioner or the 
emergency services right away. 
What are the possible benefits of taking part?  
Previous studies suggest that your painful symptoms will be helped by the ACT treatment, however 
we cannot guarantee improvements. Your information will help us gain more knowledge regarding 





end of the intervention we have added a questionnaire which will reflect the potential changes on 
your quality of life after treatment. At the conclusion of the project, we will send you a summary 
describing the major findings and alerting you to any research publications we have generated from 
the project. 
Will my taking part in the study be kept confidential?  
Yes. All information about your participation in this study will be kept confidential in accordance 
with the Data Protection Act 1998. All participants will be assigned an identification number (ID) and 
all collected data will be identified by the ID number, making it anonymous. Your personal 
information, such your name and contact details will be stored separately from all the collected 
data. Your information will be stored on secure computers, locked within offices and in locked file 
cabinets, and will only be available to members of the research team. This information will only be 
used for the purposes of the current study. The information you provide on the consent form (your 
name, contact details, and GP registration) will be destroyed at the end of the study. Your study data 
will be retained for a maximum of seven years and subsequently disposed of securely. Your 
anonymised data will be shared with other researchers and may be used for other research 
purposes.  
What will happen if I don’t want to carry on with the study?  
You are free to withdraw from the study at any time without having to give a reason even if you 
initially decided to take part. 
What will happen to the results of the research study?  
The research data will be kept for a maximum of 7 years. KCL and GSTT, acting as sponsor and co-
sponsor in this study, will also have access to the collected data for monitoring purposes. The results 





feasible, and beneficial for patients. The study will be presented at scientific conferences and be 
written up for publication in scientific journals. We will provide you with a summary sheet of the 
results, if you wish.  
Who is organising and funding the research?  
The study is funded by Diabetes UK. It is being organized and conducted by researchers from the 
Health Psychology Section, Department of Psychology, Institute of Psychiatry, Psychology, and 
Neuroscience, at King’s College London.  
Has this study obtained ethical approval? 
Yes, this study has been reviewed by the London Surrey Rec. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions [Professor Lance M. McCracken, Email: 
lance.mccracken@kcl.ac.uk, Telephone: +44 (0) 207 188 5410, Health Psychology Section, 
Psychology Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), Guy’s Campus, 
London, SE1 9RT]. If you remain unhappy and wish to complain formally, you can do this through the 
Guy’s and St Thomas’ Patients Advice and Liaison Service (PALS) on 020 7188 8801, 
pals@gstt.nhs.uk. The PALS team are based in the main entrance on the ground floor at St Thomas’ 
Hospital and on the ground floor at Guy’s Hospital in the Tower Wing. In the event that something 
does go wrong and you are harmed during the research you may have grounds for legal action for 
compensation against Guy’s and St Thomas’ NHS Foundation Trust and/or King’s College London but 
you may have to pay your legal costs. The normal National Health Service complaints mechanisms 






What if I have questions about the project? Contact details for further information  
If you have any questions or would like to discuss further your potential involvement in this study, 
please use the contact details below to get in touch with the research team. 
Name: Miss Aikaterini-Pinelopi Kioskli  
Job title: Doctoral Student 
Email address: aikaterini.kioskli@kcl.ac.uk  
Address: Health Psychology Section, Department of Psychology, Institute of Psychiatry, 
Psychology, and Neuroscience, Kings College London, 5th Floor Bermondsey Wing, Guys 
Campus, London SE1 9RT 
 
OR 
Name: Professor Lance M. McCracken 
Job title: Chief Investigator (PhD Supervisor) 
Email address: lance.mccracken@kcl.ac.uk  
Address: Health Psychology Section, Department of Psychology, Institute of Psychiatry, 
Psychology, and Neuroscience, Kings College London, 5th Floor Bermondsey Wing, Guys 
Campus, London SE1 9RT 
 
OR 
Name: Dr. Kirsty Winkley 
Job Title: Co-Investigator (PhD Supervisor) 
Email Address: kirsty.winkley@kcl.ac.uk  
Address: King's College London & Institute of Psychiatry, Psychology & Neuroscience, 
Department of Psychological Medicine, Weston Education Centre, Cutcombe Road, 
London, SE5 9RJ  
 
ALTERNATIVELY:  






Study Title: The Development of Contextual Cognitive Behavioural Approach to painful diabetic 
neuropathy: A feasibility study 
IRAS Number:  224386 
Supplementary Patient Information Sheet on the Use of Data 
King’s College London and Guy’s and St Thomas’ NHS Foundation trust are the co-sponsors for this 
study based in the United Kingdom. We will be using information from you in order to undertake this 
study and will act as the data controller for this study. This means that we are responsible for looking 
after your information and using it properly. King’s College London and Guy’s and St Thomas’ NHS 
Foundation trust will keep identifiable information about you for 7 years after the study has finished. 
Your rights to access, change or move your information are limited, as we need to manage your 
information in specific ways in order for the research to be reliable and accurate. If you withdraw 
from the study, we will keep the information about you that we have already obtained. To safeguard 
your rights, we will use the minimum personally identifiable information possible. 




Guy’s and St Thomas’ Hospital will collect information from you for this research study in accordance 
with our instructions. Guy’s and St Thomas’ NHS Foundation trust will use your name, and contact 





study is recorded for your care, and to oversee the quality of the study. Individuals from King’s 
College London, Guy’s and St Thomas’ NHS Foundation trust and regulatory organisations may look 
at your research records to check the accuracy of the research study. The only people in King’s 
College London who will have access to information that identifies you will be people who need to 
contact you to audit the data collection process. The people who analyse the information will not be 






Appendix K: Participants’ Consent Form for Feasibility Study 
 
CONSENT FORM 
Title of Project: The Development of Contextual Cognitive Behavioural Approach to painful diabetic 
neuropathy: A feasibility study 
Name of Researcher: Aikaterini-Pinelopi Kioskli 
  Please initial box  
1. I confirm that I have read the information sheet dated 26.6.2018 version 3 for the 
above study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
3. I understand that the information collected about me will be used to support 
other research in the future and may be shared anonymously with other researchers. 
4.  I agree to my General Practitioner being informed of my participation in the study.  
5. I understand that relevant sections of my medical notes and data collected during the study,  
may be looked at by individuals from King’s College London, regulatory authorities or from  
the NHS Trust, where it is relevant to my taking part in this research. I give permission for  
these individuals to have access to my records 
6. I agree to take part in the above study. 
            
  Name of Participant                   Date    Signature 
 
            
 Name of Person                    Date    Signature  





Appendix L: Email to Participants 
This was the first email I sent to participants after they made contact and expressed their interest. 
The rest of the communication was conducted through the online treatment platform called 
ACT4PAIN or via Skype. 
Subject: Online psychological treatment for individuals with painful diabetic neuropathy 
Dear <Name>, 
Thank you for getting in touch and for your interest in our psychological treatment. My name is Kitty 
Kioskli and I am part of a research team in King’s College London. My research team and I designed 
an online psychological treatment for individuals who suffer from painful diabetic neuropathy 
(neuropathy/nerve pain due to diabetes). This treatment will be completely free of charge since it is 
part of my PhD. This is a feasibility study which means that our main aims are to see investigate if 
this treatment would be acceptable and effective. If you are interest to take part the steps, you need 
to take are simple:  
Step 1: The first session is meant to be by phone or any other means preferable to you (i.e. Skype). 
After you read the information sheet (which you may find attached) and information provided in this 
email, if you decide that you would be interested in taking part, please respond to this email to 
arrange our first session at your convenience. 
Step 2: After completing our first session, I will kindly ask you to complete a baseline questionnaire 
through the following link: https://kings.onlinesurveys.ac.uk/baseline_questionnaire (it will ask you 
for a unique ID and yours is: XXX). 
Step 3: As soon as you complete the baseline questionnaire, I will register you as a patient in our 





This treatment program is a form of cognitive behavioral therapy (CBT), and is meant to be very 
practical. We know it takes skills, flexibility, persistence and focus to deal effectively with chronic 
pain, and this is what this treatment is meant to help with! My goals, as a therapist, are to help you 
reach your goals so that pain does not stop you in your everyday life. My other goal is to be there as 
a support behind the set of exercises we provide. In that sense my goal is to form a team with you 
and help you succeed! 
There are just a couple of guidelines here: This treatment is meant to last 5 weeks, you need to 
complete 8 online sessions in total, each session lasts 30 minutes. We have designed the treatment 
to be completed in this timeframe to help keep us focused and on track with your goals, so it is 
important to follow this schedule. You will be able to message me throughout the treatment via the 
online platform and I will also message you every time you complete a session!  
Step 4: When you successfully complete your treatment, I will send you a final online questionnaire 
to answer. This will help us compare your answers from the baseline questionnaire and will reveal if 
there are any differences to your pain levels and everyday life. 
Please find attached the Participant’s Information Sheet for more details. I am on your disposal for 
any further queries. 
Kind regards, 
Kitty Kioskli, PhD Candidate 
King’s College London, Health Psychology Section 
Psychology Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN) 
5th Floor Bermondsey Wing 
Guy’s Hospital Campus 


















































Appendix O: Other Publications and Accepted Abstracts 
Peer-Reviewed Papers: 
Scott, W., Arkuter, C., Kioskli, K., Kemp, H., McCracken, L. M., Rice, A. S., & de C Williams, A. C. 
(2018). Psychosocial Factors Associated with Persistent Pain in People with HIV: A Systematic Review 
with Meta-Analysis. Pain, 159(12), 2461-2476. https://doi.org/10.1097/j.pain.0000000000001369 
Conference Presentations: 
Date/Venue: 14-15 March 2018, London, UK 
Conference: Diabetes UK Professional Conference  
Type of presentation: Poster 
Category: Psychological Care 
Abstract 
Psychosocial factors associated with painful diabetic neuropathy: a systematic review  
A.P. Kioskli1, W. Scott1,3, S. Kylakos4, K. Winkley2, L. M. McCracken1,3 
1 King's College London, Health Psychology Section, Psychology Department, Institute of Psychiatry, 
London, UK 
2 King's College London, Department of Psychological Medicine, Institute of Psychiatry, London, UK 






Aims: Despite the pressing need to investigate the role of psychological factors in the experience of 
chronic pain, less is known about the role of psychological factors in Painful Diabetic Neuropathy 
(PDN). We aimed to summarise all the psychological interventions, psychosocial factors and pain 
outcomes related to PDN, within the literature, and assess their methodological quality.   
Methods: Eight electronic databases, thematically relevant reviews and associated reference lists 
were systematically searched to identify all studies examining a psychological intervention or 
psychosocial factors associated with PDN patients. The methodological quality of the eligible articles 
was assessed by the Downs and Black, (1998) quality assessment tool. Narrative synthesis was 
undertaken to summarise the data from the included studies. 
Results: From 2,919 potentially relevant titles 22 studies were included in this systematic review. 
Associations between pain and psychosocial variables and treatment outcomes were examined. 
Three psychological interventions were identified and 19 survey studies. Different methods including 
questionnaires and self-reports were adopted to assess the effects of psychosocial variables in pain. 
Depression, anxiety and quality of life were the most commonly studied independent variables 
within this literature.  
Conclusions: The current review suggests that depression, anxiety, impaired quality of life and 
disturbed sleep are consistently associated with pain. In light of the different psychological factors 
identified, it would be useful for future research to be undertaken in the context of a guiding 
theoretical model to understand how these psychological factors might work together and how 







Date/Venue: 15-18 May 2018, Malvern, UK 
Conference: The 17th Malvern Diabetic Foot Conference 
Type of presentation: Oral 
Funding: This presentation was funded through a conference grant (£300) by the ‘Doctoral Studies’ 
at King’s College London. 
Abstract 
A systematic review of psychological interventions and modifiable psychosocial factors associated 
with neuropathic pain due to diabetes 
 A.P. Kioskli1, W. Scott1, 3, K. Winkley2, L. M. McCracken1, 3 
1 King's College London, Health Psychology Section, Psychology Department, Institute of Psychiatry, 
London, UK  
2 King's College London, Department of Psychological Medicine, Institute of Psychiatry, London, UK 
3 Guy’s and St Thomas’ NHS Foundation Trust, London, UK  
Background and Aims: Painful Diabetic Neuropathy (PDN) is a multi-dimensional condition arising 
from diabetes and is considered very difficult to diagnose and treat. This systematic review aimed to 
identify the studies applying psychological interventions or investigating modifiable psychosocial 
factors related to pain outcomes, summarise the evidence and assess the methodological quality of 
these studies.   
Methods: Eight electronic databases were searched: Medline, Embase, PsycInfo, Cinahl, Web of 
Science, ISRCTN registry, ClinicalTrials.gov registry, and EU Clinical Trials registry. Also, the reference 





Results: Twenty-two studies (twenty-four papers) were included in this systematic review suggesting 
that depression and anxiety are the most studied independent variables, and quality of life the most 
studied dependent variable within the literature. Most studies had medium methodological quality.  
Conclusions and Future Work: Few modifiable psychosocial factors have been studied within the 
literature and fewer psychological treatments have been developed for PDN. It would be useful for 
future research to consider the development of a theoretical framework which will encompass these 
modifiable psychosocial factors to develop acceptable and effective psychological interventions for 
the PDN population.  
Date/Venue: 6-8 March 2019, Liverpool, UK 
Conference: Diabetes UK Professional Conference 
Type of presentation: Oral & Poster  
Category: Psychological Care 
Abstract 
Psychological flexibility processes in adults with painful diabetic neuropathy and suitability of 
Acceptance and Commitment Therapy: A cross-sectional survey 
K Kioskli1, K Winkley2, LM McCracken1,3 
1 King's College London, Health Psychology Section, Institute of Psychiatry Psychology and 
Neuroscience, London, United Kingdom 
2 King's College London, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, London, 
United Kingdom 





Aims: Painful diabetic neuropathy (PDN) is a distressing and disabling condition. However, there is 
relatively little research into the role of psychological variables related to PDN. The aim of this study 
was to investigate the association between psychological flexibility (PF) and daily functioning and 
distress in people with painful diabetic neuropathy (PDN).  
Methods: This cross-sectional study included 225 participants (mean age 52.05 + 12.06) who were 
recruited from hospital services and online. 
Results: In correlation analyses acceptance of pain negatively correlated to pain distress, r=-0.22, 
p<0.01, functional impairment, r=-0.28, p<0.01, depression severity, r=-0.22, p<0.01, and depression 
impact, r=-0.22, p<0.01. Cognitive fusion positively correlated with functional impairment, r=0.24, 
p<0.01, depression severity, r=0.37, p<0.01, and depression impact, r=0.21, p<0.01. Committed 
action also negatively correlated with functional impairment, r=-0.21, p<0.01, depression severity, 
r=-0.37, p<0.01 and depression impact, r=-0.21, p<0.01. In regression analyses, the combination of 
the four variables representing PF accounted for significant variance in all the equations except in 
pain distress. In the depression severity equation, cognitive fusion and committed action accounted 
for 13.3% of variance. In the depression impact equation, committed action and self-as-context 
accounted for 7.7% of variance. 
Conclusions: PF processes seem to participate in processes of interaction between pain, emotional 
experiences, thoughts, and daily life activities of individuals with PDN. These results highlight the 
potential utility of PF components in the design and evaluation of psychological treatments for 
individuals suffering from PDN. The generalisability of the findings needs to be established. 
Date/Venue: 4-7 September 2019, Valencia, Spain 
Conference: 11th Congress of the European Pain Federation (EFIC) 






A study of the role of psychological flexibility among UK adult patients with Painful Diabetic 
Neuropathy 
Kitty Kioskli1, Kirsty Winkley2, Lance M McCracken1,3 
1 King's College London, Health Psychology Section, Psychology Department, Institute of Psychiatry 
Psychology and Neuroscience, London, United Kingdom 
2 King's College London, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, London, 
United Kingdom 
3 Uppsala University, Psychology Department, Uppsala, Sweden 
Background and aims: Painful diabetic neuropathy (PDN) is a complex complication associated with 
poor glycaemic control. Current treatments for PDN aim to treat the symptoms of pain and 
discomfort and are mainly pharmacological but have limited effectiveness. However, less is known 
about alternatives such as psychological treatments and the role of psychological variables related to 
PDN. The aim of this study is to survey people with PDN and examine the role of psychological 
flexibility (PF) in relation to their daily functioning.  
Methods: This is a questionnaire-based, cross-sectional study with 225 participants (mean age 52.05 
+ 12.06), who were recruited from NHS and online. 
Results: In correlation analyses, acceptance of pain was shown to be negatively correlated to pain 
intensity (r=-0.21, p<0.01), pain distress (r=-0.25, p<0.01) functional impairment (r=-0.38, p<0.01), 
depression severity, (r=-0.41, p<0.01), and depression impact (r=-0.41, p<0.01). Committed action 
also correlated negatively with functional impairment (r=-0.22, p<0.01), depression severity (r=-0.43, 
p<0.01) and depression impact (r=-0.21, p<0.01). Results from regression analyses show that the 





in most equations. In the equation for depression severity, pain intensity accounted for 23.3% of 
variance. In the equation for depression impact, pain intensity accounted for 13.2% of variance. 
Conclusions: These results highlight the potential utility of PF in the design and implementation of 
psychological interventions for individuals from PDN. The reliability and generalisability of the results 
need to be established. 
Date/Venue: 23-24 October 2019, Munich, Germany 
Conference: International Conference on Controversies in Neuropathic Pain (Neuropathic-Pain2019)  
Type of presentation: Oral & Poster 
Abstract 
A feasibility study of an online Acceptance and Commitment Therapy program for people with 
Painful Diabetic Neuropathy 
Kitty Kioskli 1, Whitney Scott 1,3, Kirsty Winkley 2, Emma Godfrey 1, Lance M McCracken4 
1 King's College London, Health Psychology Section, Psychology Department, Institute of Psychiatry 
Psychology and Neuroscience, London, United Kingdom 
2 King's College London, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, London, 
United Kingdom  
3 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom 
4 Uppsala University, Psychology Department, Uppsala, Sweden 
Background: Painful diabetic neuropathy (PDN) is one of the most common complications of 
diabetes. PDN is mainly managed with medication. However, its effectiveness is limited, and most 





Objective: This study aimed to assess the feasibility of online Acceptance and Commitment Therapy 
(ACT) for people with PDN in the United Kingdom and to evaluate if a larger trial is justified. 
Methods: Participants were recruited online and from hospital services. This was an observational 
study and all participants received the online ACT program. Participants completed questionnaires at 
baseline and 3-month post-treatment. Primary outcomes were recruitment, treatment completion, 
and retention rates. Secondary outcomes were within-groups effects on pain outcomes and 
psychological flexibility and were evaluated via repeated measures ANOVA. 
Results: From 225 potentially eligible participants, 30 took part in this study. The treatment 
completion rate was 40%. All participants completed 3-month questionnaires. Outcome results for 
the whole sample suggested that pain intensity, pain distress, cognitive fusion and self-as-context 
scores had a statistically significant effect for time. Treatment completers showed significantly lower 
levels of pain intensity, pain distress, depression symptoms and functional impairment and higher 
levels of committed action scores, compared to non-completers, at post-treatment. All completers 
reported that they felt improved after treatment.  
Conclusion: Results suggest that online ACT is only acceptable to a minority of participants, as 
indicated by low completion rates. However, among those willing to complete it, they may achieve 






Appendix P: ACT Worksheet Examples 
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